0001819790-23-000080.txt : 20231109 0001819790-23-000080.hdr.sgml : 20231109 20231109160038 ACCESSION NUMBER: 0001819790-23-000080 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 231392120 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 10-Q 1 tars-20230930.htm 10-Q tars-20230930
FALSE0001819790--12-312023Q3P3YP1YP1YP1Y00018197902023-01-012023-09-3000018197902023-11-03xbrli:shares00018197902023-09-30iso4217:USD00018197902022-12-31iso4217:USDxbrli:shares0001819790us-gaap:ProductMember2023-07-012023-09-300001819790us-gaap:ProductMember2022-07-012022-09-300001819790us-gaap:ProductMember2023-01-012023-09-300001819790us-gaap:ProductMember2022-01-012022-09-300001819790tars:LicenseAndCollaborationMember2023-07-012023-09-300001819790tars:LicenseAndCollaborationMember2022-07-012022-09-300001819790tars:LicenseAndCollaborationMember2023-01-012023-09-300001819790tars:LicenseAndCollaborationMember2022-01-012022-09-3000018197902023-07-012023-09-3000018197902022-07-012022-09-3000018197902022-01-012022-09-300001819790us-gaap:CommonStockMember2022-12-310001819790us-gaap:AdditionalPaidInCapitalMember2022-12-310001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001819790us-gaap:RetainedEarningsMember2022-12-310001819790us-gaap:RetainedEarningsMember2023-01-012023-03-3100018197902023-01-012023-03-310001819790us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001819790us-gaap:CommonStockMember2023-01-012023-03-310001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-3100018197902023-03-310001819790us-gaap:CommonStockMember2023-03-310001819790us-gaap:AdditionalPaidInCapitalMember2023-03-310001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001819790us-gaap:RetainedEarningsMember2023-03-310001819790us-gaap:RetainedEarningsMember2023-04-012023-06-3000018197902023-04-012023-06-300001819790us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001819790us-gaap:CommonStockMember2023-04-012023-06-300001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000018197902023-06-300001819790us-gaap:CommonStockMember2023-06-300001819790us-gaap:AdditionalPaidInCapitalMember2023-06-300001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001819790us-gaap:RetainedEarningsMember2023-06-300001819790us-gaap:RetainedEarningsMember2023-07-012023-09-300001819790us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001819790us-gaap:CommonStockMember2023-07-012023-09-300001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001819790us-gaap:CommonStockMember2023-09-300001819790us-gaap:AdditionalPaidInCapitalMember2023-09-300001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001819790us-gaap:RetainedEarningsMember2023-09-3000018197902021-12-310001819790us-gaap:CommonStockMember2021-12-310001819790us-gaap:AdditionalPaidInCapitalMember2021-12-310001819790us-gaap:RetainedEarningsMember2021-12-310001819790us-gaap:RetainedEarningsMember2022-01-012022-03-3100018197902022-01-012022-03-310001819790us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001819790us-gaap:CommonStockMember2022-01-012022-03-3100018197902022-03-310001819790us-gaap:CommonStockMember2022-03-310001819790us-gaap:AdditionalPaidInCapitalMember2022-03-310001819790us-gaap:RetainedEarningsMember2022-03-310001819790us-gaap:RetainedEarningsMember2022-04-012022-06-3000018197902022-04-012022-06-300001819790us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001819790us-gaap:CommonStockMember2022-04-012022-06-3000018197902022-06-300001819790us-gaap:CommonStockMember2022-06-300001819790us-gaap:AdditionalPaidInCapitalMember2022-06-300001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001819790us-gaap:RetainedEarningsMember2022-06-300001819790us-gaap:RetainedEarningsMember2022-07-012022-09-300001819790us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001819790us-gaap:CommonStockMember2022-07-012022-09-300001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-3000018197902022-09-300001819790us-gaap:CommonStockMember2022-09-300001819790us-gaap:AdditionalPaidInCapitalMember2022-09-300001819790us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001819790us-gaap:RetainedEarningsMember2022-09-300001819790tars:FollowOnPublicOfferingMember2023-08-042023-08-040001819790tars:FollowOnPublicOfferingMember2023-08-040001819790us-gaap:OverAllotmentOptionMember2023-08-042023-08-040001819790us-gaap:OverAllotmentOptionMember2023-09-062023-09-060001819790us-gaap:OverAllotmentOptionMember2023-09-060001819790tars:FollowOnPublicOfferingMember2022-05-012022-05-310001819790tars:FollowOnPublicOfferingMember2022-05-310001819790us-gaap:OverAllotmentOptionMember2022-05-012022-05-310001819790tars:FollowOnPublicOfferingMember2022-06-012022-06-300001819790tars:FollowOnPublicOfferingMember2022-06-300001819790tars:FollowOnPublicOfferingMember2022-05-012022-06-30tars:segment0001819790tars:IntangibleAssetsMilestonePaymentMember2023-09-300001819790srt:MinimumMember2023-09-300001819790srt:MaximumMember2023-09-300001819790us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembertars:CustomerOneMember2023-07-012023-09-30xbrli:pure0001819790tars:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001819790tars:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001819790us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembertars:ThreeCustomersMember2023-07-012023-09-300001819790tars:LicenseAndCollaborationOtherMember2023-07-012023-09-300001819790tars:LicenseAndCollaborationOtherMember2023-01-012023-09-300001819790tars:LicenseAndCollaborationOtherMember2022-07-012022-09-300001819790tars:LicenseAndCollaborationOtherMember2022-01-012022-09-300001819790srt:MinimumMembertars:EquityIncentivePlan2016Member2023-01-012023-09-300001819790srt:MaximumMembertars:EquityIncentivePlan2016Member2023-01-012023-09-300001819790tars:EquityIncentivePlan2016Member2023-01-012023-09-300001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-09-300001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-09-300001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-09-300001819790us-gaap:MoneyMarketFundsMember2023-09-300001819790us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-09-300001819790us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-09-300001819790us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-300001819790us-gaap:USTreasurySecuritiesMember2023-09-300001819790us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2023-09-300001819790us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2023-09-300001819790us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2023-09-300001819790us-gaap:CommercialPaperMember2023-09-300001819790us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-09-300001819790us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-09-300001819790us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-300001819790us-gaap:CorporateDebtSecuritiesMember2023-09-300001819790us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMember2023-09-300001819790us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-09-300001819790us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-300001819790us-gaap:USGovernmentDebtSecuritiesMember2023-09-300001819790us-gaap:FairValueInputsLevel1Member2023-09-300001819790us-gaap:FairValueInputsLevel2Member2023-09-300001819790us-gaap:FairValueInputsLevel3Member2023-09-300001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001819790us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:MoneyMarketFundsMember2022-12-310001819790us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001819790us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001819790us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:USTreasurySecuritiesMember2022-12-310001819790us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2022-12-310001819790us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2022-12-310001819790us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:CommercialPaperMember2022-12-310001819790us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001819790us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001819790us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:CorporateDebtSecuritiesMember2022-12-310001819790us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMember2022-12-310001819790us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001819790us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001819790us-gaap:USGovernmentDebtSecuritiesMember2022-12-310001819790us-gaap:FairValueInputsLevel1Member2022-12-310001819790us-gaap:FairValueInputsLevel2Member2022-12-310001819790us-gaap:FairValueInputsLevel3Member2022-12-3100018197902021-03-012021-03-31tars:tranchetars:warrant00018197902022-01-012022-12-31tars:security0001819790srt:MinimumMembertars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2023-09-300001819790srt:MaximumMembertars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2023-09-300001819790tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2023-09-300001819790srt:MinimumMembertars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2022-12-310001819790srt:MaximumMembertars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2022-12-310001819790tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2022-12-310001819790us-gaap:FurnitureAndFixturesMember2023-09-300001819790us-gaap:FurnitureAndFixturesMember2022-12-310001819790us-gaap:OfficeEquipmentMember2023-09-300001819790us-gaap:OfficeEquipmentMember2022-12-310001819790us-gaap:OtherMachineryAndEquipmentMember2023-09-300001819790us-gaap:OtherMachineryAndEquipmentMember2022-12-310001819790us-gaap:LeaseholdImprovementsMember2023-09-300001819790us-gaap:LeaseholdImprovementsMember2022-12-31tars:vote0001819790us-gaap:CostOfSalesMember2023-07-012023-09-300001819790us-gaap:CostOfSalesMember2022-07-012022-09-300001819790us-gaap:CostOfSalesMember2023-01-012023-09-300001819790us-gaap:CostOfSalesMember2022-01-012022-09-300001819790us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001819790us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001819790us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001819790us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001819790us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001819790us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001819790us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001819790us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001819790us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001819790us-gaap:RestrictedStockUnitsRSUMember2022-12-310001819790us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001819790us-gaap:RestrictedStockUnitsRSUMember2023-03-310001819790us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001819790us-gaap:RestrictedStockUnitsRSUMember2023-06-300001819790us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001819790us-gaap:RestrictedStockUnitsRSUMember2023-09-300001819790us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001819790us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001819790us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001819790tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember2023-01-012023-09-300001819790tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember2022-01-012022-09-30tars:contract0001819790tars:ClinicalMilestonesMembertars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-09-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2019-01-012019-01-310001819790tars:ClinicalMilestonesMembertars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-09-012023-03-310001819790tars:CommercialAndSalesMilestonesMembertars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-07-012023-09-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-09-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-09-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-07-012023-09-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-09-012020-09-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-09-300001819790tars:ClinicalMilestonesMembertars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-12-012022-12-310001819790tars:ClinicalMilestonesMembertars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-09-300001819790tars:CommercialAndSalesMilestonesMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-09-300001819790tars:LianBioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-310001819790tars:LianBioMembertars:MilestoneDeterminedByTheCompanyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-310001819790tars:DevelopmentAndRegulatoryMilestoneMembertars:LianBioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-02-012023-02-280001819790tars:LianBioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-262023-09-300001819790tars:LianBioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-09-300001819790tars:DevelopmentAndRegulatoryMilestoneMembertars:LianBioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-09-300001819790us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-012021-03-310001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-04-012021-06-300001819790tars:LianBioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-04-012021-06-300001819790tars:ElancoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-10-012022-12-310001819790tars:LianBioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-10-012022-12-310001819790us-gaap:LineOfCreditMember2022-02-022022-02-020001819790us-gaap:LineOfCreditMembertars:CreditFacilityTrancheOneMember2023-01-050001819790us-gaap:LineOfCreditMembertars:CreditFacilityFirstAmendmentTrancheTwoMember2023-01-050001819790us-gaap:LineOfCreditMember2023-03-152023-03-150001819790us-gaap:LineOfCreditMember2023-09-152023-09-150001819790tars:LineOfCreditSVBMember2023-03-152023-03-150001819790tars:LineOfCreditSVBMember2023-09-152023-09-150001819790us-gaap:LineOfCreditMember2023-09-300001819790us-gaap:LineOfCreditMembertars:CreditFacilityTrancheOneMember2023-09-300001819790tars:CreditFacilityTrancheTwoMemberus-gaap:LineOfCreditMember2023-09-300001819790tars:CreditFacilityTrancheThreeMemberus-gaap:LineOfCreditMember2023-09-300001819790us-gaap:LineOfCreditMembertars:CreditFacilityTrancheFourMember2023-09-300001819790us-gaap:LineOfCreditMember2022-02-020001819790us-gaap:PrimeRateMemberus-gaap:LineOfCreditMember2022-02-022022-02-020001819790srt:MaximumMemberus-gaap:PrimeRateMemberus-gaap:LineOfCreditMember2022-02-022022-02-020001819790us-gaap:LineOfCreditMember2023-01-012023-09-300001819790us-gaap:LineOfCreditMember2022-09-300001819790srt:DirectorMember2021-12-310001819790srt:DirectorMember2021-12-012021-12-310001819790srt:DirectorMembersrt:MinimumMember2021-12-012021-12-310001819790srt:DirectorMembersrt:MaximumMember2021-12-012021-12-310001819790us-gaap:RelatedPartyMember2023-07-012023-09-300001819790us-gaap:RelatedPartyMember2023-01-012023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to ____ . 
Commission File Number: 001-39614
TARSUS PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)

Delaware81-4717861
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
15440 Laguna Canyon Road, Suite 160
Irvine, California
92618
(Address of principal executive offices)(Zip Code)
(949) 409-9820
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.0001 par value per shareTARS
The Nasdaq Global Market LLC
(Nasdaq Global Select Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐  Accelerated filer☐
Non-accelerated filer☒  Smaller reporting company☒
  Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 3, 2023, the number of outstanding shares of the registrant's common stock, par value $0.0001 per share, was 33,104,612.


TABLE OF CONTENTS


PART I—FINANCIAL INFORMATION
Item I. Financial Statements (Unaudited)
TARSUS PHARMACEUTICALS, INC.
INDEX TO THE FINANCIAL STATEMENTS

F-1
TARSUS PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEETS
(In thousands, except share and par value amounts)
 
 
September 30, 2023December 31, 2022
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents$226,672 $71,660 
Marketable securities20,213 145,366 
Accounts receivable, net5,362 — 
Inventory15 — 
Other receivables1,008 3,582 
Prepaid expenses6,007 4,767 
Total current assets259,277 225,375 
Property and equipment, net1,614 957 
Intangible assets, net3,967 — 
Operating lease right-of-use assets2,011 575 
Long-term investments210 371 
Other assets1,253 585 
Total assets$268,332 $227,863 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued liabilities$15,351 $9,910 
Accrued payroll and benefits7,898 5,519 
Total current liabilities23,249 15,429 
Term loan, net29,708 19,434 
Other long-term liabilities1,711 100 
Total liabilities54,668 34,963 
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding
— — 
Common stock, $0.0001 par value; 200,000,000 shares authorized; 33,104,087 shares issued and outstanding at September 30, 2023 (unaudited); 26,727,458 shares issued and outstanding at December 31, 2022
5 5 
Additional paid-in capital416,421 301,732 
Accumulated other comprehensive loss(8)(74)
Accumulated deficit(202,754)(108,763)
Total stockholders’ equity213,664 192,900 
Total liabilities and stockholders’ equity$268,332 $227,863 
See accompanying notes to these unaudited condensed financial statements.
F-2
TARSUS PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands, except share and per share amounts)

 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2023202220232022
Revenues:
Product sales, net$1,653 $— $1,653 $— 
License fees and collaboration revenue218 — 2,718 15,816 
Total revenues1,871 — 4,371 15,816 
Operating expenses:
Cost of sales377 — 377 — 
Cost of license fees and collaboration revenue— — — 555 
Research and development12,105 10,912 37,007 32,596 
Selling, general and administrative30,324 11,994 65,695 30,316 
Total operating expenses42,806 22,906 103,079 63,467 
Loss from operations before other income (expense) and income taxes(40,935)(22,906)(98,708)(47,651)
Other income (expense):
Interest income2,840 1,061 7,359 1,372 
Interest expense(858)(633)(2,357)(1,507)
Other (expense) income, net(48)(7)(89)136 
Unrealized loss on equity investments(111)(13)(161)(326)
Change in fair value of equity warrants issued by licensee(36)(18)(35)(520)
Total other income (expense), net 1,787 390 4,717 (845)
Benefit from income taxes— 5 — 4 
Net loss$(39,148)$(22,511)$(93,991)$(48,492)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities and cash equivalents15 (10)66 (10)
Comprehensive loss$(39,133)$(22,521)$(93,925)$(48,502)
Net loss per share, basic and diluted$(1.28)$(0.84)$(3.35)$(2.03)
Weighted-average shares outstanding, basic and diluted30,622,440 26,662,374 28,065,434 23,923,512 

See accompanying notes to these unaudited condensed financial statements.
F-3
TARSUS PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In thousands, except share data)

 Preferred StockCommon StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossAccumulated
Deficit		Total
Stockholders’
Equity
 SharesAmountSharesAmount
Balance as of December 31, 2022— $— 26,727,458 $5 $301,732 $(74)$(108,763)$192,900 
Net loss— — — — — — (23,419)(23,419)
Recognition of stock-based compensation expense — — — — 3,906 — — 3,906 
Exercise of vested stock options— — 6,443 — 13 — — 13 
Issuance of common stock upon the vesting of restricted stock units— — 66,611 — — — — — 
Other comprehensive gain— — — — — 4 — 4 
Balance as of March 31, 2023— $— 26,800,512 $5 $305,651 $(70)$(132,182)$173,404 
Net loss— — — — — — (31,424)(31,424)
Recognition of stock-based compensation expense — — — — 5,192 — — 5,192 
Exercise of vested stock options— — 16,118 — 45 — — 45 
Issuance of common stock upon the vesting of restricted stock units— — 45,653 — — — — — 
Shares issued in connection with the employee stock purchase plan— — 37,289 — 465 — — 465 
Other comprehensive gain— — — — 47 — 47 
Balance as of June 30, 2023— $— 26,899,572 $5 $311,353 $(23)$(163,606)$147,729 
Net loss — — — — — — (39,148)(39,148)
Recognition of stock-based compensation expense— — — — 5,250 — — 5,250 
Issuance of common stock upon follow-on public offering, net of issuance costs of $6,912
— — 6,069,449 — 99,302 — — 99,302 
Exercise of vested stock options— — 109,627 — 516 — — 516 
Issuance of common stock upon the vesting of restricted stock units— — 25,439 — — — — 
Other comprehensive gain— — — — — 15 — 15 
Balance as of September 30, 2023— $— 33,104,087 $5 $416,421 $(8)$(202,754)$213,664 


F-4
Preferred StockCommon StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossAccumulated
Deficit		Total
Stockholders’
Equity
SharesAmountSharesAmount
Balance as of December 31, 2021— $— 20,698,737 $4 $213,398 $— $(46,672)$166,730 
Net loss— — — — — — (20,238)(20,238)
Recognition of stock-based compensation expense— — — — 2,674 — — 2,674 
Exercise of vested stock options— — 225 — — — — — 
Issuance of common stock upon the vesting of restricted stock units— — 4,257 — — — — — 
Lapse of repurchase obligation for stock option exercises, prior to vesting— — 15,309 — 31 — — 31 
Balance as of March 31, 2022— $— 20,718,528 $4 $216,103 $— $(66,910)$149,197 
Net loss— — — — — — (5,743)(5,743)
Recognition of stock-based compensation expense— — — — 3,532 — — 3,532 
Issuance of common stock upon follow-on public offering, net of issuance costs of $5,246
— — 5,889,832 1 74,266 — — 74,267 
Shares issued in connection with the employee stock purchase plan— — 17,874 — 222 — — 222 
Exercise of vested stock options— — 7,056 — 17 — — 17 
Issuance of common stock upon the vesting of restricted stock units— — 4,257 — — — — — 
Lapse of repurchase obligation for stock option exercises, prior to vesting— — 6,705 — 13 — — 13 
Balance as of June 30, 2022— $— 26,644,252 $5 $294,153 $— $(72,653)$221,505 
Net loss— — — — — — (22,511)(22,511)
Recognition of stock-based compensation expense— — — — 3,583 — — 3,583 
Lapse of repurchase obligation for stock option exercises, prior to vesting— — 5,826 — 12 — — 12 
Exercise of vested stock options— — 21,734 — 82 — — 82 
Issuance costs related to follow-on public offering— — — — (34)— — (34)
Other comprehensive loss— — — — — (10)— (10)
Balance as of September 30, 2022— $— 26,671,812 $5 $297,796 $(10)$(95,164)$202,627 
See accompanying notes to these unaudited condensed financial statements.
F-5
TARSUS PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 Nine Months Ended
September 30,
 20232022
Cash Flows From Operating Activities:
Net loss$(93,991)$(48,492)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation497 227 
Amortization of intangible assets33 — 
Accretion of term loan-related costs274 231 
Stock-based compensation14,348 9,789 
Non-cash lease expense410 343 
Unrealized loss on equity investments161 326 
Net amortization/accretion on marketable securities(3,038)(63)
Change in fair value of equity warrants issued by licensee35 520 
Unrealized gain from transactions denominated in a foreign currency— (1)
Changes in operating assets and liabilities:
Accounts receivable, net(5,362)(17)
Inventory(15)— 
Other receivables2,574 (3,902)
Prepaid expenses(1,028)551 
Other non-current assets(608)(75)
Accounts payable and other accrued liabilities5,177 1,187 
Accrued payroll and benefits2,379 1,294 
Other long-term liabilities(4)(74)
Net cash used in operating activities(78,158)(38,156)
Cash Flows From Investing Activities:
Proceeds from maturities of marketable securities156,920 — 
Purchases of marketable securities(28,664)(57,031)
Intangible asset additions(4,000)— 
Purchases of property and equipment(1,502)(379)
Net cash provided by (used in) investing activities122,754 (57,410)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock upon follow-on public offerings, net of paid issuance costs99,377 74,352 
Proceeds from sale of common stock under employee stock purchase plan
465 222 
Proceeds from exercise of equity awards574 99 
Proceeds from term loan10,000 20,000 
Payment of term loan issuance costs— (875)
Payment of deferred offering costs
— (75)
Net cash provided by financing activities110,416 93,723 
Net increase (decrease) in cash and cash equivalents155,012 (1,843)
Cash and cash equivalents — beginning of period71,660 171,332 
Cash and cash equivalents — end of period$226,672 $169,489 
Supplemental Disclosures Noncash Investing and Financing Activities:
Operating lease right-of-use asset obtained in exchange for operating lease liability$1,846 $— 
Interest expense paid in cash$2,034 $1,094 
Additions of property and equipment included within accounts payable and other accrued liabilities$32 $44 
Deferred offering costs included within accounts payable and accrued liabilities$22 $— 
See accompanying notes to these unaudited condensed financial statements.
F-6
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)

1. DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS
Description of Business

Tarsus Pharmaceuticals, Inc. (“Tarsus” or the “Company”) is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, on August 24, 2023, after receiving United States ("U.S.") Food and Drug Administration ("FDA") approval on July 24, 2023.
Follow-On Public Offerings
On August 4, 2023, the Company completed a follow-on public offering under its shelf registration statement on Form S-3 that was declared effective by the SEC on November 5, 2021 of 5,714,285 shares of common stock at a public offering price of $17.50 per share (the "August 2023 Public Offering"). The aggregate net proceeds received by the Company were approximately $93.5 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses. The Company also granted the underwriters a 30-day option to purchase up to 857,142 additional shares of its common stock at the public offering price. On September 6, 2023, the underwriters partially exercised this option resulting in the Company's issuance of an additional 355,164 shares of common stock at the public offering price of $17.50 per share. The aggregate net proceeds received by the Company from the partially exercised option was approximately $5.8 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.

In connection with the August 2023 Public Offering, the Company terminated the prospectus (the “ATM Prospectus”) filed with Shelf Registration Statement, issuable pursuant to the terms of an Open Market Sale AgreementSM (the "Sales Agreement") dated November 1, 2021 by and between the Company and Jefferies LLC. The Company has not made any sales pursuant to the ATM Prospectus. Further, the Company will not make any sales of our common stock pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.
In May 2022, the Company completed a follow-on public offering under its Shelf Registration Statement for an initial underwritten sale of 5,600,000 shares of its common stock at the public offering price of $13.50 per share. The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of its common stock at the public offering price. In June 2022, the underwriters partially exercised this option and the Company's sale of an additional 289,832 shares at the public offering price of $13.50 per share was concurrently completed. Total aggregate net proceeds received by the Company were approximately $74.3 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.
Liquidity

The Company has a limited operating history, limited history of product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through proceeds from product sales, net, proceeds from its out-license agreement, equity capital raises; including the Company's initial public offering in 2020 and the follow-on public offerings completed in May 2022 and August 2023, and draws from its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q, which have been prepared on a going-concern basis.

Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its commercialization efforts, development programs, and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern.
F-7
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
Operating Segment
The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company’s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance.
Emerging Growth Company Status
The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES
Basis of Presentation
The Company’s Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023.
The interim Condensed Balance Sheet as of September 30, 2023, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022, and the Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.
The financial data and other information disclosed in these notes related to the three and nine-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and nine months ended September 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 or any other interim or annual period.

The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates.

The Company’s financial statements as of and for the three and nine months ended September 30, 2023, reflect the Company’s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an
F-8
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.

The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below.
Cash and Cash Equivalents

Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.
Marketable Securities and Long-Term Investments
Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see Note 3). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.
Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.

Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period.
Accounts Receivable, Net

Accounts receivable generally consists of amounts due from its customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended September 30, 2023.
Inventory

Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out (FIFO) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and
F-9
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY on July 24, 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred. The inventory balance as of September 30, 2023 consisted of finished goods.
Intangible Assets, Net
Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow. The carrying value of intangible assets as a result of commercial milestones was $4.0 million as of September 30, 2023, and will be amortized to cost of sales over its useful life of 10 years from the date of first commercial sale. Amortization expense for the three and nine months ended September 30, 2023 was not material (see Note 8). The Company had no intangible assets as of December 31, 2022.

As of September 30, 2023, the expected future amortization expense for the Company's intangible assets is as follows:

Amounts
2023 (remaining three months)$100 
2024400 
2025400 
2026400 
2027400 
Thereafter2,267 
Total future amortization$3,967 
Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the periods presented.
Fair Value Measurements
Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
F-10
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
•Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.
•Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.
•Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see Note 3).
Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.

Property and Equipment, Net

Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset’s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three and nine months ended September 30, 2023 and 2022.

Leases
The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (“ROU assets”) represent the Company’s right to control an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.

The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU asset and lease liability amounts presented in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.
Concentration Risk

Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"), a division of First Citizens Bank. These
F-11
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty.

Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.

Major Customers

The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. For the three months ended September 30, 2023, the Company's three largest customers accounted for 55%, 21% and 13% of product sales, respectively. As of September 30, 2023, amounts due from these three customers each exceeded 10% of gross accounts receivable and accounted for approximately 89% of the accounts receivable balance on a combined basis.

Major Suppliers

The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company entered into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than our existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company’s commercialization efforts.
Revenue Recognition
(i) Product Sales, Net

The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.

The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.

Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected
F-12
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Overall, these estimates reflect the Company’s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:

Distribution Service Fees: The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.

Prompt Pay Discounts: The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized.

Product Returns: The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it can not be resold.

Chargebacks: A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler’s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.

Co-payment Assistance: Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.

Rebates and Discounts: The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program. Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company’s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.
(ii) License Fees and Collaboration Revenue
    
F-13
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
China Out-License

License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")— see Note 9. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract’s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period.

The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.
The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payments for executing drug supply agreements; (vi) development milestone payments; and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.

Contractual Terms for Receipt of Payments

A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract’s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.

The contractual terms that establish the Company’s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows:

Upfront License Fees: The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.

Development Milestones: The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment.

F-14
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
Regulatory Milestones: The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.

Royalties: Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee’s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.

Sales Threshold Milestones: Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License.

The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur.

Other License Fees and Collaboration Revenue

License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service. Revenue recognized for the three and nine months ended September 30, 2023 was $0.2 million. No revenue was recognized under such arrangements for the three and nine months ended September 30, 2022.

Cost of Sales

Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company’s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY on July 24, 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss.
Research and Development Costs

Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The
F-15
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.

The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.
Stock-Based Compensation

The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company’s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.

Stock awards granted typically have one to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.
All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management’s judgment, including:
Fair Value of Common Stock — The fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant.
Expected Term — The Company’s expected term represents the period that the Company’s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history. 
Expected Volatility — Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.
F-16
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
Risk-Free Interest Rate — The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.
Dividend Yield — The Company’s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.
Net Loss per Share
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable.

Due to a net loss for the three and nine months ended September 30, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.
Comprehensive Loss
Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.
Recently Issued or Effective Accounting Standards
Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company’s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company’s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.
3. FAIR VALUE MEASUREMENTS
The table below summarizes certain financial instruments measured at fair value that are included within the accompanying Condensed Balance Sheets, and their designation among the three fair value measurement categories (see Note 2 - Fair Value Measurements):
F-17
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
 September 30, 2023
 Level 1Level 2Level 3Total
Assets:
Money market funds(1)
$226,672 $— $— $226,672 
U.S. Treasury securities7,494 — — 7,494 
Commercial paper— 6,964 — 6,964 
Corporate debt securities— 314 — 314 
Government-related debt securities— 5,441 — 5,441 
Common stock in LianBio210 — — 210 
Equity warrants (for LianBio shares)— — 73 73 
Total assets measured at fair value$234,376 $12,719 $73 $247,168 
(1) This balance includes cash requirements settled on a nightly basis.
 December 31, 2022
 Level 1Level 2Level 3Total
Assets:
Money market funds(1)
$64,685 $— $— $64,685 
U.S. Treasury securities69,644 — — 69,644 
Commercial paper— 60,355 — 60,355 
Corporate debt securities— 11,521 — 11,521 
Government-related debt securities— 10,821 — 10,821 
Common stock in LianBio371 — — 371 
Equity warrants (for LianBio shares)— — 108 108 
Total assets measured at fair value$134,700 $82,697 $108 $217,505 
(1) This balance includes cash requirements settled on a nightly basis.
Money Market Funds and U.S. Treasury Securities

Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.
Commercial Paper, Corporate Debt Securities and Government-related Debt Securities

Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.
LianBio Common Stock and Equity Warrants
In March 2021, contemporaneous with the China Out-License transaction (see Note 9), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (LianBio, a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first two tranches were vested and exercised as of December 31, 2022 and converted into 156,746 shares of LianBio common stock and were recognized at fair value within long-term investments in the Condensed Balance Sheets as of September 30, 2023 and December 31, 2022. LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price on the Nasdaq Global Market.
F-18
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
The third warrant tranche will vest upon the achievement of a regulatory event and is presented within other assets in the accompanying Condensed Balance Sheets as of September 30, 2023 and December 31, 2022. This warrant tranche remains classified as Level 3 in the fair value hierarchy. The most significant assumptions used in the option pricing valuation model as of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies); the probability of regulatory milestone achievement for vesting; and the application of an assumed discount rate.
The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:
Value of equity warrants
Fair value as of December 31, 2022$108 
Remeasurement of equity warrants(17)
Fair value as of March 31, 2023$91 
Remeasurement of equity warrants18 
Fair value as of June 30, 2023$109 
Remeasurement of equity warrants(36)
Fair value as of September 30, 2023$73 
Value of equity warrants
Fair value as of December 31, 2021$663 
Remeasurement of equity warrants(245)
Fair value as of March 31, 2022$418 
Recognition of equity warrants103 
Remeasurement of equity warrants(257)
Fair value as of June 30, 2022$264 
Remeasurement of equity warrants(18)
Fair value as of September 30, 2022$246 
F-19
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:
September 30, 2023
Amortized costUnrealized gainsUnrealized lossesEstimated fair value
Cash equivalents:
Money market funds(1)
$226,672 $— $— $226,672 
Total cash equivalents$226,672 $— $— $226,672 
Marketable securities:
U.S. Treasury securities$7,481 $17 $(4)$7,494 
Commercial paper6,966 — (2)6,964 
Corporate debt securities312 2 — 314 
Government-related debt securities5,446 — (5)5,441 
Total marketable securities$20,205 $19 $(11)$20,213 
Long-term investments:
Common stock in LianBio$1,108 $— $(898)$210 
Total long-term investments$1,108 $— $(898)$210 
(1) This balance includes cash requirements settled on a nightly basis.
December 31, 2022
Amortized costUnrealized gainsUnrealized lossesEstimated fair value
Cash equivalents:
Money market funds(1)
$64,685 $— $— $64,685 
Government-related debt securities4,978 — — 4,978 
Commercial paper1,997 — — 1,997 
Total cash equivalents$71,660 $— $— $71,660 
Marketable securities:
U.S. Treasury securities$69,720 $5 $(81)$69,644 
Commercial paper58,358 — — 58,358 
Corporate debt securities11,524 8 (11)11,521 
Government-related debt securities5,838 5 — 5,843 
Total marketable securities$145,440 $18 $(92)$145,366 
Long-term investments:
Common stock in LianBio$1,231 $— $(860)$371 
Total long-term investments$1,231 $— $(860)$371 
(1 )This balance includes cash requirements settled on a nightly basis.

As of September 30, 2023, substantially all available-for-sale debt securities had a maturity of 12 months or less. Two securities have a contractual maturity between one and two years, with an estimated fair market value of $0.3 million and amortized cost of $0.3 million. As of December 31, 2022, substantially all available-for-sale debt securities had a maturity of 12 months or less. Three securities had a contractual maturity between one and five years, with an estimated fair market value of $4.6 million and amortized cost of $4.6 million. As of September 30, 2023 and December 31, 2022, all available-for-sale debt
F-20
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
securities have gross unrealized losses in a continuous loss position for less than one year. As of September 30, 2023 and December 31, 2022, unrealized credit losses on these securities were not material, and accordingly, the Company did not recognize any other-than-temporary impairment losses.
4. BALANCE SHEET ACCOUNT DETAIL
The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below:
Property and Equipment, Net
Property and equipment, net consists of the following:
September 30, 2023December 31, 2022
Furniture and fixtures$1,149 $714 
Office equipment660 197 
Laboratory equipment167 167 
Leasehold improvements680 425 
Property and equipment, at cost2,656 1,503 
(Less): Accumulated depreciation and amortization1,042 546 
Property and equipment, net $1,614 $957 
Depreciation expense for the three months ended September 30, 2023 and 2022 was $0.2 million and $0.1 million, respectively, and for the nine months ended September 30, 2023 and 2022 was $0.5 million and $0.2 million, respectively.
Accounts Payable and Other Accrued Liabilities 
Accounts payable and other accrued liabilities consists of the following:
September 30, 2023December 31, 2022
Trade accounts payable and other$10,382 $5,498 
Accrued product sales deductions3,778 — 
Accrued clinical studies768 3,691 
Operating lease liability, current423 721 
Accounts payable and other accrued liabilities$15,351 $9,910 
5. STOCKHOLDERS’ EQUITY
Common Stock Outstanding and Reserves for Future Issuance
As of September 30, 2023 and December 31, 2022, the Company had 33.1 million and 26.7 million, respectively, of common stock issued and outstanding. Each share of common stock is entitled to one vote.
The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:
F-21
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
September 30, 2023December 31, 2022
Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans7,119,277 8,346,738 
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan2,893,305 2,663,319 
Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans4,737,575 3,899,342 
Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan1,739,693 551,258 
Total shares of common stock reserved16,489,850 15,460,657 

6. STOCK-BASED COMPENSATION
Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Cost of sales$31 $— $31 $— 
Research and development1,663 1,015 4,317 2,677 
Selling, general and administrative3,556 2,568 10,000 7,112 
Total stock-based compensation$5,250 $3,583 $14,348 $9,789 

The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Weighted average risk-free interest rate4.28 %3.20 %4.07 %2.22 %
Weighted average volatility72.6 %80.4 %71.7 %78.2 %
Expected term (in years)6.256.256.256.25
Dividend yield rate— %— %— %— %
Weighted-average grant-date fair value per stock option$17.23 $15.81 $15.43 $18.43 

Stock Option Activity

Stock option activity during the nine months ended September 30, 2023 was as follows:

F-22
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
Number of
Shares		Weighted-
Average
Exercise
Price/Share		Weighted-
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value(1)
Outstanding - December 31, 20223,899,342 $16.69 8.07$19,196 
Granted728,169 $15.07 
Exercised(6,443)$2.01 
Forfeited(24,654)$21.19 
Outstanding— March 31, 20234,596,414 $16.43 8.16$15,316 
Granted283,367 $15.55 
Exercised(16,118)$2.78 
Forfeited(144,514)$20.36 
Outstanding— June 30, 20234,719,149 $16.31 7.93$28,319 
Granted130,266 $17.23 
Exercised(109,627)$4.71 
Forfeited(2,213)$19.09 
Outstanding—September 30, 20234,737,575 $16.60 7.77$26,084 
Exercisable— September 30, 20232,471,190 $15.01 6.89$20,742 
Unvested—September 30, 20232,266,385 $18.33 8.74$5,342 
(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock as of September 30, 2023.

As of September 30, 2023, there was approximately $25.9 million of unrecognized compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of 2.2 years.

Restricted Stock Unit Activity

Restricted stock unit activity during the nine months ended September 30, 2023 was as follows:
Number of
Shares		Weighted-
Average
Exercise
Price/Share
Outstanding - December 31, 2022551,258 $17.78 
Granted647,768 $15.24 
Vested(66,611)$19.15 
Forfeited(4,042)$19.40 
Outstanding— March 31, 20231,128,373 $16.24 
Granted380,196 $15.67 
Vested(45,653)$14.04 
Forfeited(71,028)$15.84 
Outstanding— June 30, 20231,391,888 $16.17 
Granted373,244 $17.34 
Vested(25,439)$16.36 
Forfeited— $— 
Outstanding— September 30, 20231,739,693 $16.42 

As of September 30, 2023, there was approximately $24.7 million of unrecognized compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of 3.4 years.
7. NET LOSS PER SHARE
The following table sets forth the computation of basic and diluted net loss per share:
F-23
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net loss$(39,148)$(22,511)$(93,991)$(48,492)
Weighted-average shares outstanding—basic and diluted30,622,440 26,662,374 28,065,434 23,923,512 
Net loss per share—basic and diluted$(1.28)$(0.84)$(3.35)$(2.03)
The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:

As of September 30,
20232022
Stock options, unexercised—vested and unvested4,737,575 3,839,077 
Restricted stock units—unvested1,739,693 516,005 
Total6,477,268 4,355,082 


8. COMMITMENTS & CONTINGENCIES
Lease Agreements
In the ordinary course of business, the Company enters into lease agreements with unaffiliated third parties for its facilities and office equipment. As of September 30, 2023, the Company had five active leases for adjacent office and laboratory suites in Irvine, California. On May 1, 2023 the Company amended the existing facilities lease, extending the term for three years through January 31, 2027.
The below table summarizes the components of total lease expense:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Operating lease expense$179 $142 $525 $427 
Variable lease expense125 67 296 168 
Total lease expense$304 $209 $821 $595 
F-24
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
As of September 30, 2023, the Company's facility leases had a remaining lease term of 3.3 years and a weighted-average incremental borrowing rate of 10%.
The below table summarizes the (i) minimum lease payments over the next five years and thereafter, (ii) lease arrangement imputed interest, and (iii) present value of future lease payments:
Operating Leases - Future PaymentsSeptember 30, 2023
2023 (remaining three months)$226 
2024701 
2025789 
2026816 
202768 
Total future lease payments, undiscounted$2,600 
(Less): Imputed interest(381)
(Less): Tenant improvement allowance(129)
Present value of operating lease payments$2,090 
Operating lease liability, current423
Operating lease liability, noncurrent1,667 
Total operating lease liability$2,090 
In-License Agreements for Lotilaner

January 2019 Agreement for Skin and Eye Disease or Conditions in Humans
In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (“Elanco”) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.

In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone payment of $1.0 million was included in research and development expense in the accompanying Condensed Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2023.

The Company has made cash payments to Elanco under the Eye and Derm Agreement comprised of $1.0 million upfront upon contract execution in January 2019 and a total of $4.0 million for three specified clinical milestone achievements in September 2020, April 2021, and March 2023, which were all recorded in research and development expense in the Condensed Statements of Operations and Comprehensive Loss. During the three months ended September 30, 2023 a milestone of $4.0 million was achieved and paid to Elanco upon the first commercial sale of XDEMVY in the U.S., which was recorded as an intangible asset in the accompanying Condensed Balance Sheet as of September 30, 2023. The Company is amortizing the intangible asset to cost of sales over its useful life of 10 years from the date of the first commercial sale.

As of September 30, 2023, the Company is obligated to make further cash payments to Elanco of $2.0 million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $75.0 million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner.

In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license. As a result of the commercialization of XDEMVY, the Company
F-25
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
began accruing royalties payable to Elanco during the third quarter of 2023, which are recorded to cost of sales in the accompanying Condensed Statement of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and accounts payable and other accrued liabilities in the accompanying Condensed Balance Sheet as of September 30, 2023. Royalty expense during the three and nine months ended September 30, 2023 was $0.1 million.

September 2020 Agreement for All Other Diseases or Conditions in Humans

In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco 222,460 shares of its common stock with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).

The Company made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its product sales, net. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.

Employment Agreements
The Company has entered into employment agreements with seven of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.
Litigation Contingencies
From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.
Indemnities and Guarantees
The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.
9. OUT-LICENSE AGREEMENT
Out-License of TP-03 Commercial Rights in the China Territory in March 2021

In March 2021, the Company entered into the China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory, as defined in the agreement, for the treatment of Demodex blepharitis and Meibomian Gland Disease. LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.

The Company assessed this arrangement and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory; and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial (Saturn-1) and Phase 3 (Saturn-2) TP-03 trials. The promises to provide research and development services for
F-26
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.

The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $15.0 million; (ii) a second cash payment of $10.0 million; (iii) a $10.0 million milestone that was determined to be within the control of the Company; and (iv) $1.2 million representing the initial fair value of the equity warrant.

The Company accounted for each performance obligation as follows:

Out-License

The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.

Research and Development Services

The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 within license fees and collaboration revenue as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.

In February 2023, a specified milestone event was triggered resulting in $2.5 million recognized as license fees and collaboration revenue in the accompanying Condensed Statements of Operations for the nine months ended September 30, 2023. This cash payment was received in the second quarter of 2023. Through September 30, 2023, the Company received aggregate payments from LianBio totaling $82.5 million, comprised of initial consideration of $15.0 million and $67.5 million for the achievement of specified milestones.
As of September 30, 2023 the Company is eligible to receive further consideration from LianBio upon the achievement of additional TP-03 events, including: (i) additional regulatory milestones and one-time payments of up to an aggregate of $22.5 million; (ii) China-Based TP-03 sales threshold milestone payments of up to an aggregate of $100.0 million; (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales; and (iv) vesting of a LianBio equity warrant upon certain regulatory milestones.
As part of the China Out-License with LianBio the Company granted Elanco an additional 187,500 shares of the Company's common stock that otherwise would have been issuable no later than the 18-month anniversary of the All Human Uses Elanco Agreement for its continued license exclusivity. These issued shares were valued at $5.5 million, based on the Company's closing stock price of $29.30 per share on the date this issuance became contractually required.

The Company made a contractual payment in the amount of $2.5 million to Elanco following the receipt of $25 million of proceeds from LianBio during the second quarter of 2021. During the fourth quarter of 2022, the Company recognized $0.4 million of cost of license fees and collaboration revenue upon receipt of $10 million of cash proceeds from LianBio for the achievement of a clinical development milestone.

The expenses recognized under the China-Out License were not material for the three and nine months ended September 30, 2023 and 2022.

F-27
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)
10. CREDIT FACILITY AGREEMENT

On February 2, 2022, the Company executed the Credit Facility with Hercules Capital, Inc. ("Hercules") and SVB that expires on February 2, 2027. Concurrent with the execution of the Credit Facility, the Company made a $20.0 million draw.

On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to draw down the $25.0 million tranche associated with the New Drug Application ("NDA") submission, from March 15, 2023 to March 15, 2024, provided at least $5.0 million was drawn on or before March 15, 2023 and at least an additional $5.0 million is drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment.

On March 15, 2023 and September 15, 2023, respectively, the Company made separate draws of $5.0 million (including SVB's commitment of $1.25 million) from the $25.0 million tranche that became available upon submission of the NDA. As of September 30, 2023, the Credit Facility provides for a remaining aggregate principal amount of up to $125.0 million with tranched availability as follows: $15.0 million currently available related to the Company's NDA submission with the FDA for TP-03 in September 2022; $35.0 million currently available due to the FDA approval of XDEMVY on July 24, 2023; $50.0 million available upon achievement of product sales, net thresholds; and $25.0 million available upon lender approval.

Each of these tranches may be drawn down in $5.0 million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.

Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 4.45% with an aggregate cap of 11.45%, or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and increased to 8.50% as of September 30, 2023.

The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.4 million was derived by multiplying 4.75% by the $30.0 million outstanding principal balance as of September 30, 2023 and is accreted to interest expense through maturity.

As of September 30, 2023 and 2022, the effective interest rate for the full term of the Credit Facility was 11.96% and 12.37%, respectively.

During the three and nine months ended September 30, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Interest expense for term loan$757 $539 $2,083 $1,275 
Accretion of end of term charge68 48 184 127 
Amortization of debt issuance costs33 46 90 105 
Total interest expense related to term loan$858 $633 $2,357 $1,507 

The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:
F-28
TARSUS PHARMACEUTICALS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)
(Unaudited)

September 30, 2023December 31, 2022
Term loan, gross$30,000 $20,000 
Debt issuance costs(875)(875)
Accretion of end of term charge358 174 
Accumulated amortization of debt issuance costs225 135 
Term loan, net $29,708 $19,434 

11. RELATED PARTY TRANSACTIONS
Consulting Agreements

The Company has a preexisting consulting agreement with a board member who was appointed in December 2021. This Consulting Agreement provides for annual cash compensation of approximately $0.2 million and option grants to purchase 45,134 shares of the Company’s common stock, with exercise prices ranging from $2.01 to $34.72 per share. This Consulting Agreement may be terminated by either party with ten days' notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.
Sponsorship Activities
In May 2023, a board member of the Company was appointed president of the American Society of Cataract and Refractive Surgery ("ASCRS"), a society dedicated to meeting the needs of anterior segment ophthalmic surgeons.
During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.4 million, respectively, of selling, general and administrative expenses in the accompanying Condensed Statement of Operations and Comprehensive Loss for sponsorship and event-related activities associated with ASCRS.
F-29
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, future revenue, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
The words “anticipate,” “believe,” contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements. Factors that may cause actual results to differ from expected results, include, among others:
•our ability to successfully commercialize XDEMVY®, formerly known as TP-03, for the treatment of Demodex blepharitis;
•the prevalence of Demodex blepharitis and the size of the market opportunity for XDEMVY;
•our plans relating to commercializing XDEMVY and our product candidates, if approved, including commercialization timelines and sales strategy;
•any statements regarding our ability to achieve distribution and patient access for our products including XDEMVY and timing and breadth of payer coverage; our expectations of the potential market size, pricing, gross-to-net yields, eye care provider and patient acceptance of our product candidates, opportunity and patient populations for our product candidates, including XDEMVY; our sales force size and hiring plans;
•the rate and degree of market acceptance and clinical utility of XDEMVY and our product candidates;
•the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates, and other positive results;
•the timing and progress of our current clinical trials and timing of initiation of our future clinical trials, and the reporting of data from our current and future trials;
•the timing or likelihood of regulatory filings and approval for our product candidates and our ability to meet existing or future regulatory standards or comply with post-approval requirements;
•our plans relating to the clinical development of our current and future product candidates, including the size, number and disease areas to be evaluated;
•the impact of health epidemics on our business and operations;
•the impact of unfavorable global and geopolitical economic conditions on our business and operations;
•the success of competing therapies that are or may become available;
•our estimates of the number of patients in the United States ("U.S.") or globally, as applicable, who suffer from Demodex blepharitis, Meibomian Gland Disease ("MGD"), rosacea, Lyme disease and malaria and the number of patients that will enroll in our clinical trials;
•the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of our product candidates;
•our ability to obtain and maintain regulatory approval of our product candidates and our product candidates to meet existing or future regulatory standards;
•our plans relating to the further development and manufacturing of our product candidates, including additional indications for which we may pursue;
•our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;
•the expected potential benefits of strategic collaborations with third parties (including, for example, the receipt of payments, achievement and timing of milestones under license agreements, and the ability of our third-party collaborators to commercialize our product candidates in the territories under license) and our ability to attract collaborators with development, regulatory and commercialization expertise;
•existing regulations and regulatory developments in the U.S. and other jurisdictions;
30
•our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;
•our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;
•the need to hire additional personnel and our ability to attract and retain such personnel;
•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
•our financial performance;
•the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;
•our competitive position;
•our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and
•our anticipated use of our existing resources and the proceeds from our Initial Public Offering (“IPO”), our subsequent follow-on public offerings in May 2022 (the "May 2022 Public Offering") and August 2023 (the "August 2023 Public Offering", together with the May 2022 Public Offering, the “Follow-On Public Offerings”), and draw-downs from our loan and security agreement with Hercules Capital, Inc. ("Hercules") and Silicon Valley Bank ("SVB") (the "Credit Facility").

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and growth prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled “Risk Factors” elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.
You should read this report and the documents that we reference in this report and have filed with the SEC as exhibits to this report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.
Overview
Our Business
We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Our lead product, XDEMVY (lotilaner ophthalmic solution) 0.25% was approved by the U.S. Food and Drug Administration ("FDA") on July 24, 2023 for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis ("Blephar" is a reference to eyelid and “itis” is a reference to inflammation) is an ophthalmic lid margin disease characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. Poorly controlled and progressive blepharitis can lead to corneal damage over time and, in extreme cases, blindness. There are an estimated 25 million people in the U.S. who suffer from Demodex blepharitis. XDEMVY is the first and only therapeutic approved by the FDA and we believe is the definitive standard of care for the treatment of Demodex blepharitis.

31
We designed XDEMVY to target and eradicate the root cause of Demodex blepharitis — Demodex mite infestation. The active pharmaceutical ingredient ("API") of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride ("GABA-Cl") channels.

To date, we have completed seven clinical trials that include a Phase 3 Saturn-2 trial, a Phase 2b/3 Saturn-1 trial, four Phase 2 trials, and a Phase 1 trial for XDEMVY in Demodex blepharitis, all of which met their primary, secondary and/or certain exploratory endpoints, with the drug well tolerated throughout each trial.

We intend to further advance our pipeline with the lotilaner API to address several diseases across therapeutic and/or prophylactic categories in human medicine, including eye care, dermatology, and other diseases. We are investigating the development of product candidates to address targeted diseases with high unmet medical needs, which currently include TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Recent Business and Clinical Highlights

XDEMVY was approved by the FDA on July 24, 2023, as the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root cause of Demodex blepharitis and in pivotal trials demonstrated significant improvement in eyelids (reduction of collarettes, the pathognomonic sign of the disease, to no more than two collarettes per upper lid), mite eradication (mite density of zero mites per lash) and erythema cure (grade zero).

•We launched XDEMVY on August 24, 2023 with our targeted sales force and recognized $1.7 million in product sales, net during the third quarter of 2023

•Active disease education is continuing to drive awareness and encouraging eye care providers ("ECPs") to proactively diagnose Demodex blepharitis

•We actively engaged in contracting discussions with all the key commercial and Medicare accounts and we are on track to potentially secure commercial coverage sequentially throughout 2024 and Medicare coverage in 2025

•We presented additional Saturn-2 pivotal data at the American Academy of Optometry and the American Academy of Ophthalmology further demonstrating XDEMVY as the standard of care for Demodex blepharitis

•The American Academy of Ophthalmology added XDEMVY as the first and only FDA-approved therapeutic for the treatment of Demodex blepharitis in their Preferred Practice Patterns (PPP) guidelines

TP-03 Meibomian Gland Disease, Ersa Trial: In August 2022, we announced the enrollment of our first patient in the Phase 2a Ersa clinical trial studying TP-03 for the treatment of MGD. We expect topline availability during the fourth quarter of 2023.

TP-04 Rosacea, Galatea Trial: In March 2023, we initiated the Galatea trial, a Phase 2a trial evaluating TP-04, a novel gel formulation of lotilaner, for the treatment of rosacea. We expect topline availability in the first quarter of 2024.

TP-05 Lyme Disease, Callisto and Carpo Trials: In December 2022, we announced positive topline results from the completed Phase 1 Callisto trial and enrollment of the first patient in the Phase 2a Carpo trial. The Carpo trial is designed to evaluate TP-05, a novel investigative oral, non-vaccine pharmacological prophylactic for the potential prevention of Lyme disease. The Carpo trial, evaluating TP-05 for the potential prevention of Lyme disease in humans, is a randomized, double-blind trial that will evaluate the efficacy of TP-05 in killing lab grown, non-disease carrying ticks after they have attached to the skin of healthy volunteers, as well as confirm the safety, tolerability, and blood concentration of TP-05. Given enrollment delays, we now expect topline availability from the Phase 2a Carpo trial during the first quarter of 2024.

We believe TP-05 is currently the only non-vaccine, drug-based prophylaxis in development that targets ticks, and potentially prevents Lyme disease transmission. It is designed to rapidly and durably provide systemic blood levels of lotilaner potentially sufficient to kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease.

TP-03 China Territory Out-License: In March 2021, we executed an out-license agreement (the "China Out-License") with LianBio Ophthalmology Limited ("LianBio"), granting exclusive commercial rights to TP-03 for the treatment
32
of Demodex blepharitis and MGD within The People’s Republic of China, Macau, Hong Kong, and Taiwan (the "China Territory").

In February 2023, a specified milestone was triggered resulting in $2.5 million recognized as license fees and collaboration revenue in the accompanying Condensed Statements of Operations for the nine months ended September 30, 2023. This cash payment was received during the second quarter of 2023. As of the date of this filing, we have received aggregate contractual cash proceeds from LianBio of $82.5 million, representing initial consideration of $15.0 million and $67.5 million for the achievement of specified milestone events. We also received equity in LianBio as part of this China Out-License, a portion of which remains subject to a China-based regulatory vesting provision.

Corporate and Financial Overview
We were incorporated as a Delaware corporation in November 2016, and our headquarters are located in Irvine, California. Since our inception, we have devoted substantially all of our resources to organizing and staffing our company, acquiring intellectual property, clinical development of our product candidates, building our research and development capabilities, raising capital, and enhancing our corporate infrastructure.
To date we have financed our operations through private placements of preferred stock, convertible promissory notes, net proceeds from issuance of common stock in our IPO and our Follow-On Public Offerings, proceeds from product sales, net proceeds from our China Out-License, and draw-downs from the Credit Facility.
We have incurred significant net operating losses in every year since our inception and expect to continue to incur significant operating expenses as we commercialize XDEMVY for Demodex blepharitis and as we advance our other product candidates through clinical trials, regulatory submissions, and potential commercialization. Our net loss was $39.1 million and $22.5 million for the three months ended September 30, 2023 and 2022, respectively, and $94.0 million and $48.5 million for the nine months ended September 30, 2023 and 2022, respectively. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. We anticipate that our operating expenses will increase significantly as we:
•commercialize XDEMVY and our other products for which we obtain regulatory approvals;
•maintain regulatory approval for XDEMVY and seek regulatory approval for our other product candidates that successfully complete clinical development, if any;
•advance the clinical development of TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for potential Lyme prophylaxis;
•engage with contract manufacturers to ensure a sufficient supply chain capacity to provide commercial quantities of XDEMVY and any other products for which we may obtain marketing approval;
•maintain, expand and protect our intellectual property portfolio;
•hire additional staff, including clinical, scientific, technical, regulatory, marketing, operations, financial, and other support personnel, to execute our business plan; and
•add information systems and personnel to support our product development and commercialization efforts, and to enable us to operate as a public company.
We began generating product sales, net during the three months ended September 30, 2023 following the FDA approval of XDEMVY in July 2023 and our subsequent commercial launch in August 2023. Our reported revenue within license fees and collaboration revenue is from our China Out-License and clinical supply agreement; we expect to report additional revenue under this caption in future periods.
Until such time as we can generate significant revenue from product sales, net and achieve profitability, if ever, we expect to finance our operations through private or public equity or debt financings, or collaborations, strategic alliances, or licensing arrangements with third parties. Adequate funding may not be available to us when needed on acceptable terms, or at all. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital or enter into such
33
agreements as and when needed, we could be forced to significantly delay, scale back, or discontinue our product development and/or commercialization plans, which would negatively and adversely affect our financial condition.
Because of the numerous risks and uncertainties associated with drug product development and commercialization, we are unable to accurately forecast the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate significant revenue from product sales, net we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels.
As of September 30, 2023, our aggregate cash, cash equivalents and marketable securities was $246.9 million – see the section below titled “Management's Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources.”
Impact of the Macroeconomic Environment
Recently, the economy has experienced downward pressure, and together with high rates of inflation and energy supply issues experienced in certain regions, war and geopolitical conflicts, have led to regional and/or global macroeconomic challenges, the effects of which may be of an extended duration.
In addition, we may be exposed to credit risk on deposits at financial institutions to the extent our account balances exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”). We maintain cash held in deposit at financial institutions in the U.S., including SVB, a division of First Citizens Bank. While these deposits are insured by the FDIC in an amount up to $250,000 for any depositor, to the extent we hold cash deposits in amounts that exceed the FDIC insurance limitation, we may incur a loss in the event of a failure of any of the financial institutions where we maintain deposits. We invest our excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. We believe the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions.
See the section titled Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 17, 2023 and in this Quarterly Report, for a further discussion of the potential adverse impact of unfavorable global and geopolitical economic conditions on our business, results of operations and financial condition.
Results of Operations
Comparison of the Three Months Ended September 30, 2023 and 2022
The following table summarizes our results of operations:

34
 Three Months Ended September 30,Change
 20232022
 (in thousands)
Revenues:
Product sales, net$1,653 $— *
License fees and collaboration revenue218 — *
Total revenues1,871 — *
Operating expenses:
Cost of sales377 — *
Research and development12,105 10,912 1,193 
Selling, general and administrative30,324 11,994 18,330 
Total operating expenses42,806 22,906 19,900 
Loss from operations before other income (expense) and income taxes(40,935)(22,906)(18,029)
Other income (expense):
Interest income2,840 1,061 1,779 
Interest expense(858)(633)(225)
Other expense, net(48)(7)(41)
Unrealized loss on equity investments(111)(13)(98)
Change in fair value of equity warrants issued by licensee(36)(18)(18)
Total other income, net 1,787 390 1,397 
Benefit from income taxes— 5 (5)
Net loss$(39,148)$(22,511)$(16,637)
* Not meaningful for further disclosure.
Product Sales, Net
During the three months ended September 30, 2023, in conjunction with the launch of our first FDA approved product, XDEMVY, we recognized revenue of $1.7 million from product sales, net of rebates, chargebacks, discounts, and other adjustments. During the three months ended September 30, 2022, there were no product sales, net recognized.
License Fees and Collaboration Revenue
For the three months ended September 30, 2023, we recognized $0.2 million of license fees and collaboration revenue from the satisfaction of performance obligations under an existing clinical supply agreement. No revenue was recognized under such arrangements for the three months ended September 30, 2022.
No revenue was recognized under the China Out-License arrangement for the three months ended September 30, 2023 and 2022. We will recognize additional license fees and collaboration revenue under the China Out-License to the extent other events occur, specifically related to (i) milestone achievement of an additional drug supply agreement execution, (ii) milestone achievement of certain regulatory events in the China Territory, and (iii) royalties and milestones from our licensee's product sales of TP-03 in the China Territory.
Cost of Sales

For the three months ended September 30, 2023, we recognized $0.4 million in cost of sales for XDEMVY. Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, and freight-in, as well as third-party royalties payable on our product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses. Therefore, cost of sales of XDEMVY will reflect a lower average per unit cost until the related inventory is sold. During the three months ended September 30, 2022, there were no cost of sales recognized.

Cost of License Fees and Collaboration Revenue
35
For the three months ended September 30, 2023 and 2022, we did not recognize any cost of license fees and collaboration revenue.
Research and Development Expenses
Three Months Ended September 30,Change
20232022
Direct external expenses:
TP-03 program$3,070 $4,937 $(1,867)
TP-04 program590 759 (169)
TP-05 program1,001 972 29 
Other early-stage programs199 — 199 
Indirect expenses:
Compensation and personnel-related 6,549 3,736 2,813 
Other696 508 188 
Total research and development expenses$12,105 $10,912 $1,193 
Research and development expenses increased by $1.2 million for the three months ended September 30, 2023, as compared to the prior year period. This increase was primarily due to $2.8 million of increased payroll and personnel-related costs (including increased stock-based compensation expense of $0.6 million) and $0.2 million of other indirect expenses related to 25 employee additions period over period to drive our product development initiatives. These increases were partially offset by $1.9 million of decreased program spend for TP-03 primarily due to a reduction in clinical trial expenses of $1.4 million given the completion of our Saturn-2 trial in the first half of 2022 and reduced preclinical expenses of $0.2 million.
Selling, General and Administrative Expenses

Selling, general and administrative expenses increased by $18.3 million for the three months ended September 30, 2023, as compared to the prior year period. The increase was primarily due to (i) $7.9 million of increased payroll and personnel-related costs (including increased stock-based compensation expense of $1.0 million) for 130 corporate employee additions, period over period, to support our business growth and commercial leadership hires for our recent commercial launch of XDEMVY, (ii) $8.1 million of increased commercial and market research costs as we continued our commercial expansion and prepared for the recent commercial launch of XDEMVY, (iii) $1.5 million of increased IT applications, legal and other professional expenses to support the continued growth and expansion of our corporate infrastructure, and (iv) $0.8 million of increased facilities and office and administrative expenses. We expect sales and marketing headcount and associated vendor expenses to meaningfully increase during 2023 due to our commercial launch and related activities for XDEMVY.
Other Income, Net

Other income, net increased by $1.4 million primarily due to $1.8 million of increased interest income earned on our cash, cash equivalents and marketable securities, partially offset by (i) $0.1 million change in fair value of the LianBio common stock and (ii) increased interest expense of $0.2 million on the Credit Facility.
Benefit from Income Taxes
We maintain a valuation allowance against our net deferred tax assets as of September 30, 2023 and 2022 due to the uncertainty that such assets will be realized. We evaluate the recoverability of our deferred tax assets on at least an annual basis.
Comparison of the Nine Months Ended September 30, 2023 and 2022
The following table summarizes our results of operations:
36
Nine Months Ended September 30,Change
20232022
(in thousands)
Revenues:
Product sales, net$1,653 $— *
License fees and collaboration revenue2,718 15,816 (13,098)
Total revenues4,371 15,816 (11,445)
Operating expenses:
Cost of sales377 — *
Cost of license fees and collaboration revenue— 555 (555)
Research and development37,007 32,596 4,411 
Selling, general and administrative65,695 30,316 35,379 
Total operating expenses103,079 63,467 39,612 
Loss from operations before other income (expense) and income taxes(98,708)(47,651)(51,057)
Other income (expense):
Interest income7,359 1,372 5,987 
Interest expense(2,357)(1,507)(850)
Other (expense) income, net(89)136 (225)
Unrealized loss on equity investments(161)(326)165 
Change in fair value of equity warrants issued by licensee(35)(520)485 
Total other income (expense), net4,717 (845)5,562 
Benefit from income taxes— 4 (4)
Net loss$(93,991)$(48,492)$(45,499)
* Not meaningful for further disclosure.
Product Sales, Net
During the nine months ended September 30, 2023, due to the launch of our first FDA approved product, XDEMVY, we recognized revenue of $1.7 million from product sales, net of rebates, chargebacks, discounts, and other adjustments. During the nine months ended September 30, 2022, there were no product sales, net recognized.
License Fees and Collaboration Revenue
For the nine months ended September 30, 2023 and 2022, we recognized $2.5 million and $15.8 million, respectively, of license fees and collaboration revenue primarily attributable to contractual milestones under the China Out-License. These amounts represent the contractual milestones achieved or allocated under the China Out-License that have been fully or partially completed by the period end. These allocated amounts represented the satisfaction of the transfer of license rights to LianBio and the completion of related performance obligations.
We will recognize additional license fees and collaboration revenue under the China Out-License to the extent other events occur, specifically related to (i) milestone achievement of an additional drug supply agreement execution, (ii) milestone achievement of certain regulatory events in the China Territory, and (iii) royalties and milestones from our licensee's product sales of TP-03 in the China Territory.
For the nine months ended September 30, 2023, we recognized $0.2 million of other license fees and collaboration revenue from the satisfaction of performance obligations under an existing clinical supply agreement. No revenue was recognized under such arrangement for the nine months ended September 30, 2022.
Cost of Sales
For the nine months ended September 30, 2023, we recognized $0.4 million in cost of sales of XDEMVY. Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, and freight-in, as well as third-party royalties payable on our product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses. Therefore, cost of sales of
37
XDEMVY will reflect a lower average per unit cost until the related inventory is sold. For the nine months ended September 30, 2022, there were no cost of sales recognized.
Cost of License Fees and Collaboration Revenue
For the nine months ended September 30, 2023, we did not recognize any cost of license fees and collaboration revenue. Cost of license fees and collaboration revenue for the nine months ended September 30, 2022 was $0.6 million. This amount relates to our contractual payment obligations to Elanco, in proportion to our recognized license fees and collaboration revenue under the China Out-License arrangement in the same period.
Research and Development Expenses
Nine Months Ended September 30,Change
20232022
Direct external expenses:
TP-03 program$10,423 $17,130 $(6,707)
TP-04 program1,986 2,912 (926)
TP-05 program4,159 2,032 2,127 
Other early-stage programs379 88 291 
Indirect expenses:
Compensation and personnel-related17,656 9,257 8,399 
Other1,404 1,177 227 
Elanco milestone expenses1,000 — 1,000 
Total research and development expenses$37,007 $32,596 $4,411 
Research and development expenses increased by $4.4 million for the nine months ended September 30, 2023, as compared to the prior year period. The increase was primarily due to (i) $8.4 million of increased indirect expenses related to payroll and personnel-related costs (including increased stock-based compensation expense of $1.6 million) for 25 employee additions period over period to drive our product development initiatives, (ii) $1.0 million of milestone expense related to our in-license agreement with Elanco, (iii) $2.1 million of increased TP-05 program expenses primarily related to the Phase 2a Carpo trial initiated in December 2022 and the new food effect study initiated during the first quarter of 2023, and (iv) $0.3 million of increased spend related to other early-stage programs. These increases were partially offset by decreases in direct external spend for the TP-03 and TP-04 programs of $6.7 million and $0.9 million, respectively. The decrease in our TP-03 program expenses was primarily due to significantly reduced clinical trial costs of $7.0 million given the completion of our Saturn-2 trial in the first half of 2022, partially offset by $0.6 million of clinical trial expenses related to the Phase 2a Ersa clinical trial studying TP-03 for the treatment of MGD. The decrease in our TP-04 program expenses were primarily due to $1.4 million of decreased preclinical expenses, partially offset by $0.7 million of increased clinical trial expenses related to the Galatea trial.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased by $35.4 million for the nine months ended September 30, 2023, as compared to the prior year period. The increase was primarily due to (i) $16.0 million of increased payroll and personnel-related costs (including increased stock-based compensation expense of $2.9 million) for 130 corporate employee additions period-over-period to support our business growth and commercial leadership hires for our recent commercial launch of XDEMVY, (ii) $0.9 million of severance costs related to our former Chief Financial Officer's separation from the Company in June 2023, (iii) $14.6 million of increased commercial and market research costs as we continued our commercial expansion and prepared for the recent commercial launch of XDEMVY, (iv) $2.6 million of increased IT applications, legal and other professional expenses to support the continued growth and expansion of our corporate infrastructure, and (v) $1.3 million of increased facilities and office and administrative expenses. We expect sales and marketing headcount and associated vendor spend to meaningfully ramp during 2023 due to our commercial launch and related activities for XDEMVY.
Other Income (Expense), Net
Other income (expense), net increased by $5.6 million primarily due to (i) $6.0 million of increased interest income earned on our cash, cash equivalents and marketable securities, (ii) $0.5 million change in estimated fair value of the LianBio equity warrants we received as part of our China Out-License in March 2021, and (iii) $0.2 million change in fair value of the
38
LianBio common stock. These increases to other income were partially offset by increased interest expense of $0.9 million on the Credit Facility.
Benefit from Income Taxes
We maintain a valuation allowance against our net deferred tax assets as of September 30, 2023 and 2022 due to the uncertainty that such assets will be realized. We evaluate the recoverability of our deferred tax assets on at least an annual basis.
Liquidity and Capital Resources
Sources of Liquidity
Overview
Since our inception, we have financed our operations substantially through private placements of preferred stock, net proceeds from issuance of common stock through our IPO and Follow-on Public Offerings, proceeds from product sales, net, proceeds from our China Out-License, and draw-downs from our Credit Facility. As of September 30, 2023, we had cash, cash equivalents and marketable securities of $246.9 million.
IPO and Follow-On Public Offerings
In connection with our October 2020 IPO, we sold 6,325,000 shares of our common stock (inclusive of the full exercise of the underwriters’ option to purchase 825,000 shares of common stock). After deducting underwriting discounts, commissions and other related expenses, our IPO proceeds were $91.7 million.
In May 2022, we completed a Follow-On Public Offering. We also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. In June 2022, the underwriters partially exercised their option to purchase an additional 289,832 shares of common stock at the offering price of $13.50 per share, before underwriting discounts and commissions. After giving effect to the exercise of the underwriters’ option, we sold 5,889,832 shares for net proceeds received of $74.3 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.
On August 4, 2023, we completed a Follow-On Public Offering of 5,714,285 shares of common stock at an offering price of $17.50 per share. The aggregate net proceeds received were approximately $93.5 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses. We also granted the underwriters a 30-day option to purchase up to 857,142 additional shares of our common stock at the public offering price. On September 6, 2023, the underwriters partially exercised this option and the sale of an additional 355,164 shares at the public offering price of $17.50 per share was concurrently completed. We received $5.8 million of aggregate net proceeds, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.
China Out-License
As of the date of this filing, we have received $82.5 million of total proceeds in connection with our China Out-License. We expect to receive an additional $2.5 million during the first half of 2024 for the achievement of a specific milestone, for expected cumulative milestone receipts of $85.0 million through December 2024. The remaining $120.0 million of available milestones under this arrangement will potentially be received upon future regulatory and sales achievements all within the China Territory.
Credit Facility
In February 2022, we executed the Credit Facility with Hercules and SVB. Capital draws are at our election and are in $5.0 million increments. Concurrent with the execution of the Credit Facility we drew $20.0 million. This Credit Facility was amended in January 2023. The Credit Facility, as amended, set a maximum interest rate, updated the terms of prepayment under the Credit Facility and includes an extended period to draw down the tranche associated with the NDA submission, from March 15, 2023 to March 15, 2024 provided at least $5.0 million was drawn on or before March 15, 2023 and at least an additional $5.0 million was drawn on or before September 15, 2023. On March 15, 2023 and September 15, 2023, respectively, we made draws of $5.0 million (including SVB's commitment of $1.25 million) from the $25.0 million tranche associated with the NDA submission of TP-03. The Credit Facility includes four-year period of interest-only payments and is extendable for a fifth year
39
to February 2027 maturity, upon our expected achievement of required conditions. We currently have no other financing commitments, such as lines of credit or guarantees.

As of the date of this filing, we have $125.0 million of tranched availability as follows:

• $15.0 million, which became available in September 2022 upon our NDA submission of TP-03 to the FDA;
• $35.0 million, which became available in July 2023 upon FDA approval of XDEMVY;
• $50.0 million available upon achievement of certain quarterly revenue thresholds; and
• $25.0 million available with lender approval.
Funding Requirements
Liquidity
Our operating expenditures currently consist of cost of sales, research and development costs (including activities within our preclinical, clinical, regulatory, and drug manufacturing initiatives) and selling, general and administrative costs. Our use of cash is impacted by the timing and extent of payments for each of these activities and other business requirements. We have incurred significant losses and negative cash flows from operations since our inception and had an accumulated deficit of $202.8 million as of September 30, 2023.
As of September 30, 2023, we had cash, cash equivalents and marketable securities of $246.9 million. We received aggregate net proceeds of approximately $99.4 million from the August 2023 Public Offering. We anticipate having at least $50.0 million of available capital from our Credit Facility through March 2024 and an additional $75.0 million of additional tranched availability through December 2024. The Credit Facility requires interest-only debt service payments that are expected to remain through its maturity in February 2027 and its remaining tranches are subject to undrawn expiry in either March 2024 or December 2024 (see Note 10).
We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our current and planned operations for at least the next twelve months from the date of this filing on Form 10-Q. Our cash runway estimate is predicated on current assumptions for future revenue, operating expenses, and debt availability and may require future adjustments. Accordingly, we may be required to raise additional capital earlier than we currently expect based on our cash requirements and market dynamics.
Shelf Registration Statement

On November 1, 2021, we filed a shelf registration statement on Form S-3 that was declared effective by the SEC on November 5, 2021 (the “Shelf Registration Statement”), which permitted us to offer up to $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time. We have approximately $120 million remaining under our Shelf Registration Statement, after giving effect to the Follow-On Public Offerings (and exclusive of the sales agreement prospectus described below). Our Shelf Registration Statement is intended to provide us with additional flexibility to access capital markets for general corporate expenses and acquisitions of complementary products, technologies, or businesses. We completed the Follow-On Public Offering under this Shelf Registration Statement.

Also, as part of this Shelf Registration Statement, we concurrently filed a sales agreement prospectus covering the sale of up to $100.0 million of our common stock pursuant to an Open Market Sale AgreementTM (the “ATM Agreement”) with Jefferies LLC. Through the date of this filing, we have not sold any shares of our common stock under the ATM Agreement. On July 31, 2023, in connection with the August 2023 Public Offering, we terminated the sales agreement prospectus relating to the ATM.

Other Liquidity Risks
We expect to incur significant operating losses for the foreseeable future, and expect these losses to further increase, as we expand our clinical development programs for our other product candidates and given the recent commercial launch of XDEMVY. We may also encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business.
We may require additional capital to fully develop our product candidates and to execute our business strategy. Our requirements of a future capital raise will depend on many factors, including:
40
•the amount of revenue, if any, received from commercial sales of XDEMVY or our product candidates, should any of our product candidates receive marketing approval;
•the cost and timing associated with commercializing XDEMVY or our product candidates, if they receive marketing approval;
•the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;
•the number and scope of clinical programs we decide to pursue;
•the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;
•the scope and costs of development and commercial manufacturing activities;
•the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time and availability of our Credit Facility;
•the extent to which we acquire or in-license other product candidates and technologies;
•the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
•our ability to establish and maintain collaborations on favorable terms, if at all;
•our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;
•our implementation of various computerized information systems;
•impact of health epidemics on our clinical development or operations; and
•the costs associated with being a public company.
A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.
Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially and adversely affect our business and financial prospects. See the section titled “Risk Factors” in this report for additional risks associated with our substantial capital requirements.
41
Summary Statements of Cash Flows
The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below:
 Nine Months Ended
September 30,
 20232022
 (in thousands)
Net cash provided by (used in) provided by:
Operating activities$(78,158)$(38,156)
Investing activities122,754 (57,410)
Financing activities110,416 93,723 
Net increase (decrease) in cash and cash equivalents$155,012 $(1,843)

Net Cash Used in Operating Activities
Net cash used in operating activities was $78.2 million for the nine months ended September 30, 2023, which primarily consisted of our net loss of $94.0 million partially offset by stock-based compensation of $14.3 million. For the nine months ended September 30, 2023, our cash payments for operating activities primarily consisted of $54.9 million related to vendors and $30.8 million for payroll-related activities (inclusive of 2022 bonus payouts).

Net cash used in operating activities was $38.2 million for the nine months ended September 30, 2022. We recognized $15.8 million of license fees and collaboration revenue in connection with our China Out-License of which we received $15.0 million in June 2022. In the prior year period, our cash payments for operating activities included: (i) $38.4 million related to vendors (ii) $14.0 million for payroll-related activities (inclusive of 2021 bonus payouts), and (iii) $1.8 million to our lotilaner licensor as required by our in-license agreements.

Net Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities was $122.8 million for the nine months ended September 30, 2023, and primarily relates to $156.9 million of proceeds from maturities of investments, partially offset by $28.7 million of purchased investments and $1.5 million of purchased furniture, fixtures, office equipment and leasehold improvements for our laboratory and administrative offices.
Net cash used in investing activities was $57.4 million for the nine months ended September 30, 2022, and primarily related to $57.0 million of purchased investments and $0.4 million of purchased leasehold improvements for our laboratory and administrative offices and various purchases of office equipment.

Net Cash Provided by Financing Activities
Net cash provided by financing activities was $110.4 million for the nine months ended September 30, 2023 which primarily relates to (i) $99.4 million of net proceeds from the issuance of common stock related to the August 2023 Public Offering, (ii) $10.0 million of proceeds from our Credit Facility, (iii) $0.5 million of proceeds from our employee stock purchase plan, and (iv) $0.6 million of proceeds from employee option exercises.
Net cash provided by financing activities was $93.7 million for the nine months ended September 30, 2022, which primarily consisted of (i) $74.4 million of net proceeds from the issuance of common stock upon the May 2022 Public Offering, (ii) $20.0 million of proceeds from the Credit Facility, partially offset by our $0.9 million payment for its issuance costs, and (iii) $0.2 million of proceeds from our employee stock purchase plan.
Critical Accounting Policies, Significant Judgments and Use of Estimates

42
Our management's discussion and analysis of financial condition and results of operations is based on our Condensed Financial Statements, which have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of these condensed financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in our filed Annual Report on Form 10-K for the year ended December 31, 2022.
Recent Accounting Pronouncements
A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows are disclosed in the footnote to which each relates within these accompanying Condensed Financial Statements.
Off-Balance Sheet Arrangements
Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
Indemnification Agreements
As permitted under Delaware law and in accordance with our bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our officers and directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of September 30, 2023.
JOBS Act Accounting Election
The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted.
We will remain an emerging growth company until the earliest of (1) December 31, 2025, which is the last day of our first fiscal year following the fifth anniversary of the completion of our IPO, (2) the last day of our first fiscal year (a) in which we have total annual gross revenues of at least $1.235 billion or (b) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million, as of the prior June 30th and (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.
43
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk
The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of September 30, 2023, we had cash, cash equivalents, and marketable securities of $246.9 million, consisting of interest-bearing money market accounts, U.S. Treasury securities, commercial paper, corporate debt securities and government-related debt securities for which the fair market value would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities and the low-risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash, cash equivalents and marketable securities.
As of September 30, 2023, we had $30.0 million of debt principal outstanding. Our Credit Facility bears interest at an annual rate equal to the greater of (i) the prime rate as reported in the Wall Street Journal plus 4.45% with an aggregate cap of 11.45% or (ii) 8.45%. Assuming our interest rate is the aggregate cap of 11.45% our reported interest expense would aggregate $0.9 million and $2.6 million, respectively, for the three and nine months ended September 30, 2023.
We do not believe inflation, interest rate changes, and foreign currency exchange rate fluctuations had a significant impact on our results of operations for any periods presented herein. However, with further inflationary pressures, certain significant increased costs could have an adverse impact on the results of our operations.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended ("Exchange Act")) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
44
PART II—OTHER INFORMATION
Item 1. Legal Proceedings
We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
Item 1A. Risk Factors

As of the date of this filing, there have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023, as updated by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 10, 2023.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Use of Proceeds from Initial Public Offering

There has been no material change in the planned use of proceeds from our IPO as described in the Registration Statement on Form S-1 (File No. 333-249076), declared effective by the SEC on October 15, 2020, and the related final prospectus, dated October 15, 2020, filed with the SEC on October 16, 2020, pursuant to Rule 424(b) of the Securities Act of 1933, as amended.
Item 3. Defaults Upon Senior Securities.

None.
Item 4. Mine Safety Disclosures.

None.
Item 5. Other Information.

None.
45
Item 6. Exhibits

Exhibit
Number		DescriptionFormFile NumberIncorporated by Reference ExhibitDateFiled Herewith
10.1X
31.1X
31.2X
32.1*X
32.2*X
101.INSInline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.X
101.SCHInline XBRL Taxonomy Extension Schema Document.X
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.X
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.X
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.X
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.X
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).X
*
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Tarsus Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

46
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


TARSUS PHARMACEUTICALS, INC.
Date:November 9, 2023/s/ Bobak Azamian, M.D., Ph.D.
Bobak Azamian, M.D., Ph.D.
President, Chief Executive Officer and Chairman
(Principal Executive Director)
Date:November 9, 2023/s/ Jeffrey Farrow
Jeffrey Farrow
Chief Financial Officer and Chief Strategy Officer
(Principal Financial Officer and Principal Accounting Officer)



47
 EX-10.1 2 hercules_tarsus-secondamen.htm EX-10.1 Document

Exhibit 10.1
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of August 28, 2023 (the “Amendment Effective Date”), is entered into by and among TARSUS PHARMACEUTICALS, INC., a Delaware corporation, and each of its Subsidiaries joined hereafter from time to time pursuant to Section 7.13 of the Loan and Security Agreement (hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (each, a “Lender”, and collectively, referred to as the “Lenders”), and HERCULES CAPITAL, INC., a Maryland corporation (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lender (in such capacity, together with its successors and assigns in such capacity, “Agent”).
The Borrower, the Lenders and Agent are parties to a Loan and Security Agreement dated as of February 2, 2022 (as amended by the First Amendment, dated as of January 5, 2023, and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan and Security Agreement”). The Borrower has requested that Agent and Lenders agree to certain amendments to the Loan and Security Agreement. Agent and Lenders have agreed to such request, subject to the terms and conditions hereof.

Accordingly, the parties hereto agree as follows:

SECTION 1. Definitions; Interpretation.
(a)Terms Defined in Loan and Security Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan and Security Agreement.
(b)Interpretation. The rules of interpretation set forth in Section 1.3 of the Loan and Security Agreement shall be applicable to this Amendment and are incorporated herein by this reference.

SECTION 2. Amendments to the Loan and Security Agreement.
(a)    The Loan and Security Agreement shall be amended as follows effective as of the Amendment Effective Date:
(i)    Section 7.12 is hereby amended and restated in its entirety as follows:
“7.12 Deposit Accounts. Borrower shall maintain at all times in Deposit Accounts (including cash sweep accounts) or securities accounts with SVB or SVB’s Affiliates an aggregate balance not less than the greater of (a) $40,000,000 and (b) twenty-five percent (25%) of the aggregate Cash of Borrower; provided, notwithstanding the foregoing, that if Borrower’s aggregate Cash, wherever located, is less than $40,000,000 at any time, Borrower shall maintain not less than seventy-five percent (75%) of the aggregate Cash of Borrower in Deposit Accounts (including cash sweep accounts) or securities accounts with SVB or


SVB’s Affiliates. To the extent any of Borrower’s Cash is not required to be maintained with SVB or SVB’s Affiliates pursuant to the terms of this Section 7.12, Borrower

is permitted to maintain such Cash in Deposit Accounts (including cash sweep accounts) or securities accounts with other financial institutions, subject, in each case, to an Account Control Agreement in favor of Agent. In addition to the foregoing, except as permitted pursuant to clause (iv) or (vii) of the definition of Permitted Indebtedness, Borrower and any Subsidiary of Borrower, shall obtain any business credit card and any letter of credit exclusively from SVB. Notwithstanding anything herein to contrary, in no event shall Borrower be obligated to deliver any Account Control Agreement with respect to an Excluded Account.”
(b)    References Within Loan and Security Agreement. Each reference in the Loan and Security Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment.

SECTION 3. Conditions of Effectiveness. The effectiveness of Section 2 of this Amendment shall be subject to the satisfaction of each of the following conditions precedent:
(a)This Amendment. Agent shall have received this Amendment, executed by Agent, the Lenders and Borrower.
(b)Representations and Warranties; No Default. On the Amendment Effective Date, after giving effect to the amendment of the Loan and Security Agreement contemplated hereby:
(i)The representations and warranties contained in Section 5 of the Loan and Security Agreement shall be true and correct on and as of the Amendment Effective Date as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Agreement as to such representations and warranties; and
(ii)There exist no Events of Default or events that with the passage of time would result in an Event of Default.


SECTION 4. Representations and Warranties. To induce Agent and Lender to enter into this Amendment, Borrower hereby confirms, as of the date hereof, (a) that the representations and warranties made by it in Section 5 of the Loan and Security Agreement and in the other Loan Documents are true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; (b) that there has not been and there does not exist a Material Adverse Change; and (c) that the information included in the Perfection Certificate delivered to Agent on the Amendment Effective Date is true and correct in all material respects. For the purposes of this Section 4, (i) each reference in Section 5 of the Loan and Security Agreement to “this Agreement,” and the words “hereof,” “herein,” “hereunder,” or words of like import in such Section, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment, and (ii) any representations and warranties which relate solely to an earlier date shall not be deemed confirmed and restated as of the date hereof (provided that such representations and warranties shall be true, correct and complete as of such earlier date).

2



SECTION 5. Miscellaneous.

(a)     Loan Documents Otherwise Not Affected; Reaffirmation. Except as expressly amended pursuant hereto or referenced herein, the Loan and Security Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects. The Lenders’ and Agent’s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future. Borrower hereby reaffirms the grant of security under Section 4.1 of the Loan and Security Agreement, and hereby reaffirms that such grant of security in the Collateral secures all Obligations under the Loan and Security Agreement and the other Loan Documents.

(b)    Conditions. For purposes of determining compliance with the conditions specified in Section 3, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless Agent shall have received notice from such Lender prior to the Amendment Effective Date specifying its objection thereto.

(c)    [Reserved].

(d)    No Reliance. Each Borrower hereby acknowledges and confirms to Agent and the Lender that such Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.

(e)    Costs and Expenses. Each Borrower agrees to pay to Agent on the Amendment Effective Date the out-of-pocket costs and expenses of Agent and the Lenders party hereto, and the reasonable and documented fees and disbursements of counsel to Agent and the Lenders party hereto, in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the Amendment Effective Date or after such date.

(f)    Binding Effect. This Amendment binds and is for the benefit of the successors and permitted assigns of each party.

(g)    Governing Law. This Amendment and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

(h)    Complete Agreement; Amendments. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.

(i)    Severability of Provisions. Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.

(j)    Counterparts. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf)
3

or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

(k)    Loan Documents. This Amendment shall constitute a Loan Document.

[Balance of Page Intentionally Left Blank; Signature Pages Follow]
4

IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.
BORROWER:
TARSUS PHARMACEUTICALS, INC.
By:/s/ Jeffrey S. Farrow
Name: Jeffrey S. Farrow
Title: Chief Financial Officer and Chief Strategy Officer




































[Signature Page to Second Amendment to Loan and Security Agreement]




AGENT:
HERCULES CAPITAL, INC.
By/s/ Seth Meyer
Name: Seth Meyer
Title: Chief Financial Officer
LENDER:
HERCULES CAPITAL FUNDING TRUST 2022-1
By: Hercules Capital, Inc., its Administrator
By/s/ Seth Meyer
Name: Seth Meyer
Title: Chief Financial Officer
HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.
By:Hercules Adviser LLC,
its Investment Advisor
By:/s/ Seth Meyer
Name: Seth Meyer
Title: Authorized Signatory
HERCULES PRIVATE CREDIT FUND I L.P.
By:Hercules Adviser LLC,
its Investment Advisor
By:/s/ Seth Meyer
Name: Seth Meyer
Title: Authorized Signatory
FIRST-CITIZENS BANK & TRUST COMPANY
By:/s/ Kristine Rohmer
Name: Kristine Rohmer
Title: Director


[Signature Page to Second Amendment to Loan and Security Agreement]

 EX-31.1 3 exhibit311-93023.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002


I, Bobak Azamian, M.D., Ph.D., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023
By:/s/ Bobak Azamian, M.D., Ph.D.
Bobak Azamian, M.D., Ph.D.
President, Chief Executive Officer and Board Chairman
(Principal Executive Officer)

 EX-31.2 4 exhibit312-93023.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002


I, Jeffrey Farrow, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023
By:/s/ Jeffrey Farrow
Jeffrey Farrow
Chief Financial Officer and Chief Strategy Officer
(Principal Financial Officer and Principal Accounting Officer)

 EX-32.1 5 exhibit321-93023.htm EX-32.1 Document


Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bobak Azamian, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.    


Date: November 9, 2023
By:/s/ Bobak Azamian, M.D., Ph.D.
Bobak Azamian, M.D., Ph.D.
President, Chief Executive Officer and Board Chairman
(Principal Executive Officer)

 EX-32.2 6 exhibit322-93023.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey Farrow, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2023
By:/s/ Jeffrey Farrow
Jeffrey Farrow
Chief Financial Officer and Chief Strategy Officer
(Principal Financial Officer and Principal Accounting Officer)

 EX-101.SCH 7 tars-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Description of Business and Presentation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Balance Sheet Account Detail link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Commitment & Contingencies link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Out-License Agreement link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Credit Facility Agreement link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Balance Sheet Account Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Commitment & Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Credit Facility Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Description of Business and Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Stock-Based Compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Commitment & Contingencies - Lease Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Commitment & Contingencies - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Commitment and Contingencies - Summary of Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Commitment and Contingencies - Summary of Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Commitment & Contingencies - In-License Agreement for Lotilaner (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Commitment & Contingencies - Employment Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Out-License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Credit Facility Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 tars-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 tars-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 tars-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Payment of deferred offering costs Payments of Deferred Stock Issuance Costs Payments of Deferred Stock Issuance Costs Variable Rate [Domain] Variable Rate [Domain] Underwriters' option Over-Allotment Option [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Credit facility, aggregate principal amount Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Interest income Interest Income, Other Recognition of equity warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances Award Type [Domain] Award Type [Domain] Outstanding, beginning balance (shares) Outstanding, ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Credit Facility Agreement Debt Disclosure [Text Block] License agreement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Statement of Stockholders' Equity [Abstract] Credit Facility, Tranche Three Credit Facility, Tranche Three [Member] Credit Facility, Tranche Three Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Maximum milestone payments Collaborative Arrangement, Maximum Milestone Payment Collaborative Arrangement, Maximum Milestone Payment Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Corporate debt securities Corporate Debt Securities [Member] Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Fair value, beginning of period Fair value, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Total other income (expense), net Nonoperating Income (Expense) Commitments and contingencies (Note 8) Commitments and Contingencies Exercisable (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Stockholders' Equity Equity [Text Block] Proceeds from issuance of common stock upon follow-on public offerings, net of paid issuance costs Proceeds from Issuance of Common Stock Other non-current assets Increase (Decrease) in Other Noncurrent Assets Service condition period for full vesting Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Proceeds from sale of common stock under employee stock purchase plan Proceeds from Stock Plans Description of Business and Presentation of Financial Statements Business Description and Basis of Presentation [Text Block] Dividend yield rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 2016 Plan Equity Incentive Plan 2016 [Member] Equity Incentive Plan 2016 Director Director [Member] Leases Lessee, Leases [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding Preferred Stock, Value, Issued Weighted Average Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Net loss per share, diluted (usd per share) Earnings Per Share, Diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Intangible Assets, Net Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Level 3 Fair Value, Inputs, Level 3 [Member] Line of Credit Line of Credit [Member] Beginning balance (shares) Ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of vested stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Granted (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average grant-date fair value per stock option (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net (loss) income Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Long-term investments: Equity Securities, FV-NI [Abstract] Non-cash lease expense Operating Lease, Noncash Expense Operating Lease, Noncash Expense LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Entity Ex Transition Period Entity Ex Transition Period Accretion of end of term charge Amortization of Debt Discount (Premium) Stockholders’ equity: Equity, Attributable to Parent [Abstract] Unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Upfront payment Contract with Customer, Liability Exercise of vested stock options (shares) Exercised (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Net (loss) income per share, basis and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of license fees and collaboration revenue Cost of Goods and Services Sold Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Changes in fair value of equity warrants Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies and Use of Estimates Significant Accounting Policies [Text Block] Exercised (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Marketable securities Marketable Securities, Current Property and equipment, net of accumulated depreciation Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Smaller Reporting Company Entity Small Business Weighted average volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Laboratory equipment Other Machinery and Equipment [Member] Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Unrealized gain from transactions denominated in a foreign currency Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Selling, general and administrative Selling, General and Administrative Expenses [Member] Accounts Receivable Accounts Receivable [Member] Stock options reserved for future grant (shares) Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant Milestone Determined by the Company Milestone Determined by the Company [Member] Milestone Determined by the Company Number of leases Lessee, Operating Lease, Number Of Lease Contracts Lessee, Operating Lease, Number Of Lease Contracts Operating lease liability, noncurrent Operating Lease, Liability, Noncurrent Restricted stock Restricted Stock Units (RSUs) [Member] Restricted stock unit activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Issuance costs Payments of Stock Issuance Costs Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Payment of term loan issuance costs Payments of Debt Issuance Costs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Additional cash payment Revenue, Remaining Performance Obligation, Additional Cash Payment Revenue, Remaining Performance Obligation, Additional Cash Payment Future contractual lease payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Issuance costs related to follow-on public offering Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Stock issued (shares) Sale of Stock, Number of Shares Issued in Transaction Cost of Sales Cost of Goods and Service [Policy Text Block] Total revenues Revenues Number of vested warrants Number Of Vested Warrants Number Of Vested Warrants Financial instruments measured at fair value Fair Value, by Balance Sheet Grouping [Table Text Block] End of term charge, interest rate Line of Credit Facility, Periodic Payment, Interest Rate Line of Credit Facility, Periodic Payment, Interest Rate Outstanding potentially dilutive securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Beginning balance Ending balance Temporary Equity, Carrying Amount, Attributable to Parent Product and Service [Domain] Product and Service [Domain] Total interest expense related to term loan Interest Expense, Debt Components of lease cost Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Accounts payable and other accrued liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Research and development Research and Development Expense [Member] Cash Flows From Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Antidilutive securities excluded from computation of net income (loss) per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Follow-On Public Offering Follow-On Public Offering [Member] Follow-On Public Offering Document Quarterly Report Document Quarterly Report Supplemental Disclosures Noncash Investing and Financing Activities: Noncash Investing and Financing Items [Abstract] Interest expense Interest Expense Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount License And Collaboration, Other License And Collaboration, Other [Member] License And Collaboration, Other Additions of property and equipment included within accounts payable and other accrued liabilities Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Property and equipment, at cost Property, Plant and Equipment, Gross Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Operating lease right-of-use asset obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Unvested Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value 2023 (remaining three months) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Related Party Transactions Related Party Transactions Disclosure [Text Block] (Less): Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Summary of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Marketable securities: Debt Securities, Available-for-Sale [Abstract] Entity File Number Entity File Number End of term charge Line of Credit Facility, Periodic Payment, Interest Additional shares to be issued upon 18-month anniversary of contract execution (shares) Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Upfront payment received Collaborative Arrangement, Rights And Obligations, Upfront Payment Collaborative Arrangement, Rights And Obligations, Upfront Payment Operating lease liability, current Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current Shares issued in connection with the employee stock purchase plan (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Customer Three Customer Three [Member] Customer Three Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Long-term investments Long-Term Investments Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Total future amortization Finite-Lived Intangible Assets, Net Recently Issued or Effective Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses Increase (Decrease) in Prepaid Expense Counterparty Name [Domain] Counterparty Name [Domain] Stock details Schedule of Stock by Class [Table Text Block] Cash and cash equivalents — beginning of period Cash and cash equivalents — end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Future cash payments Collaborative Arrangement, Future Cash Payments Collaborative Arrangement, Future Cash Payments Long-Lived Assets Held-for-Sale by Asset Type [Axis] Long-Lived Assets Held-for-Sale by Asset Type [Axis] Original issue price (usd per share) Sale of Stock, Price Per Share Variable Lease, Cost Variable Lease, Cost Operating lease expense Operating Lease, Cost Common stock, issued (shares) Common Stock, Shares, Issued Vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities Unrealized Gain (Loss) on Investments [Table Text Block] Valuation assumptions of stock options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Unvested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Security Exchange Name Security Exchange Name Term loan, net Long-Term Debt Total assets measured at fair value Assets, Fair Value Disclosure Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Stock issued, net proceeds Sale of Stock, Consideration Received on Transaction Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Out-License Agreement Collaborative Arrangement Disclosure [Text Block] Stock options Stock options, unexercised—vested and unvested Employee Stock Option [Member] Unrecognized compensation expense, weighted average period of recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total operating expenses Costs and Expenses Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Unvested Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term Interest rate Line of Credit Facility, Interest Rate During Period Entity Address, Address Line One Entity Address, Address Line One Inventory Inventory, Policy [Policy Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Equity securities (in shares) Equity Securities, FV-NI, Number Of Shares Equity Securities, FV-NI, Number Of Shares Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Unrealized losses Equity Securities, FV-NI, Unrealized Loss Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Customer Concentration Risk Customer Concentration Risk [Member] Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Issuance of common stock upon follow-up public offering, net of issuance costs (shares) Stock Issued During Period, Shares, New Issues Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Long-Lived Assets Held-for-Sale, Name [Domain] Long-Lived Assets Held-for-Sale, Name [Domain] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Related Party [Domain] Related Party, Type [Domain] LianBio LianBio [Member] LianBio Outstanding, beginning balance (usd per share) Outstanding, ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Deferred offering costs included within accounts payable and accrued liabilities Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant Share-Based Payment Arrangement [Abstract] Lapse of repurchase obligation for stock option exercises, prior to vesting Stock Issued During Period, Value, Lapse Of Repurchase Rights Stock Issued During Period, Value, Lapse Of Repurchase Rights Entity Tax Identification Number Entity Tax Identification Number Related party transaction, termination notice, period Related Part Transaction, Termination Notice, Period Related Part Transaction, Termination Notice, Period Inventory Inventory, Net Lease, Cost, Total Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Number of tranches Warrant Agreement, Number of Tranches Warrant Agreement, Number of Tranches Interest expense for term loan Interest Expense, Debt, Excluding Amortization Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Product Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accumulated amortization of debt issuance costs Accumulated Amortization, Debt Issuance Costs Number of securities with contractual maturity between one and five years Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Issuance of common stock upon the vesting of restricted stock units (shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Accounts payable and other accrued liabilities Accounts payable and other accrued liabilities Accounts Payable and Other Accrued Liabilities, Current Common stock in LianBio Estimated fair value Equity Securities, FV-NI Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Cash Flows From Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Unrealized gain (loss) on marketable securities and cash equivalents Other comprehensive gain (loss) OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, outstanding (shares) Beginning balance (shares) Ending balance (shares) Common Stock, Shares, Outstanding Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic [Abstract] Concentration Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Total operating lease liability Total operating lease liability Operating Lease, Liability Development and Regulatory Milestone Development And Regulatory Milestone [Member] Development And Regulatory Milestone Total liabilities Liabilities Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Line of Credit, SVB Line of Credit, SVB [Member] Line of Credit, SVB Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Total shares of common stock reserved (shares) Common Stock, Capital Shares Reserved for Future Issuance Commercial and sales milestones Commercial And Sales Milestones [Member] Commercial And Sales Milestones Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Change in fair value of equity warrants issued by licensee Change in fair value of equity warrants issued by licensee Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Credit Facility, Tranche Four Credit Facility, Tranche Four [Member] Credit Facility, Tranche Four Marketable Securities and Long-Term Investments Marketable Securities, Policy [Policy Text Block] Common stock, $0.0001 par value; 200,000,000 shares authorized; 33,104,087 shares issued and outstanding at September 30, 2023 (unaudited); 26,727,458 shares issued and outstanding at December 31, 2022 Common Stock, Value, Issued Government-related debt securities US Government Debt Securities [Member] Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Intangible Assets, Milestone Payment Intangible Assets, Milestone Payment [Member] Intangible Assets, Milestone Payment Weighted-Average Remaining Contractual Term Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract] Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value Operating Segment Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Common stock votes Common Stock, Number Of Votes Common Stock, Number Of Votes Other (expense) income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Stock options issued and outstanding (shares) Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Related party transaction, annual cash compensation Related Party Transaction, Annual Cash Compensation Related Party Transaction, Annual Cash Compensation Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Trade accounts payable and other Accounts Payable, Trade, Current Lapse of repurchase obligation for stock option exercises, prior to vesting (shares) Stock Issued During Period, Shares, Lapse Of Repurchase Rights Stock Issued During Period, Shares, Lapse Of Repurchase Rights Contractual maturity Debt Securities, Available-for-Sale, Term Concentration risk Concentration Risk, Percentage Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Preferred stock, authorized (shares) Preferred Stock, Shares Authorized Granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Preferred stock, outstanding (shares) Preferred Stock, Shares Outstanding Accounts Receivable, Net Accounts Receivable [Policy Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Expected Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Furniture and fixtures Furniture and Fixtures [Member] Interest rate Debt Instrument, Interest Rate, Stated Percentage Accrued payroll and benefits Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Accrued clinical studies Accrued Clinical Studies, Current Accrued Clinical Studies, Current Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Commercial paper Commercial Paper [Member] Additional shares to be issued upon 18-month anniversary of contract execution, value Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Accrued product sales deductions Accrued Sales Commission, Current Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share) Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services Intangible asset additions Payments to Acquire Intangible Assets Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, issued (shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Debt issuance costs Debt Issuance Costs, Line of Credit Arrangements, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Useful life Finite-Lived Intangible Asset, Useful Life Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Credit Facility, First Amendment, Tranche Two Credit Facility, First Amendment, Tranche Two [Member] Credit Facility, First Amendment, Tranche Two City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Loss Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Accretion of end of term charge Debt Instrument, Unamortized Discount (Premium), Net (Less): Tenant improvement allowance Lessee, Operating Lease, Liability, Tenant Improvement Allowance Lessee, Operating Lease, Liability, Tenant Improvement Allowance Document Fiscal Year Focus Document Fiscal Year Focus Minimum Minimum [Member] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Unvested (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Restricted stock units—unvested Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member] Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested Statement of Cash Flows [Abstract] ASSETS Assets: Assets [Abstract] Proceeds from term loan Proceeds from Issuance of Long-Term Debt License fees and Collaboration License And Collaboration [Member] License And Collaboration Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months [Member] Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months U.S. Treasury securities US Treasury Securities [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Commitment & Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Net amortization/accretion on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Credit Facility, Tranche Two Credit Facility, Tranche Two [Member] Credit Facility, Tranche Two Clinical milestones Clinical Milestones [Member] Clinical Milestones Amortized cost Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Other income (expense): Nonoperating Income (Expense) [Abstract] Other assets Other Assets, Noncurrent Weighted average risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Net loss per share, basic (usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Shares issued in connection with the employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] 2023 (remaining three months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Entity Address, City or Town Entity Address, City or Town Related Party Related Party [Member] Three Customers Three Customers [Member] Three Customers Balance Sheet Account Detail Supplemental Balance Sheet Disclosures [Text Block] Common stock issued for license agreement, value Stock Issued During Period, Value, Issued for Services Document Transition Report Document Transition Report Common stock, authorized (shares) Common Stock, Shares Authorized Corporate debt securities Debt Securities, Available-for-Sale Unrealized gains Equity Securities, FV-NI, Unrealized Gain Unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Customer Two Customer Two [Member] Customer Two Principal outstanding Term loan, gross Long-Term Debt, Gross Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan Related Party Transactions [Abstract] Elanco Elanco [Member] Elanco Royalty expense Royalty Expense Additional paid-in capital Additional Paid in Capital Forfeited (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Credit Facility, Tranche One Credit Facility, Tranche One [Member] Credit Facility, Tranche One Customer One Customer One [Member] Customer One Other receivables Increase (Decrease) in Other Receivables Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Forfeited (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Upfront payment received Upfront Payment Upfront Payment Common stock issued for license agreement, share price (usd per share) Share Price Related Party [Axis] Related Party, Type [Axis] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Milestone payments to be achieved Revenue, Remaining Performance Obligation, Variable Consideration, Amount Revenue, Remaining Performance Obligation, Variable Consideration, Amount Unrealized loss on equity investments Unrealized loss on equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) Cost of sales Cost of Sales [Member] Document Period End Date Document Period End Date Draw on credit facility Proceeds from Lines of Credit (Less): Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Exercisable (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Accretion of term loan-related costs Amortization of Debt Issuance Costs and Discounts Remeasurement of equity warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Total stock-based compensation Share-Based Payment Arrangement, Expense Benefit from income taxes Income Tax Expense (Benefit) Accrued payroll and benefits Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Revenue Benchmark Revenue Benchmark [Member] Cash equivalents: Cash and Cash Equivalents [Abstract] Issuance of common stock upon follow-on public offering, net of issuance costs of $5,246 Stock Issued During Period, Value, New Issues Equity [Abstract] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other Receivables, Net, Current Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Beginning balance (shares) Ending balance (shares) Temporary Equity, Shares Outstanding Money market funds(1) Money Market Funds [Member] Amortized cost Cash and Cash Equivalents, at Carrying Value Estimated incremental borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Common stock issued for license agreement (shares) Stock Issued During Period, Shares, Issued for Services Useful lives of assets Property, Plant and Equipment, Useful Life Term loan, net Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Weighted-average shares outstanding, diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Contractual milestone payment Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment Operating expenses: Operating Expenses [Abstract] Debt securities, available for sale and cash and cash equivalents Debt Securities, Available-For-Sale And Cash And Cash Equivalents Debt Securities, Available-For-Sale And Cash And Cash Equivalents Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Additional Paid-In Capital Additional Paid-in Capital [Member] Total assets Assets Cover [Abstract] Recognition of stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs Other long-term liabilities Other Liabilities, Noncurrent Vested (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Number of employment arrangements with executive officers Number Of Employment Arrangements With Executive Officers Number Of Employment Arrangements With Executive Officers Total future lease payments, undiscounted Lessee, Operating Lease, Liability, to be Paid Increments to draw on credit facility at company's election Line of Credit Facility, Draw Down Increments Line of Credit Facility, Draw Down Increments Prime Rate Prime Rate [Member] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flows From Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Equity Component [Domain] Equity Component [Domain] Amortized cost Equity Securities, FV-NI, Cost Fair market value of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted-average shares outstanding, basic (shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations before other income (expense) and income taxes Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Office equipment Office Equipment [Member] Revenues: Revenues [Abstract] Proceeds from exercise of equity awards Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Statement [Line Items] Statement [Line Items] Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Equity warrants (for LianBio shares) Equity Warrants, Fair Value Disclosure Equity Warrants, Fair Value Disclosure Balances of Debt, Debt Issuance Costs, and Accumulated Accretion Schedule of Debt [Table Text Block] EX-101.PRE 11 tars-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 03, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-39614  
Entity Registrant Name TARSUS PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-4717861  
Entity Address, Address Line One 15440 Laguna Canyon Road, Suite 160  
Entity Address, City or Town Irvine  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92618  
City Area Code (949)  
Local Phone Number 409-9820  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol TARS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Smaller Reporting Company true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   33,104,612
Amendment Flag false  
Entity Central Index Key 0001819790  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 226,672,000 $ 71,660,000
Marketable securities 20,213,000 145,366,000
Accounts receivable, net 5,362,000 0
Inventory 15,000 0
Other receivables 1,008,000 3,582,000
Prepaid expenses 6,007,000 4,767,000
Total current assets 259,277,000 225,375,000
Property and equipment, net 1,614,000 957,000
Intangible assets, net 3,967,000 0
Operating lease right-of-use assets 2,011,000 575,000
Long-term investments 210,000 371,000
Other assets 1,253,000 585,000
Total assets 268,332,000 227,863,000
Current liabilities:    
Accounts payable and other accrued liabilities 15,351,000 9,910,000
Accrued payroll and benefits 7,898,000 5,519,000
Total current liabilities 23,249,000 15,429,000
Term loan, net 29,708,000 19,434,000
Other long-term liabilities 1,711,000 100,000
Total liabilities 54,668,000 34,963,000
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding 0 0
Common stock, $0.0001 par value; 200,000,000 shares authorized; 33,104,087 shares issued and outstanding at September 30, 2023 (unaudited); 26,727,458 shares issued and outstanding at December 31, 2022 5,000 5,000
Additional paid-in capital 416,421,000 301,732,000
Accumulated other comprehensive loss (8,000) (74,000)
Accumulated deficit (202,754,000) (108,763,000)
Total stockholders’ equity 213,664,000 192,900,000
Total liabilities and stockholders’ equity $ 268,332,000 $ 227,863,000
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (shares) 10,000,000 10,000,000
Preferred stock, issued (shares) 0 0
Preferred stock, outstanding (shares) 0 0
Common stock, par value (usd per share) $ 0.0001 $ 0.0001
Common stock, authorized (shares) 200,000,000 200,000,000
Common stock, issued (shares) 33,104,087 26,727,458
Common stock, outstanding (shares) 33,104,087 26,727,458
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:        
Total revenues $ 1,871 $ 0 $ 4,371 $ 15,816
Operating expenses:        
Research and development 12,105 10,912 37,007 32,596
Selling, general and administrative 30,324 11,994 65,695 30,316
Total operating expenses 42,806 22,906 103,079 63,467
Loss from operations before other income (expense) and income taxes (40,935) (22,906) (98,708) (47,651)
Other income (expense):        
Interest income 2,840 1,061 7,359 1,372
Interest expense (858) (633) (2,357) (1,507)
Other (expense) income, net (48) (7) (89) 136
Unrealized loss on equity investments (111) (13) (161) (326)
Change in fair value of equity warrants issued by licensee (36) (18) (35) (520)
Total other income (expense), net 1,787 390 4,717 (845)
Benefit from income taxes 0 5 0 4
Net (loss) income (39,148) (22,511) (93,991) (48,492)
Other comprehensive loss:        
Unrealized gain (loss) on marketable securities and cash equivalents 15 (10) 66 (10)
Comprehensive loss $ (39,133) $ (22,521) $ (93,925) $ (48,502)
Earnings Per Share [Abstract]        
Net loss per share, basic (usd per share) $ (1.28) $ (0.84) $ (3.35) $ (2.03)
Net loss per share, diluted (usd per share) $ (1.28) $ (0.84) $ (3.35) $ (2.03)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]        
Weighted-average shares outstanding, basic (shares) 30,622,440 26,662,374 28,065,434 23,923,512
Weighted-average shares outstanding, diluted (shares) 30,622,440 26,662,374 28,065,434 23,923,512
Product        
Revenues:        
Total revenues $ 1,653 $ 0 $ 1,653 $ 0
Operating expenses:        
Cost of license fees and collaboration revenue 377 0 377 0
License fees and Collaboration        
Revenues:        
Total revenues 218 0 2,718 15,816
Operating expenses:        
Cost of license fees and collaboration revenue $ 0 $ 0 $ 0 $ 555
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (shares) at Dec. 31, 2021 0        
Ending balance (shares) at Mar. 31, 2022 0        
Beginning balance at Dec. 31, 2021 $ 0        
Ending balance at Mar. 31, 2022 0        
Beginning balance (shares) at Dec. 31, 2021   20,698,737      
Beginning balance at Dec. 31, 2021 166,730 $ 4 $ 213,398   $ (46,672)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (20,238)       (20,238)
Recognition of stock-based compensation expense 2,674   2,674    
Exercise of vested stock options (shares)   225      
Issuance of common stock upon the vesting of restricted stock units (shares)   4,257      
Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)   15,309      
Lapse of repurchase obligation for stock option exercises, prior to vesting 31   31    
Ending balance (shares) at Mar. 31, 2022   20,718,528      
Ending balance at Mar. 31, 2022 $ 149,197 $ 4 216,103   (66,910)
Beginning balance (shares) at Dec. 31, 2021 0        
Ending balance (shares) at Sep. 30, 2022 0        
Beginning balance at Dec. 31, 2021 $ 0        
Ending balance at Sep. 30, 2022 0        
Beginning balance (shares) at Dec. 31, 2021   20,698,737      
Beginning balance at Dec. 31, 2021 166,730 $ 4 213,398   (46,672)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (48,492)        
Other comprehensive gain (loss) (10)        
Ending balance (shares) at Sep. 30, 2022   26,671,812      
Ending balance at Sep. 30, 2022 $ 202,627 $ 5 297,796 $ (10) (95,164)
Beginning balance (shares) at Mar. 31, 2022 0        
Ending balance (shares) at Jun. 30, 2022 0        
Beginning balance at Mar. 31, 2022 $ 0        
Ending balance at Jun. 30, 2022 0        
Beginning balance (shares) at Mar. 31, 2022   20,718,528      
Beginning balance at Mar. 31, 2022 149,197 $ 4 216,103   (66,910)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (5,743)       (5,743)
Recognition of stock-based compensation expense 3,532   3,532    
Issuance of common stock upon follow-up public offering, net of issuance costs (shares)   5,889,832      
Issuance of common stock upon follow-on public offering, net of issuance costs of $5,246 74,267 $ 1 74,266    
Shares issued in connection with the employee stock purchase plan (shares)   17,874      
Shares issued in connection with the employee stock purchase plan 222   222    
Exercise of vested stock options (shares)   7,056      
Exercise of vested stock options 17   17    
Issuance of common stock upon the vesting of restricted stock units (shares)   4,257      
Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)   6,705      
Lapse of repurchase obligation for stock option exercises, prior to vesting 13   13    
Ending balance (shares) at Jun. 30, 2022   26,644,252      
Ending balance at Jun. 30, 2022 $ 221,505 $ 5 294,153 0 (72,653)
Ending balance (shares) at Sep. 30, 2022 0        
Ending balance at Sep. 30, 2022 $ 0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (22,511)       (22,511)
Recognition of stock-based compensation expense 3,583   3,583    
Exercise of vested stock options (shares)   21,734      
Exercise of vested stock options 82   82    
Other comprehensive gain (loss) (10)     (10)  
Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)   5,826      
Lapse of repurchase obligation for stock option exercises, prior to vesting 12   12    
Issuance costs related to follow-on public offering (34)   (34)    
Ending balance (shares) at Sep. 30, 2022   26,671,812      
Ending balance at Sep. 30, 2022 $ 202,627 $ 5 297,796 (10) (95,164)
Beginning balance (shares) at Dec. 31, 2022 0        
Ending balance (shares) at Mar. 31, 2023 0        
Beginning balance at Dec. 31, 2022 $ 0        
Ending balance at Mar. 31, 2023 $ 0        
Beginning balance (shares) at Dec. 31, 2022 26,727,458 26,727,458      
Beginning balance at Dec. 31, 2022 $ 192,900 $ 5 301,732 (74) (108,763)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (23,419)       (23,419)
Recognition of stock-based compensation expense $ 3,906   3,906    
Exercise of vested stock options (shares) 6,443 6,443      
Exercise of vested stock options $ 13   13    
Issuance of common stock upon the vesting of restricted stock units (shares)   66,611      
Other comprehensive gain (loss) 4     4  
Ending balance (shares) at Mar. 31, 2023   26,800,512      
Ending balance at Mar. 31, 2023 $ 173,404 $ 5 305,651 (70) (132,182)
Beginning balance (shares) at Dec. 31, 2022 0        
Ending balance (shares) at Sep. 30, 2023 0        
Beginning balance at Dec. 31, 2022 $ 0        
Ending balance at Sep. 30, 2023 $ 0        
Beginning balance (shares) at Dec. 31, 2022 26,727,458 26,727,458      
Beginning balance at Dec. 31, 2022 $ 192,900 $ 5 301,732 (74) (108,763)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (93,991)        
Other comprehensive gain (loss) $ 66        
Ending balance (shares) at Sep. 30, 2023 33,104,087 33,104,087      
Ending balance at Sep. 30, 2023 $ 213,664 $ 5 416,421 (8) (202,754)
Beginning balance (shares) at Mar. 31, 2023 0        
Ending balance (shares) at Jun. 30, 2023 0        
Beginning balance at Mar. 31, 2023 $ 0        
Ending balance at Jun. 30, 2023 0        
Beginning balance (shares) at Mar. 31, 2023   26,800,512      
Beginning balance at Mar. 31, 2023 173,404 $ 5 305,651 (70) (132,182)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (31,424)       (31,424)
Recognition of stock-based compensation expense 5,192   5,192    
Shares issued in connection with the employee stock purchase plan (shares)   37,289      
Shares issued in connection with the employee stock purchase plan $ 465   465    
Exercise of vested stock options (shares) 16,118 16,118      
Exercise of vested stock options $ 45   45    
Issuance of common stock upon the vesting of restricted stock units (shares)   45,653      
Other comprehensive gain (loss) 47     47  
Ending balance (shares) at Jun. 30, 2023   26,899,572      
Ending balance at Jun. 30, 2023 $ 147,729 $ 5 311,353 (23) (163,606)
Ending balance (shares) at Sep. 30, 2023 0        
Ending balance at Sep. 30, 2023 $ 0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (39,148)       (39,148)
Recognition of stock-based compensation expense 5,250   5,250    
Issuance of common stock upon follow-up public offering, net of issuance costs (shares)   6,069,449      
Issuance of common stock upon follow-on public offering, net of issuance costs of $5,246 $ 99,302   99,302    
Exercise of vested stock options (shares) 109,627 109,627      
Exercise of vested stock options $ 516   516    
Issuance of common stock upon the vesting of restricted stock units (shares)   25,439      
Other comprehensive gain (loss) $ 15     15  
Ending balance (shares) at Sep. 30, 2023 33,104,087 33,104,087      
Ending balance at Sep. 30, 2023 $ 213,664 $ 5 $ 416,421 $ (8) $ (202,754)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flows From Operating Activities:    
Net loss $ (93,991) $ (48,492)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 497 227
Amortization of intangible assets 33 0
Accretion of term loan-related costs 274 231
Stock-based compensation 14,348 9,789
Non-cash lease expense 410 343
Unrealized loss on equity investments 161 326
Net amortization/accretion on marketable securities (3,038) (63)
Change in fair value of equity warrants issued by licensee 35 520
Unrealized gain from transactions denominated in a foreign currency 0 (1)
Changes in operating assets and liabilities:    
Accounts receivable, net (5,362) (17)
Inventory (15) 0
Other receivables 2,574 (3,902)
Prepaid expenses (1,028) 551
Other non-current assets (608) (75)
Accounts payable and other accrued liabilities 5,177 1,187
Accrued payroll and benefits 2,379 1,294
Other long-term liabilities (4) (74)
Net cash used in operating activities (78,158) (38,156)
Cash Flows From Investing Activities:    
Proceeds from maturities of marketable securities 156,920 0
Purchases of marketable securities (28,664) (57,031)
Intangible asset additions (4,000) 0
Purchases of property and equipment (1,502) (379)
Net cash provided by (used in) investing activities 122,754 (57,410)
Cash Flows From Financing Activities:    
Proceeds from issuance of common stock upon follow-on public offerings, net of paid issuance costs 99,377 74,352
Proceeds from sale of common stock under employee stock purchase plan 465 222
Proceeds from exercise of equity awards 574 99
Proceeds from term loan 10,000 20,000
Payment of term loan issuance costs 0 (875)
Payment of deferred offering costs 0 (75)
Net cash provided by financing activities 110,416 93,723
Net increase (decrease) in cash and cash equivalents 155,012 (1,843)
Cash and cash equivalents — beginning of period 71,660 171,332
Cash and cash equivalents — end of period 226,672 169,489
Supplemental Disclosures Noncash Investing and Financing Activities:    
Operating lease right-of-use asset obtained in exchange for operating lease liability 1,846 0
Interest expense paid in cash 2,034 1,094
Additions of property and equipment included within accounts payable and other accrued liabilities 32 44
Deferred offering costs included within accounts payable and accrued liabilities $ 22 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Stockholders' Equity (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Jun. 30, 2022
Statement of Stockholders' Equity [Abstract]    
Issuance costs $ 6,912 $ 5,246
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Description of Business and Presentation of Financial Statements
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business and Presentation of Financial Statements DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS
Description of Business

Tarsus Pharmaceuticals, Inc. (“Tarsus” or the “Company”) is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, on August 24, 2023, after receiving United States ("U.S.") Food and Drug Administration ("FDA") approval on July 24, 2023.
Follow-On Public Offerings
On August 4, 2023, the Company completed a follow-on public offering under its shelf registration statement on Form S-3 that was declared effective by the SEC on November 5, 2021 of 5,714,285 shares of common stock at a public offering price of $17.50 per share (the "August 2023 Public Offering"). The aggregate net proceeds received by the Company were approximately $93.5 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses. The Company also granted the underwriters a 30-day option to purchase up to 857,142 additional shares of its common stock at the public offering price. On September 6, 2023, the underwriters partially exercised this option resulting in the Company's issuance of an additional 355,164 shares of common stock at the public offering price of $17.50 per share. The aggregate net proceeds received by the Company from the partially exercised option was approximately $5.8 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.

In connection with the August 2023 Public Offering, the Company terminated the prospectus (the “ATM Prospectus”) filed with Shelf Registration Statement, issuable pursuant to the terms of an Open Market Sale AgreementSM (the "Sales Agreement") dated November 1, 2021 by and between the Company and Jefferies LLC. The Company has not made any sales pursuant to the ATM Prospectus. Further, the Company will not make any sales of our common stock pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.
In May 2022, the Company completed a follow-on public offering under its Shelf Registration Statement for an initial underwritten sale of 5,600,000 shares of its common stock at the public offering price of $13.50 per share. The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of its common stock at the public offering price. In June 2022, the underwriters partially exercised this option and the Company's sale of an additional 289,832 shares at the public offering price of $13.50 per share was concurrently completed. Total aggregate net proceeds received by the Company were approximately $74.3 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.
Liquidity

The Company has a limited operating history, limited history of product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through proceeds from product sales, net, proceeds from its out-license agreement, equity capital raises; including the Company's initial public offering in 2020 and the follow-on public offerings completed in May 2022 and August 2023, and draws from its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q, which have been prepared on a going-concern basis.

Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its commercialization efforts, development programs, and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern.
Operating Segment
The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company’s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance.
Emerging Growth Company Status
The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies and Use of Estimates
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies and Use of Estimates SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES
Basis of Presentation
The Company’s Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023.
The interim Condensed Balance Sheet as of September 30, 2023, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022, and the Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.
The financial data and other information disclosed in these notes related to the three and nine-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and nine months ended September 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 or any other interim or annual period.

The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates.

The Company’s financial statements as of and for the three and nine months ended September 30, 2023, reflect the Company’s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an
update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.

The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below.
Cash and Cash Equivalents

Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.
Marketable Securities and Long-Term Investments
Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see Note 3). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.
Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.

Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period.
Accounts Receivable, Net

Accounts receivable generally consists of amounts due from its customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended September 30, 2023.
Inventory

Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out (FIFO) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and
adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY on July 24, 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred. The inventory balance as of September 30, 2023 consisted of finished goods.
Intangible Assets, Net
Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow. The carrying value of intangible assets as a result of commercial milestones was $4.0 million as of September 30, 2023, and will be amortized to cost of sales over its useful life of 10 years from the date of first commercial sale. Amortization expense for the three and nine months ended September 30, 2023 was not material (see Note 8). The Company had no intangible assets as of December 31, 2022.

As of September 30, 2023, the expected future amortization expense for the Company's intangible assets is as follows:

Amounts
2023 (remaining three months)$100 
2024400 
2025400 
2026400 
2027400 
Thereafter2,267 
Total future amortization$3,967 
Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the periods presented.
Fair Value Measurements
Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
•Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.
•Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.
•Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see Note 3).
Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.

Property and Equipment, Net

Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset’s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three and nine months ended September 30, 2023 and 2022.

Leases
The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (“ROU assets”) represent the Company’s right to control an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.

The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU asset and lease liability amounts presented in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.
Concentration Risk

Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"), a division of First Citizens Bank. These
deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty.

Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.

Major Customers

The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. For the three months ended September 30, 2023, the Company's three largest customers accounted for 55%, 21% and 13% of product sales, respectively. As of September 30, 2023, amounts due from these three customers each exceeded 10% of gross accounts receivable and accounted for approximately 89% of the accounts receivable balance on a combined basis.

Major Suppliers

The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company entered into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than our existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company’s commercialization efforts.
Revenue Recognition
(i) Product Sales, Net

The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.

The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.

Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected
value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Overall, these estimates reflect the Company’s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:

Distribution Service Fees: The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.

Prompt Pay Discounts: The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized.

Product Returns: The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it can not be resold.

Chargebacks: A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler’s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.

Co-payment Assistance: Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.

Rebates and Discounts: The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program. Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company’s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.
(ii) License Fees and Collaboration Revenue
    
China Out-License

License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")— see Note 9. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract’s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period.

The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.
The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payments for executing drug supply agreements; (vi) development milestone payments; and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.

Contractual Terms for Receipt of Payments

A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract’s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.

The contractual terms that establish the Company’s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows:

Upfront License Fees: The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.

Development Milestones: The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment.
Regulatory Milestones: The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.

Royalties: Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee’s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.

Sales Threshold Milestones: Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License.

The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur.

Other License Fees and Collaboration Revenue

License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service. Revenue recognized for the three and nine months ended September 30, 2023 was $0.2 million. No revenue was recognized under such arrangements for the three and nine months ended September 30, 2022.

Cost of Sales

Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company’s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY on July 24, 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss.
Research and Development Costs

Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The
Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.

The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.
Stock-Based Compensation

The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company’s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.

Stock awards granted typically have one to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.
All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management’s judgment, including:
Fair Value of Common Stock — The fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant.
Expected Term — The Company’s expected term represents the period that the Company’s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history. 
Expected Volatility — Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.
Risk-Free Interest Rate — The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.
Dividend Yield — The Company’s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.
Net Loss per Share
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable.

Due to a net loss for the three and nine months ended September 30, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.
Comprehensive Loss
Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.
Recently Issued or Effective Accounting Standards
Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company’s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company’s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTSThe table below summarizes certain financial instruments measured at fair value that are included within the accompanying Condensed Balance Sheets, and their designation among the three fair value measurement categories (see Note 2 - Fair Value Measurements):
 September 30, 2023
 Level 1Level 2Level 3Total
Assets:
Money market funds(1)
$226,672 $— $— $226,672 
U.S. Treasury securities7,494 — — 7,494 
Commercial paper— 6,964 — 6,964 
Corporate debt securities— 314 — 314 
Government-related debt securities— 5,441 — 5,441 
Common stock in LianBio210 — — 210 
Equity warrants (for LianBio shares)— — 73 73 
Total assets measured at fair value$234,376 $12,719 $73 $247,168 
(1) This balance includes cash requirements settled on a nightly basis.
 December 31, 2022
 Level 1Level 2Level 3Total
Assets:
Money market funds(1)
$64,685 $— $— $64,685 
U.S. Treasury securities69,644 — — 69,644 
Commercial paper— 60,355 — 60,355 
Corporate debt securities— 11,521 — 11,521 
Government-related debt securities— 10,821 — 10,821 
Common stock in LianBio371 — — 371 
Equity warrants (for LianBio shares)— — 108 108 
Total assets measured at fair value$134,700 $82,697 $108 $217,505 
(1) This balance includes cash requirements settled on a nightly basis.
Money Market Funds and U.S. Treasury Securities

Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.
Commercial Paper, Corporate Debt Securities and Government-related Debt Securities

Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.
LianBio Common Stock and Equity Warrants
In March 2021, contemporaneous with the China Out-License transaction (see Note 9), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (LianBio, a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first two tranches were vested and exercised as of December 31, 2022 and converted into 156,746 shares of LianBio common stock and were recognized at fair value within long-term investments in the Condensed Balance Sheets as of September 30, 2023 and December 31, 2022. LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price on the Nasdaq Global Market.
The third warrant tranche will vest upon the achievement of a regulatory event and is presented within other assets in the accompanying Condensed Balance Sheets as of September 30, 2023 and December 31, 2022. This warrant tranche remains classified as Level 3 in the fair value hierarchy. The most significant assumptions used in the option pricing valuation model as of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies); the probability of regulatory milestone achievement for vesting; and the application of an assumed discount rate.
The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:
Value of equity warrants
Fair value as of December 31, 2022$108 
Remeasurement of equity warrants(17)
Fair value as of March 31, 2023$91 
Remeasurement of equity warrants18 
Fair value as of June 30, 2023$109 
Remeasurement of equity warrants(36)
Fair value as of September 30, 2023$73 
Value of equity warrants
Fair value as of December 31, 2021$663 
Remeasurement of equity warrants(245)
Fair value as of March 31, 2022$418 
Recognition of equity warrants103 
Remeasurement of equity warrants(257)
Fair value as of June 30, 2022$264 
Remeasurement of equity warrants(18)
Fair value as of September 30, 2022$246 
The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:
September 30, 2023
Amortized costUnrealized gainsUnrealized lossesEstimated fair value
Cash equivalents:
Money market funds(1)
$226,672 $— $— $226,672 
Total cash equivalents$226,672 $— $— $226,672 
Marketable securities:
U.S. Treasury securities$7,481 $17 $(4)$7,494 
Commercial paper6,966 — (2)6,964 
Corporate debt securities312 2 — 314 
Government-related debt securities5,446 — (5)5,441 
Total marketable securities$20,205 $19 $(11)$20,213 
Long-term investments:
Common stock in LianBio$1,108 $— $(898)$210 
Total long-term investments$1,108 $— $(898)$210 
(1) This balance includes cash requirements settled on a nightly basis.
December 31, 2022
Amortized costUnrealized gainsUnrealized lossesEstimated fair value
Cash equivalents:
Money market funds(1)
$64,685 $— $— $64,685 
Government-related debt securities4,978 — — 4,978 
Commercial paper1,997 — — 1,997 
Total cash equivalents$71,660 $— $— $71,660 
Marketable securities:
U.S. Treasury securities$69,720 $5 $(81)$69,644 
Commercial paper58,358 — — 58,358 
Corporate debt securities11,524 8 (11)11,521 
Government-related debt securities5,838 5 — 5,843 
Total marketable securities$145,440 $18 $(92)$145,366 
Long-term investments:
Common stock in LianBio$1,231 $— $(860)$371 
Total long-term investments$1,231 $— $(860)$371 
(1 )This balance includes cash requirements settled on a nightly basis.

As of September 30, 2023, substantially all available-for-sale debt securities had a maturity of 12 months or less. Two securities have a contractual maturity between one and two years, with an estimated fair market value of $0.3 million and amortized cost of $0.3 million. As of December 31, 2022, substantially all available-for-sale debt securities had a maturity of 12 months or less. Three securities had a contractual maturity between one and five years, with an estimated fair market value of $4.6 million and amortized cost of $4.6 million. As of September 30, 2023 and December 31, 2022, all available-for-sale debt
securities have gross unrealized losses in a continuous loss position for less than one year. As of September 30, 2023 and December 31, 2022, unrealized credit losses on these securities were not material, and accordingly, the Company did not recognize any other-than-temporary impairment losses.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Balance Sheet Account Detail
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Account Detail BALANCE SHEET ACCOUNT DETAIL
The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below:
Property and Equipment, Net
Property and equipment, net consists of the following:
September 30, 2023December 31, 2022
Furniture and fixtures$1,149 $714 
Office equipment660 197 
Laboratory equipment167 167 
Leasehold improvements680 425 
Property and equipment, at cost2,656 1,503 
(Less): Accumulated depreciation and amortization1,042 546 
Property and equipment, net $1,614 $957 
Depreciation expense for the three months ended September 30, 2023 and 2022 was $0.2 million and $0.1 million, respectively, and for the nine months ended September 30, 2023 and 2022 was $0.5 million and $0.2 million, respectively.
Accounts Payable and Other Accrued Liabilities 
Accounts payable and other accrued liabilities consists of the following:
September 30, 2023December 31, 2022
Trade accounts payable and other$10,382 $5,498 
Accrued product sales deductions3,778 — 
Accrued clinical studies768 3,691 
Operating lease liability, current423 721 
Accounts payable and other accrued liabilities$15,351 $9,910 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stockholders' Equity STOCKHOLDERS’ EQUITY
Common Stock Outstanding and Reserves for Future Issuance
As of September 30, 2023 and December 31, 2022, the Company had 33.1 million and 26.7 million, respectively, of common stock issued and outstanding. Each share of common stock is entitled to one vote.
The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:
September 30, 2023December 31, 2022
Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans7,119,277 8,346,738 
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan2,893,305 2,663,319 
Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans4,737,575 3,899,342 
Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan1,739,693 551,258 
Total shares of common stock reserved16,489,850 15,460,657 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation STOCK-BASED COMPENSATION
Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Cost of sales$31 $— $31 $— 
Research and development1,663 1,015 4,317 2,677 
Selling, general and administrative3,556 2,568 10,000 7,112 
Total stock-based compensation$5,250 $3,583 $14,348 $9,789 

The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Weighted average risk-free interest rate4.28 %3.20 %4.07 %2.22 %
Weighted average volatility72.6 %80.4 %71.7 %78.2 %
Expected term (in years)6.256.256.256.25
Dividend yield rate— %— %— %— %
Weighted-average grant-date fair value per stock option$17.23 $15.81 $15.43 $18.43 

Stock Option Activity

Stock option activity during the nine months ended September 30, 2023 was as follows:
Number of
Shares		Weighted-
Average
Exercise
Price/Share		Weighted-
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value(1)
Outstanding - December 31, 20223,899,342 $16.69 8.07$19,196 
Granted728,169 $15.07 
Exercised(6,443)$2.01 
Forfeited(24,654)$21.19 
Outstanding— March 31, 20234,596,414 $16.43 8.16$15,316 
Granted283,367 $15.55 
Exercised(16,118)$2.78 
Forfeited(144,514)$20.36 
Outstanding— June 30, 20234,719,149 $16.31 7.93$28,319 
Granted130,266 $17.23 
Exercised(109,627)$4.71 
Forfeited(2,213)$19.09 
Outstanding—September 30, 20234,737,575 $16.60 7.77$26,084 
Exercisable— September 30, 20232,471,190 $15.01 6.89$20,742 
Unvested—September 30, 20232,266,385 $18.33 8.74$5,342 
(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock as of September 30, 2023.

As of September 30, 2023, there was approximately $25.9 million of unrecognized compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of 2.2 years.

Restricted Stock Unit Activity

Restricted stock unit activity during the nine months ended September 30, 2023 was as follows:
Number of
Shares		Weighted-
Average
Exercise
Price/Share
Outstanding - December 31, 2022551,258 $17.78 
Granted647,768 $15.24 
Vested(66,611)$19.15 
Forfeited(4,042)$19.40 
Outstanding— March 31, 20231,128,373 $16.24 
Granted380,196 $15.67 
Vested(45,653)$14.04 
Forfeited(71,028)$15.84 
Outstanding— June 30, 20231,391,888 $16.17 
Granted373,244 $17.34 
Vested(25,439)$16.36 
Forfeited— $— 
Outstanding— September 30, 20231,739,693 $16.42 
As of September 30, 2023, there was approximately $24.7 million of unrecognized compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of 3.4 years.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net Loss Per Share NET LOSS PER SHAREThe following table sets forth the computation of basic and diluted net loss per share:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net loss$(39,148)$(22,511)$(93,991)$(48,492)
Weighted-average shares outstanding—basic and diluted30,622,440 26,662,374 28,065,434 23,923,512 
Net loss per share—basic and diluted$(1.28)$(0.84)$(3.35)$(2.03)
The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:

As of September 30,
20232022
Stock options, unexercised—vested and unvested4,737,575 3,839,077 
Restricted stock units—unvested1,739,693 516,005 
Total6,477,268 4,355,082 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Commitment & Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitment & Contingencies COMMITMENTS & CONTINGENCIES
Lease Agreements
In the ordinary course of business, the Company enters into lease agreements with unaffiliated third parties for its facilities and office equipment. As of September 30, 2023, the Company had five active leases for adjacent office and laboratory suites in Irvine, California. On May 1, 2023 the Company amended the existing facilities lease, extending the term for three years through January 31, 2027.
The below table summarizes the components of total lease expense:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Operating lease expense$179 $142 $525 $427 
Variable lease expense125 67 296 168 
Total lease expense$304 $209 $821 $595 
As of September 30, 2023, the Company's facility leases had a remaining lease term of 3.3 years and a weighted-average incremental borrowing rate of 10%.
The below table summarizes the (i) minimum lease payments over the next five years and thereafter, (ii) lease arrangement imputed interest, and (iii) present value of future lease payments:
Operating Leases - Future PaymentsSeptember 30, 2023
2023 (remaining three months)$226 
2024701 
2025789 
2026816 
202768 
Total future lease payments, undiscounted$2,600 
(Less): Imputed interest(381)
(Less): Tenant improvement allowance(129)
Present value of operating lease payments$2,090 
Operating lease liability, current423
Operating lease liability, noncurrent1,667 
Total operating lease liability$2,090 
In-License Agreements for Lotilaner

January 2019 Agreement for Skin and Eye Disease or Conditions in Humans
In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (“Elanco”) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.

In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone payment of $1.0 million was included in research and development expense in the accompanying Condensed Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2023.

The Company has made cash payments to Elanco under the Eye and Derm Agreement comprised of $1.0 million upfront upon contract execution in January 2019 and a total of $4.0 million for three specified clinical milestone achievements in September 2020, April 2021, and March 2023, which were all recorded in research and development expense in the Condensed Statements of Operations and Comprehensive Loss. During the three months ended September 30, 2023 a milestone of $4.0 million was achieved and paid to Elanco upon the first commercial sale of XDEMVY in the U.S., which was recorded as an intangible asset in the accompanying Condensed Balance Sheet as of September 30, 2023. The Company is amortizing the intangible asset to cost of sales over its useful life of 10 years from the date of the first commercial sale.

As of September 30, 2023, the Company is obligated to make further cash payments to Elanco of $2.0 million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $75.0 million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner.

In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license. As a result of the commercialization of XDEMVY, the Company
began accruing royalties payable to Elanco during the third quarter of 2023, which are recorded to cost of sales in the accompanying Condensed Statement of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and accounts payable and other accrued liabilities in the accompanying Condensed Balance Sheet as of September 30, 2023. Royalty expense during the three and nine months ended September 30, 2023 was $0.1 million.

September 2020 Agreement for All Other Diseases or Conditions in Humans

In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco 222,460 shares of its common stock with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).

The Company made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its product sales, net. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.

Employment Agreements
The Company has entered into employment agreements with seven of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.
Litigation Contingencies
From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.
Indemnities and Guarantees
The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Out-License Agreement
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Out-License Agreement OUT-LICENSE AGREEMENT
Out-License of TP-03 Commercial Rights in the China Territory in March 2021

In March 2021, the Company entered into the China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory, as defined in the agreement, for the treatment of Demodex blepharitis and Meibomian Gland Disease. LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.

The Company assessed this arrangement and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory; and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial (Saturn-1) and Phase 3 (Saturn-2) TP-03 trials. The promises to provide research and development services for
Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.

The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $15.0 million; (ii) a second cash payment of $10.0 million; (iii) a $10.0 million milestone that was determined to be within the control of the Company; and (iv) $1.2 million representing the initial fair value of the equity warrant.

The Company accounted for each performance obligation as follows:

Out-License

The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.

Research and Development Services

The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 within license fees and collaboration revenue as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.

In February 2023, a specified milestone event was triggered resulting in $2.5 million recognized as license fees and collaboration revenue in the accompanying Condensed Statements of Operations for the nine months ended September 30, 2023. This cash payment was received in the second quarter of 2023. Through September 30, 2023, the Company received aggregate payments from LianBio totaling $82.5 million, comprised of initial consideration of $15.0 million and $67.5 million for the achievement of specified milestones.
As of September 30, 2023 the Company is eligible to receive further consideration from LianBio upon the achievement of additional TP-03 events, including: (i) additional regulatory milestones and one-time payments of up to an aggregate of $22.5 million; (ii) China-Based TP-03 sales threshold milestone payments of up to an aggregate of $100.0 million; (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales; and (iv) vesting of a LianBio equity warrant upon certain regulatory milestones.
As part of the China Out-License with LianBio the Company granted Elanco an additional 187,500 shares of the Company's common stock that otherwise would have been issuable no later than the 18-month anniversary of the All Human Uses Elanco Agreement for its continued license exclusivity. These issued shares were valued at $5.5 million, based on the Company's closing stock price of $29.30 per share on the date this issuance became contractually required.

The Company made a contractual payment in the amount of $2.5 million to Elanco following the receipt of $25 million of proceeds from LianBio during the second quarter of 2021. During the fourth quarter of 2022, the Company recognized $0.4 million of cost of license fees and collaboration revenue upon receipt of $10 million of cash proceeds from LianBio for the achievement of a clinical development milestone.
The expenses recognized under the China-Out License were not material for the three and nine months ended September 30, 2023 and 2022.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facility Agreement
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Credit Facility Agreement CREDIT FACILITY AGREEMENT
On February 2, 2022, the Company executed the Credit Facility with Hercules Capital, Inc. ("Hercules") and SVB that expires on February 2, 2027. Concurrent with the execution of the Credit Facility, the Company made a $20.0 million draw.

On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to draw down the $25.0 million tranche associated with the New Drug Application ("NDA") submission, from March 15, 2023 to March 15, 2024, provided at least $5.0 million was drawn on or before March 15, 2023 and at least an additional $5.0 million is drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment.

On March 15, 2023 and September 15, 2023, respectively, the Company made separate draws of $5.0 million (including SVB's commitment of $1.25 million) from the $25.0 million tranche that became available upon submission of the NDA. As of September 30, 2023, the Credit Facility provides for a remaining aggregate principal amount of up to $125.0 million with tranched availability as follows: $15.0 million currently available related to the Company's NDA submission with the FDA for TP-03 in September 2022; $35.0 million currently available due to the FDA approval of XDEMVY on July 24, 2023; $50.0 million available upon achievement of product sales, net thresholds; and $25.0 million available upon lender approval.

Each of these tranches may be drawn down in $5.0 million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.

Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 4.45% with an aggregate cap of 11.45%, or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and increased to 8.50% as of September 30, 2023.

The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.4 million was derived by multiplying 4.75% by the $30.0 million outstanding principal balance as of September 30, 2023 and is accreted to interest expense through maturity.

As of September 30, 2023 and 2022, the effective interest rate for the full term of the Credit Facility was 11.96% and 12.37%, respectively.

During the three and nine months ended September 30, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Interest expense for term loan$757 $539 $2,083 $1,275 
Accretion of end of term charge68 48 184 127 
Amortization of debt issuance costs33 46 90 105 
Total interest expense related to term loan$858 $633 $2,357 $1,507 

The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:
September 30, 2023December 31, 2022
Term loan, gross$30,000 $20,000 
Debt issuance costs(875)(875)
Accretion of end of term charge358 174 
Accumulated amortization of debt issuance costs225 135 
Term loan, net $29,708 $19,434 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions RELATED PARTY TRANSACTIONS
Consulting Agreements

The Company has a preexisting consulting agreement with a board member who was appointed in December 2021. This Consulting Agreement provides for annual cash compensation of approximately $0.2 million and option grants to purchase 45,134 shares of the Company’s common stock, with exercise prices ranging from $2.01 to $34.72 per share. This Consulting Agreement may be terminated by either party with ten days' notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.
Sponsorship Activities
In May 2023, a board member of the Company was appointed president of the American Society of Cataract and Refractive Surgery ("ASCRS"), a society dedicated to meeting the needs of anterior segment ophthalmic surgeons.
During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.4 million, respectively, of selling, general and administrative expenses in the accompanying Condensed Statement of Operations and Comprehensive Loss for sponsorship and event-related activities associated with ASCRS.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies and Use of Estimates (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Operating Segment The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company’s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance.
Basis of Presentation
Basis of Presentation
The Company’s Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023.
The interim Condensed Balance Sheet as of September 30, 2023, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022, and the Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.
The financial data and other information disclosed in these notes related to the three and nine-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and nine months ended September 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 or any other interim or annual period.

The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates.

The Company’s financial statements as of and for the three and nine months ended September 30, 2023, reflect the Company’s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an
update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.
Cash and Cash Equivalents Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.
Marketable Securities and Long-Term Investments
Marketable Securities and Long-Term Investments
Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see Note 3). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.
Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.
Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period.
Accounts Receivable, Net Accounts Receivable, NetAccounts receivable generally consists of amounts due from its customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended September 30, 2023.
Inventory
Inventory

Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out (FIFO) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and
adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY on July 24, 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred. The inventory balance as of September 30, 2023 consisted of finished goods.
Intangible Assets, Net Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the periods presented.
Fair Value Measurements
Fair Value Measurements
Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
•Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.
•Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.
•Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see Note 3).
Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.
Property and Equipment, Net
Property and Equipment, Net

Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset’s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three and nine months ended September 30, 2023 and 2022.
Leases
Leases
The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (“ROU assets”) represent the Company’s right to control an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.
The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU asset and lease liability amounts presented in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.
Concentration Risk
Concentration Risk

Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"), a division of First Citizens Bank. These
deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty.

Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.

Major Customers

The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. For the three months ended September 30, 2023, the Company's three largest customers accounted for 55%, 21% and 13% of product sales, respectively. As of September 30, 2023, amounts due from these three customers each exceeded 10% of gross accounts receivable and accounted for approximately 89% of the accounts receivable balance on a combined basis.

Major Suppliers

The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company entered into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than our existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company’s commercialization efforts.
Revenue Recognition
Revenue Recognition
(i) Product Sales, Net

The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.

The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.

Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected
value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Overall, these estimates reflect the Company’s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:

Distribution Service Fees: The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.

Prompt Pay Discounts: The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized.

Product Returns: The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it can not be resold.

Chargebacks: A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler’s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.

Co-payment Assistance: Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.

Rebates and Discounts: The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program. Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company’s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.
(ii) License Fees and Collaboration Revenue
    
China Out-License

License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")— see Note 9. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract’s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period.

The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.
The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payments for executing drug supply agreements; (vi) development milestone payments; and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.

Contractual Terms for Receipt of Payments

A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract’s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.

The contractual terms that establish the Company’s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows:

Upfront License Fees: The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.

Development Milestones: The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment.
Regulatory Milestones: The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.

Royalties: Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee’s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.

Sales Threshold Milestones: Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License.

The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur.

Other License Fees and Collaboration Revenue
License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service. Revenue recognized for the three and nine months ended September 30, 2023 was $0.2 million. No revenue was recognized under such arrangements for the three and nine months ended September 30, 2022.
Cost of Sales
Cost of Sales

Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company’s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY on July 24, 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss.
Research and Development Costs
Research and Development Costs

Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The
Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.

The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.
Stock-Based Compensation
Stock-Based Compensation

The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company’s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date.

Stock awards granted typically have one to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.
All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management’s judgment, including:
Fair Value of Common Stock — The fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant.
Expected Term — The Company’s expected term represents the period that the Company’s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history. 
Expected Volatility — Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.
Risk-Free Interest Rate — The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.Dividend Yield — The Company’s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.
Net Loss per Share
Net Loss per Share
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable.

Due to a net loss for the three and nine months ended September 30, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.
Comprehensive Loss
Comprehensive Loss
Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.
Recently Issued or Effective Accounting Standards
Recently Issued or Effective Accounting Standards
Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company’s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company’s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies and Use of Estimates (Tables)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of Expected Future Amortization Expense
As of September 30, 2023, the expected future amortization expense for the Company's intangible assets is as follows:

Amounts
2023 (remaining three months)$100 
2024400 
2025400 
2026400 
2027400 
Thereafter2,267 
Total future amortization$3,967 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Financial instruments measured at fair value The table below summarizes certain financial instruments measured at fair value that are included within the accompanying Condensed Balance Sheets, and their designation among the three fair value measurement categories (see Note 2 - Fair Value Measurements):
 September 30, 2023
 Level 1Level 2Level 3Total
Assets:
Money market funds(1)
$226,672 $— $— $226,672 
U.S. Treasury securities7,494 — — 7,494 
Commercial paper— 6,964 — 6,964 
Corporate debt securities— 314 — 314 
Government-related debt securities— 5,441 — 5,441 
Common stock in LianBio210 — — 210 
Equity warrants (for LianBio shares)— — 73 73 
Total assets measured at fair value$234,376 $12,719 $73 $247,168 
(1) This balance includes cash requirements settled on a nightly basis.
 December 31, 2022
 Level 1Level 2Level 3Total
Assets:
Money market funds(1)
$64,685 $— $— $64,685 
U.S. Treasury securities69,644 — — 69,644 
Commercial paper— 60,355 — 60,355 
Corporate debt securities— 11,521 — 11,521 
Government-related debt securities— 10,821 — 10,821 
Common stock in LianBio371 — — 371 
Equity warrants (for LianBio shares)— — 108 108 
Total assets measured at fair value$134,700 $82,697 $108 $217,505 
(1) This balance includes cash requirements settled on a nightly basis.
Changes in fair value of equity warrants
The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:
Value of equity warrants
Fair value as of December 31, 2022$108 
Remeasurement of equity warrants(17)
Fair value as of March 31, 2023$91 
Remeasurement of equity warrants18 
Fair value as of June 30, 2023$109 
Remeasurement of equity warrants(36)
Fair value as of September 30, 2023$73 
Value of equity warrants
Fair value as of December 31, 2021$663 
Remeasurement of equity warrants(245)
Fair value as of March 31, 2022$418 
Recognition of equity warrants103 
Remeasurement of equity warrants(257)
Fair value as of June 30, 2022$264 
Remeasurement of equity warrants(18)
Fair value as of September 30, 2022$246 
Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities
The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:
September 30, 2023
Amortized costUnrealized gainsUnrealized lossesEstimated fair value
Cash equivalents:
Money market funds(1)
$226,672 $— $— $226,672 
Total cash equivalents$226,672 $— $— $226,672 
Marketable securities:
U.S. Treasury securities$7,481 $17 $(4)$7,494 
Commercial paper6,966 — (2)6,964 
Corporate debt securities312 2 — 314 
Government-related debt securities5,446 — (5)5,441 
Total marketable securities$20,205 $19 $(11)$20,213 
Long-term investments:
Common stock in LianBio$1,108 $— $(898)$210 
Total long-term investments$1,108 $— $(898)$210 
(1) This balance includes cash requirements settled on a nightly basis.
December 31, 2022
Amortized costUnrealized gainsUnrealized lossesEstimated fair value
Cash equivalents:
Money market funds(1)
$64,685 $— $— $64,685 
Government-related debt securities4,978 — — 4,978 
Commercial paper1,997 — — 1,997 
Total cash equivalents$71,660 $— $— $71,660 
Marketable securities:
U.S. Treasury securities$69,720 $5 $(81)$69,644 
Commercial paper58,358 — — 58,358 
Corporate debt securities11,524 8 (11)11,521 
Government-related debt securities5,838 5 — 5,843 
Total marketable securities$145,440 $18 $(92)$145,366 
Long-term investments:
Common stock in LianBio$1,231 $— $(860)$371 
Total long-term investments$1,231 $— $(860)$371 
(1 )This balance includes cash requirements settled on a nightly basis.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Balance Sheet Account Detail (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Property and equipment, net of accumulated depreciation
Property and equipment, net consists of the following:
September 30, 2023December 31, 2022
Furniture and fixtures$1,149 $714 
Office equipment660 197 
Laboratory equipment167 167 
Leasehold improvements680 425 
Property and equipment, at cost2,656 1,503 
(Less): Accumulated depreciation and amortization1,042 546 
Property and equipment, net $1,614 $957 
Accounts payable and accrued liabilities
Accounts payable and other accrued liabilities consists of the following:
September 30, 2023December 31, 2022
Trade accounts payable and other$10,382 $5,498 
Accrued product sales deductions3,778 — 
Accrued clinical studies768 3,691 
Operating lease liability, current423 721 
Accounts payable and other accrued liabilities$15,351 $9,910 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stock details The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:
September 30, 2023December 31, 2022
Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans7,119,277 8,346,738 
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan2,893,305 2,663,319 
Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans4,737,575 3,899,342 
Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan1,739,693 551,258 
Total shares of common stock reserved16,489,850 15,460,657 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based compensation
Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Cost of sales$31 $— $31 $— 
Research and development1,663 1,015 4,317 2,677 
Selling, general and administrative3,556 2,568 10,000 7,112 
Total stock-based compensation$5,250 $3,583 $14,348 $9,789 
Valuation assumptions of stock options
The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Weighted average risk-free interest rate4.28 %3.20 %4.07 %2.22 %
Weighted average volatility72.6 %80.4 %71.7 %78.2 %
Expected term (in years)6.256.256.256.25
Dividend yield rate— %— %— %— %
Weighted-average grant-date fair value per stock option$17.23 $15.81 $15.43 $18.43 
Stock option activity Stock option activity during the nine months ended September 30, 2023 was as follows:
Number of
Shares		Weighted-
Average
Exercise
Price/Share		Weighted-
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value(1)
Outstanding - December 31, 20223,899,342 $16.69 8.07$19,196 
Granted728,169 $15.07 
Exercised(6,443)$2.01 
Forfeited(24,654)$21.19 
Outstanding— March 31, 20234,596,414 $16.43 8.16$15,316 
Granted283,367 $15.55 
Exercised(16,118)$2.78 
Forfeited(144,514)$20.36 
Outstanding— June 30, 20234,719,149 $16.31 7.93$28,319 
Granted130,266 $17.23 
Exercised(109,627)$4.71 
Forfeited(2,213)$19.09 
Outstanding—September 30, 20234,737,575 $16.60 7.77$26,084 
Exercisable— September 30, 20232,471,190 $15.01 6.89$20,742 
Unvested—September 30, 20232,266,385 $18.33 8.74$5,342 
(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock as of September 30, 2023.
Restricted stock unit activity
Restricted stock unit activity during the nine months ended September 30, 2023 was as follows:
Number of
Shares		Weighted-
Average
Exercise
Price/Share
Outstanding - December 31, 2022551,258 $17.78 
Granted647,768 $15.24 
Vested(66,611)$19.15 
Forfeited(4,042)$19.40 
Outstanding— March 31, 20231,128,373 $16.24 
Granted380,196 $15.67 
Vested(45,653)$14.04 
Forfeited(71,028)$15.84 
Outstanding— June 30, 20231,391,888 $16.17 
Granted373,244 $17.34 
Vested(25,439)$16.36 
Forfeited— $— 
Outstanding— September 30, 20231,739,693 $16.42 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net (loss) income per share, basis and diluted The following table sets forth the computation of basic and diluted net loss per share:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net loss$(39,148)$(22,511)$(93,991)$(48,492)
Weighted-average shares outstanding—basic and diluted30,622,440 26,662,374 28,065,434 23,923,512 
Net loss per share—basic and diluted$(1.28)$(0.84)$(3.35)$(2.03)
Outstanding potentially dilutive securities
The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:

As of September 30,
20232022
Stock options, unexercised—vested and unvested4,737,575 3,839,077 
Restricted stock units—unvested1,739,693 516,005 
Total6,477,268 4,355,082 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Commitment & Contingencies (Tables)
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Components of lease cost
The below table summarizes the components of total lease expense:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Operating lease expense$179 $142 $525 $427 
Variable lease expense125 67 296 168 
Total lease expense$304 $209 $821 $595 
Future contractual lease payments
The below table summarizes the (i) minimum lease payments over the next five years and thereafter, (ii) lease arrangement imputed interest, and (iii) present value of future lease payments:
Operating Leases - Future PaymentsSeptember 30, 2023
2023 (remaining three months)$226 
2024701 
2025789 
2026816 
202768 
Total future lease payments, undiscounted$2,600 
(Less): Imputed interest(381)
(Less): Tenant improvement allowance(129)
Present value of operating lease payments$2,090 
Operating lease liability, current423
Operating lease liability, noncurrent1,667 
Total operating lease liability$2,090 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facility Agreement (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Summary of Interest Expense
During the three and nine months ended September 30, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Interest expense for term loan$757 $539 $2,083 $1,275 
Accretion of end of term charge68 48 184 127 
Amortization of debt issuance costs33 46 90 105 
Total interest expense related to term loan$858 $633 $2,357 $1,507 
Balances of Debt, Debt Issuance Costs, and Accumulated Accretion The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:
September 30, 2023December 31, 2022
Term loan, gross$30,000 $20,000 
Debt issuance costs(875)(875)
Accretion of end of term charge358 174 
Accumulated amortization of debt issuance costs225 135 
Term loan, net $29,708 $19,434 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Description of Business and Presentation of Financial Statements (Details)
$ / shares in Units, $ in Millions
 1 Months Ended 2 Months Ended 9 Months Ended
Sep. 06, 2023
USD ($)
$ / shares
shares
Aug. 04, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
$ / shares
shares
May 31, 2022
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
Sep. 30, 2023
segment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of reportable segments | segment           1
Number of operating segments | segment           1
Follow-On Public Offering            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock issued (shares) | shares   5,714,285 289,832 5,600,000    
Original issue price (usd per share) | $ / shares   $ 17.50 $ 13.50 $ 13.50 $ 13.50  
Stock issued, net proceeds | $   $ 93.5     $ 74.3  
Underwriters' option            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock issued (shares) | shares 355,164 857,142   840,000    
Original issue price (usd per share) | $ / shares $ 17.50          
Stock issued, net proceeds | $ $ 5.8          
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Intangible assets, net $ 3,967,000 $ 0
Intangible Assets, Milestone Payment    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Intangible assets, net $ 4,000,000  
Useful life 10 years  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Accounting Policies [Abstract]  
2023 (remaining three months) $ 100
2024 400
2025 400
2026 400
2027 400
Thereafter 2,267
Total future amortization $ 3,967
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies and Use of Estimates (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Property, Plant and Equipment [Line Items]        
Fair market value of common stock     100.00%  
Expected term (in years) 6 years 3 months 6 years 3 months 6 years 3 months 6 years 3 months
Total revenues $ 1,871,000 $ 0 $ 4,371,000 $ 15,816,000
Dividend yield rate 0.00% 0.00% 0.00% 0.00%
License And Collaboration, Other        
Property, Plant and Equipment [Line Items]        
Total revenues $ 200,000 $ 0 $ 200,000 $ 0
Revenue Benchmark | Customer Concentration Risk | Customer One        
Property, Plant and Equipment [Line Items]        
Concentration risk 55.00%      
Revenue Benchmark | Customer Concentration Risk | Customer Two        
Property, Plant and Equipment [Line Items]        
Concentration risk 21.00%      
Revenue Benchmark | Customer Concentration Risk | Customer Three        
Property, Plant and Equipment [Line Items]        
Concentration risk 13.00%      
Accounts Receivable | Customer Concentration Risk | Three Customers        
Property, Plant and Equipment [Line Items]        
Concentration risk 89.00%      
2016 Plan        
Property, Plant and Equipment [Line Items]        
Expected term (in years)     10 years  
Minimum        
Property, Plant and Equipment [Line Items]        
Useful lives of assets 3 years   3 years  
Minimum | 2016 Plan        
Property, Plant and Equipment [Line Items]        
Service condition period for full vesting     1 year  
Maximum        
Property, Plant and Equipment [Line Items]        
Useful lives of assets 5 years   5 years  
Maximum | 2016 Plan        
Property, Plant and Equipment [Line Items]        
Service condition period for full vesting     4 years  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Assets:    
Cash and cash equivalents $ 226,672 $ 71,660
Corporate debt securities 20,213 145,366
Common stock in LianBio 210 371
Equity warrants (for LianBio shares) 73 108
Total assets measured at fair value 247,168 217,505
Money market funds(1)    
Assets:    
Cash and cash equivalents 226,672 64,685
U.S. Treasury securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 7,494 69,644
Corporate debt securities 7,494 69,644
Commercial paper    
Assets:    
Cash and cash equivalents   1,997
Debt securities, available for sale and cash and cash equivalents 6,964 60,355
Corporate debt securities 6,964 58,358
Corporate debt securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 314 11,521
Corporate debt securities 314 11,521
Government-related debt securities    
Assets:    
Cash and cash equivalents 226,672 4,978
Debt securities, available for sale and cash and cash equivalents 5,441 10,821
Corporate debt securities 5,441 5,843
Level 1    
Assets:    
Common stock in LianBio 210 371
Equity warrants (for LianBio shares) 0 0
Total assets measured at fair value 234,376 134,700
Level 1 | Money market funds(1)    
Assets:    
Cash and cash equivalents 226,672 64,685
Level 1 | U.S. Treasury securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 7,494 69,644
Level 1 | Commercial paper    
Assets:    
Debt securities, available for sale and cash and cash equivalents 0 0
Level 1 | Corporate debt securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 0 0
Level 1 | Government-related debt securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 0 0
Level 2    
Assets:    
Common stock in LianBio 0 0
Equity warrants (for LianBio shares) 0 0
Total assets measured at fair value 12,719 82,697
Level 2 | Money market funds(1)    
Assets:    
Cash and cash equivalents 0 0
Level 2 | U.S. Treasury securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 0 0
Level 2 | Commercial paper    
Assets:    
Debt securities, available for sale and cash and cash equivalents 6,964 60,355
Level 2 | Corporate debt securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 314 11,521
Level 2 | Government-related debt securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 5,441 10,821
Level 3    
Assets:    
Common stock in LianBio 0 0
Equity warrants (for LianBio shares) 73 108
Total assets measured at fair value 73 108
Level 3 | Money market funds(1)    
Assets:    
Cash and cash equivalents 0 0
Level 3 | U.S. Treasury securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 0 0
Level 3 | Commercial paper    
Assets:    
Debt securities, available for sale and cash and cash equivalents 0 0
Level 3 | Corporate debt securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents 0 0
Level 3 | Government-related debt securities    
Assets:    
Debt securities, available for sale and cash and cash equivalents $ 0 $ 0
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Additional Information (Details)
$ in Thousands
 1 Months Ended
Mar. 31, 2021
tranche
Sep. 30, 2023
USD ($)
security
shares
Dec. 31, 2022
USD ($)
security
warrant
Debt Securities, Available-for-Sale [Line Items]      
Number of tranches | tranche 3    
Number of vested warrants | warrant     2
Equity securities (in shares) | shares   156,746  
Number of securities with contractual maturity between one and five years | security   2 3
Corporate debt securities   $ 20,213 $ 145,366
Amortized cost   20,205 145,440
Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months      
Debt Securities, Available-for-Sale [Line Items]      
Corporate debt securities   300 4,600
Amortized cost   $ 300 $ 4,600
Minimum | Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months      
Fair Value Disclosures [Abstract]      
Contractual maturity   1 year 1 year
Debt Securities, Available-for-Sale [Line Items]      
Contractual maturity   1 year 1 year
Maximum | Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months      
Fair Value Disclosures [Abstract]      
Contractual maturity   2 years 5 years
Debt Securities, Available-for-Sale [Line Items]      
Contractual maturity   2 years 5 years
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]            
Fair value, beginning of period $ 109 $ 91 $ 108 $ 264 $ 418 $ 663
Recognition of equity warrants         103  
Remeasurement of equity warrants (36) 18 (17) (18) (257) (245)
Fair value, end of period $ 73 $ 109 $ 91 $ 246 $ 264 $ 418
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Cash equivalents:    
Amortized cost $ 226,672 $ 71,660
Cash and cash equivalents 226,672 71,660
Marketable securities:    
Amortized cost 20,205 145,440
Unrealized gains 19 18
Unrealized losses (11) (92)
Corporate debt securities 20,213 145,366
Long-term investments:    
Amortized cost 1,108 1,231
Unrealized gains 0 0
Unrealized losses (898) (860)
Estimated fair value 210 371
Money market funds(1)    
Cash equivalents:    
Amortized cost   64,685
Cash and cash equivalents 226,672 64,685
U.S. Treasury securities    
Marketable securities:    
Amortized cost 7,481 69,720
Unrealized gains 17 5
Unrealized losses (4) (81)
Corporate debt securities 7,494 69,644
Commercial paper    
Cash equivalents:    
Amortized cost   1,997
Cash and cash equivalents   1,997
Marketable securities:    
Amortized cost 6,966 58,358
Unrealized gains 0 0
Unrealized losses (2) 0
Corporate debt securities 6,964 58,358
Government-related debt securities    
Cash equivalents:    
Amortized cost 226,672 4,978
Cash and cash equivalents 226,672 4,978
Marketable securities:    
Amortized cost 5,446 5,838
Unrealized gains 0 5
Unrealized losses (5) 0
Corporate debt securities 5,441 5,843
Corporate debt securities    
Marketable securities:    
Amortized cost 312 11,524
Unrealized gains 2 8
Unrealized losses 0 (11)
Corporate debt securities $ 314 $ 11,521
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost $ 2,656   $ 2,656   $ 1,503
(Less): Accumulated depreciation and amortization 1,042   1,042   546
Property and equipment, net 1,614   1,614   957
Depreciation 200 $ 100 497 $ 227  
Furniture and fixtures          
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost 1,149   1,149   714
Office equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost 660   660   197
Laboratory equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost 167   167   167
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost $ 680   $ 680   $ 425
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Trade accounts payable and other $ 10,382 $ 5,498
Accrued product sales deductions 3,778 0
Accrued clinical studies 768 3,691
Operating lease liability, current 423 721
Accounts payable and other accrued liabilities $ 15,351 $ 9,910
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Additional Information (Details)
Sep. 30, 2023
vote
shares
Dec. 31, 2022
shares
Equity [Abstract]    
Common stock, outstanding (shares) 33,104,087 26,727,458
Common stock, issued (shares) 33,104,087 26,727,458
Common stock votes | vote 1  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Shares Reserved for Issuance (Details) - shares
Sep. 30, 2023
Dec. 31, 2022
Equity [Abstract]    
Stock options reserved for future grant (shares) 7,119,277 8,346,738
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan 2,893,305 2,663,319
Stock options issued and outstanding (shares) 4,737,575 3,899,342
Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan 1,739,693 551,258
Total shares of common stock reserved (shares) 16,489,850 15,460,657
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation - Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation $ 5,250 $ 3,583 $ 14,348 $ 9,789
Cost of sales        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation 31 0 31 0
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation 1,663 1,015 4,317 2,677
Selling, general and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation $ 3,556 $ 2,568 $ 10,000 $ 7,112
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation - Valuation Assumptions of Stock Options (Details) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]        
Weighted average risk-free interest rate 4.28% 3.20% 4.07% 2.22%
Weighted average volatility 72.60% 80.40% 71.70% 78.20%
Expected term (in years) 6 years 3 months 6 years 3 months 6 years 3 months 6 years 3 months
Dividend yield rate 0.00% 0.00% 0.00% 0.00%
Weighted-average grant-date fair value per stock option (usd per share) $ 17.23 $ 15.81 $ 15.43 $ 18.43
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]          
Beginning balance (shares) 4,719,149 4,596,414 3,899,342 3,899,342  
Granted (shares) 130,266 283,367 728,169    
Exercised (shares) (109,627) (16,118) (6,443)    
Forfeited (shares) (2,213) (144,514) (24,654)    
Ending balance (shares) 4,737,575 4,719,149 4,596,414 4,737,575 3,899,342
Exercisable (shares) 2,471,190     2,471,190  
Unvested (shares) 2,266,385     2,266,385  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]          
Beginning balance (usd per share) $ 16.31 $ 16.43 $ 16.69 $ 16.69  
Granted (usd per share) 17.23 15.55 15.07    
Exercised (usd per share) 4.71 2.78 2.01    
Forfeited (usd per share) 19.09 20.36 21.19    
Ending balance (usd per share) 16.60 $ 16.31 $ 16.43 16.60 $ 16.69
Exercisable (usd per share) 15.01     15.01  
Unvested (usd per share) $ 18.33     $ 18.33  
Weighted-Average Remaining Contractual Term          
Outstanding 7 years 9 months 7 days 7 years 11 months 4 days 8 years 1 month 28 days   8 years 25 days
Exercisable       6 years 10 months 20 days  
Unvested       8 years 8 months 26 days  
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]          
Outstanding $ 26,084 $ 28,319 $ 15,316 $ 26,084 $ 19,196
Exercisable 20,742     20,742  
Unvested $ 5,342     $ 5,342  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation - Additional Information (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation expense $ 25.9
Stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation expense, weighted average period of recognition 2 years 2 months 12 days
Restricted stock  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation expense, weighted average period of recognition 3 years 4 months 24 days
Unrecognized compensation expense $ 24.7
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted stock - $ / shares
 3 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Number of Shares      
Outstanding, beginning balance (shares) 1,391,888 1,128,373 551,258
Granted (shares) 373,244 380,196 647,768
Vested (shares) (25,439) (45,653) (66,611)
Forfeited (shares) 0 (71,028) (4,042)
Outstanding, ending balance (shares) 1,739,693 1,391,888 1,128,373
Weighted Average Value per Share      
Outstanding, beginning balance (usd per share) $ 16.17 $ 16.24 $ 17.78
Granted (usd per share) 17.34 15.67 15.24
Vested (usd per share) 16.36 14.04 19.15
Forfeited (usd per share) 0 15.84 19.40
Outstanding, ending balance (usd per share) $ 16.42 $ 16.17 $ 16.24
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share, Basic [Abstract]                
Net loss $ (39,148) $ (31,424) $ (23,419) $ (22,511) $ (5,743) $ (20,238) $ (93,991) $ (48,492)
Weighted-average shares outstanding, basic (shares) 30,622,440     26,662,374     28,065,434 23,923,512
Weighted-average shares outstanding, diluted (shares) 30,622,440     26,662,374     28,065,434 23,923,512
Net loss per share, basic (usd per share) $ (1.28)     $ (0.84)     $ (3.35) $ (2.03)
Net loss per share, diluted (usd per share) $ (1.28)     $ (0.84)     $ (3.35) $ (2.03)
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share - Antidilutive Securities (Details) - shares
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net income (loss) per share 6,477,268 4,355,082
Stock options, unexercised—vested and unvested    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net income (loss) per share 4,737,575 3,839,077
Restricted stock units—unvested    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net income (loss) per share 1,739,693 516,005
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Commitment & Contingencies - Lease Agreements (Details)
Sep. 30, 2023
contract
Commitments and Contingencies Disclosure [Abstract]  
Number of leases 5
Weighted average remaining lease term 3 years 3 months 18 days
Estimated incremental borrowing rate 10.00%
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Commitment & Contingencies - Lease Cost (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]        
Operating lease expense $ 179 $ 142 $ 525 $ 427
Variable Lease, Cost 125 67 296 168
Lease, Cost, Total $ 304 $ 209 $ 821 $ 595
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Commitment and Contingencies - Summary of Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
2023 (remaining three months) $ 226  
2024 701  
2025 789  
2026 816  
2027 68  
Total future lease payments, undiscounted 2,600  
(Less): Imputed interest (381)  
(Less): Tenant improvement allowance (129)  
Total operating lease liability 2,090  
Operating lease liability, current 423 $ 721
Operating lease liability, noncurrent 1,667  
Total operating lease liability $ 2,090  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Commitment & Contingencies - In-License Agreement for Lotilaner (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 31 Months Ended
Dec. 31, 2022
Sep. 30, 2020
Jan. 31, 2019
Sep. 30, 2023
Sep. 30, 2023
Mar. 31, 2023
Intangible Assets, Milestone Payment            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Useful life       10 years 10 years  
License agreement | Elanco            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront payment received     $ 1.0      
Future cash payments       $ 2.0 $ 2.0  
Maximum milestone payments       75.0 75.0  
Royalty expense       0.1 0.1  
Common stock issued for license agreement (shares)   222,460        
Common stock issued for license agreement, value   $ 3.1        
Common stock issued for license agreement, share price (usd per share)   $ 14.0003        
License agreement | Clinical milestones | Elanco            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contractual milestone payment $ 0.5       1.0 $ 4.0
Maximum milestone payments       4.0 4.0  
License agreement | Commercial and sales milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum milestone payments       77.0 $ 77.0  
License agreement | Commercial and sales milestones | Elanco            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contractual milestone payment       $ 4.0    
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Commitment & Contingencies - Employment Arrangements (Details)
Sep. 30, 2023
contract
Commitments and Contingencies Disclosure [Abstract]  
Number of employment arrangements with executive officers 7
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Out-License Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 30 Months Ended
Feb. 28, 2023
Mar. 31, 2021
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2021
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Amortized cost     $ 1,108 $ 1,231     $ 1,108   $ 1,108
Research and development     12,105   $ 10,912   37,007 $ 32,596  
License agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Additional shares to be issued upon 18-month anniversary of contract execution (shares)   187,500              
Additional shares to be issued upon 18-month anniversary of contract execution, value   $ 5,500              
Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)   $ 29.30              
LianBio | License agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront payment   $ 15,000 15,000       15,000   15,000
Additional cash payment   10,000              
Amortized cost   1,200              
Revenue recognized                 82,500
Maximum milestone payments     100,000       100,000   100,000
Upfront payment received       10,000   $ 25,000      
LianBio | License agreement | Milestone Determined by the Company                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone payments to be achieved   $ 10,000              
LianBio | License agreement | Development and Regulatory Milestone                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone payments to be achieved     67,500       67,500   67,500
Revenue recognized $ 2,500                
Maximum milestone payments     22,500       22,500   22,500
Elanco | License agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Maximum milestone payments     $ 75,000       $ 75,000   $ 75,000
Upfront payment received           $ 2,500      
Research and development       $ 400          
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facility Agreement (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 15, 2023
Mar. 15, 2023
Feb. 02, 2022
Sep. 30, 2023
Jan. 05, 2023
Dec. 31, 2022
Sep. 30, 2022
Debt Instrument [Line Items]              
Principal outstanding       $ 30,000   $ 20,000  
Line of Credit              
Debt Instrument [Line Items]              
Draw on credit facility $ 5,000 $ 5,000 $ 20,000        
Credit facility, aggregate principal amount       $ 125,000      
Increments to draw on credit facility at company's election     $ 5,000        
Interest rate     8.45%        
Interest rate     3.25% 8.50%      
End of term charge       $ 1,400      
End of term charge, interest rate     4.75%        
Effective interest rate       11.96%     12.37%
Line of Credit | Prime Rate              
Debt Instrument [Line Items]              
Basis spread on variable rate     4.45%        
Line of Credit | Prime Rate | Maximum              
Debt Instrument [Line Items]              
Basis spread on variable rate     11.45%        
Line of Credit | Credit Facility, Tranche One              
Debt Instrument [Line Items]              
Credit facility, aggregate principal amount       $ 15,000 $ 25,000    
Line of Credit | Credit Facility, Tranche Two              
Debt Instrument [Line Items]              
Credit facility, aggregate principal amount       35,000      
Line of Credit | Credit Facility, Tranche Three              
Debt Instrument [Line Items]              
Credit facility, aggregate principal amount       50,000      
Line of Credit | Credit Facility, Tranche Four              
Debt Instrument [Line Items]              
Credit facility, aggregate principal amount       $ 25,000      
Line of Credit | Credit Facility, First Amendment, Tranche Two              
Debt Instrument [Line Items]              
Increments to draw on credit facility at company's election         $ 5,000    
Line of Credit, SVB              
Debt Instrument [Line Items]              
Draw on credit facility $ 1,250 $ 1,250          
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facility Agreement - Summary of Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Debt Disclosure [Abstract]        
Interest expense for term loan $ 757 $ 539 $ 2,083 $ 1,275
Accretion of end of term charge 68 48 184 127
Amortization of debt issuance costs 33 46 90 105
Total interest expense related to term loan $ 858 $ 633 $ 2,357 $ 1,507
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
Term loan, gross $ 30,000 $ 20,000
Debt issuance costs (875) (875)
Accretion of end of term charge 358 174
Accumulated amortization of debt issuance costs 225 135
Term loan, net $ 29,708 $ 19,434
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2021
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Related Party Transaction [Line Items]              
Granted (shares)   130,266 283,367 728,169      
Granted (usd per share)   $ 17.23 $ 15.55 $ 15.07      
Selling, general and administrative   $ 30,324     $ 11,994 $ 65,695 $ 30,316
Director              
Related Party Transaction [Line Items]              
Related party transaction, annual cash compensation $ 200            
Granted (shares) 45,134            
Related party transaction, termination notice, period 10 days            
Director | Minimum              
Related Party Transaction [Line Items]              
Granted (usd per share) $ 2.01            
Director | Maximum              
Related Party Transaction [Line Items]              
Granted (usd per share) $ 34.72            
Related Party              
Related Party Transaction [Line Items]              
Selling, general and administrative   $ 200       $ 400  
XML 68 tars-20230930_htm.xml IDEA: XBRL DOCUMENT 0001819790 2023-01-01 2023-09-30 0001819790 2023-11-03 0001819790 2023-09-30 0001819790 2022-12-31 0001819790 us-gaap:ProductMember 2023-07-01 2023-09-30 0001819790 us-gaap:ProductMember 2022-07-01 2022-09-30 0001819790 us-gaap:ProductMember 2023-01-01 2023-09-30 0001819790 us-gaap:ProductMember 2022-01-01 2022-09-30 0001819790 tars:LicenseAndCollaborationMember 2023-07-01 2023-09-30 0001819790 tars:LicenseAndCollaborationMember 2022-07-01 2022-09-30 0001819790 tars:LicenseAndCollaborationMember 2023-01-01 2023-09-30 0001819790 tars:LicenseAndCollaborationMember 2022-01-01 2022-09-30 0001819790 2023-07-01 2023-09-30 0001819790 2022-07-01 2022-09-30 0001819790 2022-01-01 2022-09-30 0001819790 us-gaap:CommonStockMember 2022-12-31 0001819790 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001819790 us-gaap:RetainedEarningsMember 2022-12-31 0001819790 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001819790 2023-01-01 2023-03-31 0001819790 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001819790 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001819790 2023-03-31 0001819790 us-gaap:CommonStockMember 2023-03-31 0001819790 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001819790 us-gaap:RetainedEarningsMember 2023-03-31 0001819790 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001819790 2023-04-01 2023-06-30 0001819790 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001819790 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001819790 2023-06-30 0001819790 us-gaap:CommonStockMember 2023-06-30 0001819790 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001819790 us-gaap:RetainedEarningsMember 2023-06-30 0001819790 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001819790 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001819790 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001819790 us-gaap:CommonStockMember 2023-09-30 0001819790 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001819790 us-gaap:RetainedEarningsMember 2023-09-30 0001819790 2021-12-31 0001819790 us-gaap:CommonStockMember 2021-12-31 0001819790 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001819790 us-gaap:RetainedEarningsMember 2021-12-31 0001819790 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001819790 2022-01-01 2022-03-31 0001819790 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001819790 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001819790 2022-03-31 0001819790 us-gaap:CommonStockMember 2022-03-31 0001819790 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001819790 us-gaap:RetainedEarningsMember 2022-03-31 0001819790 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001819790 2022-04-01 2022-06-30 0001819790 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001819790 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001819790 2022-06-30 0001819790 us-gaap:CommonStockMember 2022-06-30 0001819790 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001819790 us-gaap:RetainedEarningsMember 2022-06-30 0001819790 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001819790 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001819790 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001819790 2022-09-30 0001819790 us-gaap:CommonStockMember 2022-09-30 0001819790 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001819790 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001819790 us-gaap:RetainedEarningsMember 2022-09-30 0001819790 tars:FollowOnPublicOfferingMember 2023-08-04 2023-08-04 0001819790 tars:FollowOnPublicOfferingMember 2023-08-04 0001819790 us-gaap:OverAllotmentOptionMember 2023-08-04 2023-08-04 0001819790 us-gaap:OverAllotmentOptionMember 2023-09-06 2023-09-06 0001819790 us-gaap:OverAllotmentOptionMember 2023-09-06 0001819790 tars:FollowOnPublicOfferingMember 2022-05-01 2022-05-31 0001819790 tars:FollowOnPublicOfferingMember 2022-05-31 0001819790 us-gaap:OverAllotmentOptionMember 2022-05-01 2022-05-31 0001819790 tars:FollowOnPublicOfferingMember 2022-06-01 2022-06-30 0001819790 tars:FollowOnPublicOfferingMember 2022-06-30 0001819790 tars:FollowOnPublicOfferingMember 2022-05-01 2022-06-30 0001819790 tars:IntangibleAssetsMilestonePaymentMember 2023-09-30 0001819790 srt:MinimumMember 2023-09-30 0001819790 srt:MaximumMember 2023-09-30 0001819790 tars:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001819790 tars:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001819790 tars:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001819790 tars:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001819790 tars:LicenseAndCollaborationOtherMember 2023-07-01 2023-09-30 0001819790 tars:LicenseAndCollaborationOtherMember 2023-01-01 2023-09-30 0001819790 tars:LicenseAndCollaborationOtherMember 2022-07-01 2022-09-30 0001819790 tars:LicenseAndCollaborationOtherMember 2022-01-01 2022-09-30 0001819790 srt:MinimumMember tars:EquityIncentivePlan2016Member 2023-01-01 2023-09-30 0001819790 srt:MaximumMember tars:EquityIncentivePlan2016Member 2023-01-01 2023-09-30 0001819790 tars:EquityIncentivePlan2016Member 2023-01-01 2023-09-30 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2023-09-30 0001819790 us-gaap:MoneyMarketFundsMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2023-09-30 0001819790 us-gaap:USTreasurySecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2023-09-30 0001819790 us-gaap:CommercialPaperMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001819790 us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0001819790 us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0001819790 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001819790 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001819790 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001819790 us-gaap:MoneyMarketFundsMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001819790 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2022-12-31 0001819790 us-gaap:CommercialPaperMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001819790 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001819790 us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0001819790 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001819790 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001819790 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001819790 2021-03-01 2021-03-31 0001819790 2022-01-01 2022-12-31 0001819790 srt:MinimumMember tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember 2023-09-30 0001819790 srt:MaximumMember tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember 2023-09-30 0001819790 tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember 2023-09-30 0001819790 srt:MinimumMember tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember 2022-12-31 0001819790 srt:MaximumMember tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember 2022-12-31 0001819790 tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember 2022-12-31 0001819790 us-gaap:FurnitureAndFixturesMember 2023-09-30 0001819790 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001819790 us-gaap:OfficeEquipmentMember 2023-09-30 0001819790 us-gaap:OfficeEquipmentMember 2022-12-31 0001819790 us-gaap:OtherMachineryAndEquipmentMember 2023-09-30 0001819790 us-gaap:OtherMachineryAndEquipmentMember 2022-12-31 0001819790 us-gaap:LeaseholdImprovementsMember 2023-09-30 0001819790 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001819790 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001819790 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0001819790 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001819790 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0001819790 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001819790 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001819790 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001819790 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001819790 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001819790 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001819790 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001819790 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001819790 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001819790 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001819790 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001819790 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001819790 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001819790 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001819790 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001819790 us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0001819790 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001819790 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001819790 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001819790 tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember 2023-01-01 2023-09-30 0001819790 tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember 2022-01-01 2022-09-30 0001819790 tars:ElancoMember tars:ClinicalMilestonesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-09-30 0001819790 tars:ElancoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2019-01-01 2019-01-31 0001819790 tars:ElancoMember tars:ClinicalMilestonesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-09-01 2023-03-31 0001819790 tars:ElancoMember tars:CommercialAndSalesMilestonesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-07-01 2023-09-30 0001819790 tars:ElancoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-09-30 0001819790 tars:ElancoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-09-30 0001819790 tars:ElancoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-07-01 2023-09-30 0001819790 tars:ElancoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-09-01 2020-09-30 0001819790 tars:ElancoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-09-30 0001819790 tars:ElancoMember tars:ClinicalMilestonesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-12-01 2022-12-31 0001819790 tars:ElancoMember tars:ClinicalMilestonesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-09-30 0001819790 tars:CommercialAndSalesMilestonesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-09-30 0001819790 tars:LianBioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-03-31 0001819790 tars:LianBioMember tars:MilestoneDeterminedByTheCompanyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-03-31 0001819790 tars:LianBioMember tars:DevelopmentAndRegulatoryMilestoneMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-02-01 2023-02-28 0001819790 tars:LianBioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-03-26 2023-09-30 0001819790 tars:LianBioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-09-30 0001819790 tars:LianBioMember tars:DevelopmentAndRegulatoryMilestoneMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-09-30 0001819790 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-03-01 2021-03-31 0001819790 tars:ElancoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-04-01 2021-06-30 0001819790 tars:LianBioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-04-01 2021-06-30 0001819790 tars:ElancoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-10-01 2022-12-31 0001819790 tars:LianBioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-10-01 2022-12-31 0001819790 us-gaap:LineOfCreditMember 2022-02-02 2022-02-02 0001819790 tars:CreditFacilityTrancheOneMember us-gaap:LineOfCreditMember 2023-01-05 0001819790 tars:CreditFacilityFirstAmendmentTrancheTwoMember us-gaap:LineOfCreditMember 2023-01-05 0001819790 us-gaap:LineOfCreditMember 2023-03-15 2023-03-15 0001819790 us-gaap:LineOfCreditMember 2023-09-15 2023-09-15 0001819790 tars:LineOfCreditSVBMember 2023-03-15 2023-03-15 0001819790 tars:LineOfCreditSVBMember 2023-09-15 2023-09-15 0001819790 us-gaap:LineOfCreditMember 2023-09-30 0001819790 tars:CreditFacilityTrancheOneMember us-gaap:LineOfCreditMember 2023-09-30 0001819790 tars:CreditFacilityTrancheTwoMember us-gaap:LineOfCreditMember 2023-09-30 0001819790 tars:CreditFacilityTrancheThreeMember us-gaap:LineOfCreditMember 2023-09-30 0001819790 tars:CreditFacilityTrancheFourMember us-gaap:LineOfCreditMember 2023-09-30 0001819790 us-gaap:LineOfCreditMember 2022-02-02 0001819790 us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2022-02-02 2022-02-02 0001819790 srt:MaximumMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2022-02-02 2022-02-02 0001819790 us-gaap:LineOfCreditMember 2023-01-01 2023-09-30 0001819790 us-gaap:LineOfCreditMember 2022-09-30 0001819790 srt:DirectorMember 2021-12-31 0001819790 srt:DirectorMember 2021-12-01 2021-12-31 0001819790 srt:MinimumMember srt:DirectorMember 2021-12-01 2021-12-31 0001819790 srt:MaximumMember srt:DirectorMember 2021-12-01 2021-12-31 0001819790 us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001819790 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 shares iso4217:USD iso4217:USD shares tars:segment pure tars:tranche tars:warrant tars:security tars:vote tars:contract false 0001819790 --12-31 2023 Q3 P3Y P1Y P1Y P1Y 10-Q true 2023-09-30 false 001-39614 TARSUS PHARMACEUTICALS, INC. DE 81-4717861 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618 (949) 409-9820 Common Stock, $0.0001 par value per share TARS NASDAQ Yes Yes Non-accelerated Filer true true true false 33104612 226672000 71660000 20213000 145366000 5362000 0 15000 0 1008000 3582000 6007000 4767000 259277000 225375000 1614000 957000 3967000 0 2011000 575000 210000 371000 1253000 585000 268332000 227863000 15351000 9910000 7898000 5519000 23249000 15429000 29708000 19434000 1711000 100000 54668000 34963000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 200000000 200000000 33104087 33104087 26727458 26727458 5000 5000 416421000 301732000 -8000 -74000 -202754000 -108763000 213664000 192900000 268332000 227863000 1653000 0 1653000 0 218000 0 2718000 15816000 1871000 0 4371000 15816000 377000 0 377000 0 0 0 0 555000 12105000 10912000 37007000 32596000 30324000 11994000 65695000 30316000 42806000 22906000 103079000 63467000 -40935000 -22906000 -98708000 -47651000 2840000 1061000 7359000 1372000 858000 633000 2357000 1507000 -48000 -7000 -89000 136000 -111000 -13000 -161000 -326000 -36000 -18000 -35000 -520000 1787000 390000 4717000 -845000 0 -5000 0 -4000 -39148000 -22511000 -93991000 -48492000 15000 -10000 66000 -10000 -39133000 -22521000 -93925000 -48502000 -1.28 -1.28 -0.84 -0.84 -3.35 -3.35 -2.03 -2.03 30622440 30622440 26662374 26662374 28065434 28065434 23923512 23923512 0 0 26727458 5000 301732000 -74000 -108763000 192900000 -23419000 -23419000 3906000 3906000 6443 13000 13000 66611 4000 4000 0 0 26800512 5000 305651000 -70000 -132182000 173404000 -31424000 -31424000 5192000 5192000 16118 45000 45000 45653 37289 465000 465000 47000 47000 0 0 26899572 5000 311353000 -23000 -163606000 147729000 -39148000 -39148000 5250000 5250000 6912000 6069449 99302000 99302000 109627 516000 516000 25439 15000 15000 0 0 33104087 5000 416421000 -8000 -202754000 213664000 0 0 20698737 4000 213398000 -46672000 166730000 -20238000 -20238000 2674000 2674000 225 4257 15309 31000 31000 0 0 20718528 4000 216103000 -66910000 149197000 -5743000 -5743000 3532000 3532000 5246000 5889832 1000 74266000 74267000 17874 222000 222000 7056 17000 17000 4257 6705 13000 13000 0 0 26644252 5000 294153000 0 -72653000 221505000 -22511000 -22511000 3583000 3583000 5826 12000 12000 21734 82000 82000 34000 34000 -10000 -10000 0 0 26671812 5000 297796000 -10000 -95164000 202627000 -93991000 -48492000 497000 227000 33000 0 274000 231000 14348000 9789000 410000 343000 -161000 -326000 3038000 63000 -35000 -520000 0 1000 5362000 17000 15000 0 -2574000 3902000 1028000 -551000 608000 75000 5177000 1187000 2379000 1294000 -4000 -74000 -78158000 -38156000 156920000 0 28664000 57031000 4000000 0 1502000 379000 122754000 -57410000 99377000 74352000 465000 222000 574000 99000 10000000 20000000 0 875000 0 75000 110416000 93723000 155012000 -1843000 71660000 171332000 226672000 169489000 1846000 0 2034000 1094000 32000 44000 22000 0 DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (“Tarsus” or the “Company”) is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company launched XDEMVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis, on August 24, 2023, after receiving United States ("U.S.") Food and Drug Administration ("FDA") approval on July 24, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Follow-On Public Offerings</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 4, 2023, the Company completed a follow-on public offering under its shelf registration statement on Form S-3 that was declared effective by the SEC on November 5, 2021 of 5,714,285 shares of common stock at a public offering price of $17.50 per share (the "August 2023 Public Offering"). The aggregate net proceeds received by the Company were approximately $93.5 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses. The Company also granted the underwriters a 30-day option to purchase up to 857,142 additional shares of its common stock at the public offering price. On September 6, 2023, the underwriters partially exercised this option resulting in the Company's issuance of an additional 355,164 shares of common stock at the public offering price of $17.50 per share. The aggregate net proceeds received by the Company from the partially exercised option was approximately $5.8 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the August 2023 Public Offering, the Company terminated the prospectus (the “ATM Prospectus”) filed with Shelf Registration Statement, issuable pursuant to the terms of an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the "Sales Agreement") dated November 1, 2021 by and between the Company and Jefferies LLC. The Company has not made any sales pursuant to the ATM Prospectus. Further, the Company will not make any sales of our common stock pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company completed a follow-on public offering under its Shelf Registration Statement for an initial underwritten sale of 5,600,000 shares of its common stock at the public offering price of $13.50 per share. The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of its common stock at the public offering price. In June 2022, the underwriters partially exercised this option and the Company's sale of an additional 289,832 shares at the public offering price of $13.50 per share was concurrently completed. Total aggregate net proceeds received by the Company were approximately $74.3 million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a limited operating history, limited history of product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through proceeds from product sales, net, proceeds from its out-license agreement, equity capital raises; including the Company's initial public offering in 2020 and the follow-on public offerings completed in May 2022 and August 2023, and draws from its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q, which have been prepared on a going-concern basis. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its commercialization efforts, development programs, and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Segment </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company’s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div> 5714285 17.50 93500000 857142 355164 17.50 5800000 5600000 13.50 840000 289832 13.50 74300000 The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purposes of evaluating financial performance and the allocation of capital and personnel resources. The Company’s chief operating decision-maker (CODM), its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. 1 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of September 30, 2023, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022, and the Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three and nine-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and nine months ended September 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 or any other interim or annual period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s financial statements as of and for the three and nine months ended September 30, 2023, reflect the Company’s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Long-Term Investments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts receivable generally consists of amounts due from its customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended September 30, 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out (FIFO) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY on July 24, 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred. The inventory balance as of September 30, 2023 consisted of finished goods. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow. The carrying value of intangible assets as a result of commercial milestones was $4.0 million as of September 30, 2023, and will be amortized to cost of sales over its useful life of 10 years from the date of first commercial sale. Amortization expense for the three and nine months ended September 30, 2023 was not material (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company had no intangible assets as of December 31, 2022.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the expected future amortization expense for the Company's intangible assets is as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,967 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the periods presented. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from <span style="-sec-ix-hidden:f-447">three</span> to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset’s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three and nine months ended September 30, 2023 and 2022.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (“ROU assets”) represent the Company’s right to control an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU asset and lease liability amounts presented in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Credit Risk</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"), a division of First Citizens Bank. These </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Major Customers</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. For the three months ended September 30, 2023, the Company's three largest customers accounted for 55%, 21% and 13% of product sales, respectively. As of September 30, 2023, amounts due from these three customers each exceeded 10% of gross accounts receivable and accounted for approximately 89% of the accounts receivable balance on a combined basis.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Major Suppliers</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company entered into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than our existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company’s commercialization efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Product Sales, Net</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Overall, these estimates reflect the Company’s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it can not be resold. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler’s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program. Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company’s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) License Fees and Collaboration Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">China Out-License </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")— see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract’s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payments for executing drug supply agreements; (vi) development milestone payments; and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract’s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company’s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee’s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Threshold Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other License Fees and Collaboration Revenue</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service. Revenue recognized for the three and nine months ended September 30, 2023 was $0.2 million. No revenue was recognized under such arrangements for the three and nine months ended September 30, 2022. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cost of Sales</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company’s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY on July 24, 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Costs</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company’s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock awards granted typically have <span style="-sec-ix-hidden:f-464">one</span> to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management’s judgment, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company’s expected term represents the period that the Company’s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company’s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three and nine months ended September 30, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued or Effective Accounting Standards</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company’s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company’s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of September 30, 2023, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022, and the Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three and nine-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2022 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and nine months ended September 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 or any other interim or annual period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. Actual results could differ materially from those estimates. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s financial statements as of and for the three and nine months ended September 30, 2023, reflect the Company’s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an </span></div>update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements. Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Long-Term Investments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are recorded at fair value with unrealized losses and gains reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized losses and gains as well as credit losses, if any, on marketable securities identified on a specific identification basis and are included in other income (expense), net on the accompanying Condensed Statement of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div>Long-term investments consist of holdings of common stock in the publicly-traded parent company of LianBio Ophthalmology Limited ("LianBio"), reflecting the intent to hold these shares for at least one year from the balance sheet date. These equity securities are designated as available-for-sale with associated gains or losses reported in other income (expense), net within the Condensed Statements of Operations and Comprehensive Loss for each reported period. Accounts Receivable, NetAccounts receivable generally consists of amounts due from its customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended September 30, 2023. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out (FIFO) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and </span></div>adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY on July 24, 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred. The inventory balance as of September 30, 2023 consisted of finished goods. 4000000 P10Y 0 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the expected future amortization expense for the Company's intangible assets is as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,967 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 100000 400000 400000 400000 400000 2267000 3967000 Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the periods presented. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from <span style="-sec-ix-hidden:f-447">three</span> to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or changes in circumstances of the business indicate that the asset’s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three and nine months ended September 30, 2023 and 2022.</span></div> P5Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (“ROU assets”) represent the Company’s right to control an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div>The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU asset and lease liability amounts presented in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Credit Risk</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including Silicon Valley Bank ("SVB"), a division of First Citizens Bank. These </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Major Customers</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. For the three months ended September 30, 2023, the Company's three largest customers accounted for 55%, 21% and 13% of product sales, respectively. As of September 30, 2023, amounts due from these three customers each exceeded 10% of gross accounts receivable and accounted for approximately 89% of the accounts receivable balance on a combined basis.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Major Suppliers</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company entered into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than our existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company’s commercialization efforts.</span></div> 0.55 0.21 0.13 0.89 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Product Sales, Net</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Overall, these estimates reflect the Company’s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it can not be resold. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler’s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program. Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company’s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) License Fees and Collaboration Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">China Out-License </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to one out-license agreement (the "China Out-License") that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong Kong, Macau, and Taiwan (the "China territory")— see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract’s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payments for executing drug supply agreements; (vi) development milestone payments; and (vii) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract’s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company’s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee’s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Threshold Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other License Fees and Collaboration Revenue</span></div>License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service. Revenue recognized for the three and nine months ended September 30, 2023 was $0.2 million. No revenue was recognized under such arrangements for the three and nine months ended September 30, 2022. 200000 200000 0 0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cost of Sales</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company’s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY on July 24, 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Costs</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company’s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's stock on the date preceding the award grant date. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock awards granted typically have <span style="-sec-ix-hidden:f-464">one</span> to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management’s judgment, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company’s expected term represents the period that the Company’s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.</span>Dividend Yield — The Company’s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future. 1 P4Y P10Y 0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three and nine months ended September 30, 2023 and 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in each period presented.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued or Effective Accounting Standards</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company’s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company’s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.</span></div> FAIR VALUE MEASUREMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying Condensed Balance Sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">- Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234,376 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,719 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,168 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This balance includes cash requirements settled on a nightly basis.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,697 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,505 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds and U.S. Treasury Securities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper, Corporate Debt Securities and Government-related Debt Securities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LianBio Common Stock and Equity Warrants</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (LianBio, a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first two tranches were vested and exercised as of December 31, 2022 and converted into 156,746 shares of LianBio common stock and were recognized at fair value within long-term investments in the Condensed Balance Sheets as of September 30, 2023 and December 31, 2022. LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price on the Nasdaq Global Market. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third warrant tranche will vest upon the achievement of a regulatory event and is presented within other assets in the accompanying Condensed Balance Sheets as of September 30, 2023 and December 31, 2022. This warrant tranche remains classified as Level 3 in the fair value hierarchy. The most significant assumptions used in the option pricing valuation model as of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies); the probability of regulatory milestone achievement for vesting; and the application of an assumed discount rate.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:80.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:80.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of September 30, 2022</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,205 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,440 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,366 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1 )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2023, substantially all available-for-sale debt securities had a maturity of 12 months or less. Two securities have a contractual maturity between <span style="-sec-ix-hidden:f-626">one</span> and two years, with an estimated fair market value of $0.3 million and amortized cost of $0.3 million. As of December 31, 2022, substantially all available-for-sale debt securities had a maturity of 12 months or less. Three securities had a contractual maturity between <span style="-sec-ix-hidden:f-631">one</span> and five years, with an estimated fair market value of $4.6 million and amortized cost of $4.6 million. As of September 30, 2023 and December 31, 2022, all available-for-sale debt </span></div>securities have gross unrealized losses in a continuous loss position for less than one year. As of September 30, 2023 and December 31, 2022, unrealized credit losses on these securities were not material, and accordingly, the Company did not recognize any other-than-temporary impairment losses. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying Condensed Balance Sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">- Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234,376 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,719 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,168 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This balance includes cash requirements settled on a nightly basis.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,697 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,505 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span> 226672000 0 0 226672000 7494000 0 0 7494000 0 6964000 0 6964000 0 314000 0 314000 0 5441000 0 5441000 210000 0 0 210000 0 0 73000 73000 234376000 12719000 73000 247168000 64685000 0 0 64685000 69644000 0 0 69644000 0 60355000 0 60355000 0 11521000 0 11521000 0 10821000 0 10821000 371000 0 0 371000 0 0 108000 108000 134700000 82697000 108000 217505000 3 2 156746 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the equity warrants are reported within other assets on the accompanying Condensed Balance Sheets and will be remeasured each reporting period with adjustments reported within other income (expense), net on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised or expired. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:80.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:80.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of equity warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of September 30, 2022</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 108000 -17000 91000 18000 109000 -36000 73000 663000 -245000 418000 103000 -257000 264000 -18000 246000 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,205 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,440 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,366 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1 )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div> 226672000 226672000 226672000 226672000 7481000 17000 4000 7494000 6966000 0 2000 6964000 312000 2000 0 314000 5446000 0 5000 5441000 20205000 19000 11000 20213000 1108000 0 898000 210000 1108000 0 898000 210000 64685000 64685000 4978000 4978000 1997000 1997000 71660000 71660000 69720000 5000 81000 69644000 58358000 0 0 58358000 11524000 8000 11000 11521000 5838000 5000 0 5843000 145440000 18000 92000 145366000 1231000 0 860000 371000 1231000 0 860000 371000 2 P2Y 300000 300000 3 P5Y 4600000 4600000 BALANCE SHEET ACCOUNT DETAIL<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,614 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended September 30, 2023 and 2022 was $0.2 million and $0.1 million, respectively, and for the nine months ended September 30, 2023 and 2022 was $0.5 million and $0.2 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Other Accrued Liabilities </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other accrued liabilities consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product sales deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,351 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,910 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,614 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1149000 714000 660000 197000 167000 167000 680000 425000 2656000 1503000 1042000 546000 1614000 957000 200000 100000 500000 200000 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other accrued liabilities consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product sales deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,351 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,910 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10382000 5498000 3778000 0 768000 3691000 423000 721000 15351000 9910000 STOCKHOLDERS’ EQUITY <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Outstanding and Reserves for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the Company had 33.1 million and 26.7 million, respectively, of common stock issued and outstanding. Each share of common stock is entitled to one vote. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,119,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,346,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,893,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,663,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,737,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,899,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,489,850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,460,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 33100000 33100000 26700000 26700000 1 The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,119,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,346,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,893,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,663,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,737,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,899,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,489,850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,460,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 7119277 8346738 2893305 2663319 4737575 3899342 1739693 551258 16489850 15460657 STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,583 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,348 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,789 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per stock option</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the nine months ended September 30, 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,899,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144,514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,719,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding—September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,737,575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.77</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable— September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,471,190 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested—September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266,385 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock as of September 30, 2023. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, there was approximately $25.9 million of unrecognized compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of 2.2 years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity during the nine months ended September 30, 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.78 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">647,768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>As of September 30, 2023, there was approximately $24.7 million of unrecognized compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of 3.4 years. <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,583 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,348 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,789 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 31000 0 31000 0 1663000 1015000 4317000 2677000 3556000 2568000 10000000 7112000 5250000 3583000 14348000 9789000 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per stock option</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.0428 0.0320 0.0407 0.0222 0.726 0.804 0.717 0.782 P6Y3M P6Y3M P6Y3M P6Y3M 0 0 0 0 17.23 15.81 15.43 18.43 Stock option activity during the nine months ended September 30, 2023 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,899,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144,514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,719,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding—September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,737,575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.77</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable— September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,471,190 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested—September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266,385 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock as of September 30, 2023. 3899342 16.69 P8Y25D 19196000 728169 15.07 6443 2.01 24654 21.19 4596414 16.43 P8Y1M28D 15316000 283367 15.55 16118 2.78 144514 20.36 4719149 16.31 P7Y11M4D 28319000 130266 17.23 109627 4.71 2213 19.09 4737575 16.60 P7Y9M7D 26084000 2471190 15.01 P6Y10M20D 20742000 2266385 18.33 P8Y8M26D 5342000 25900000 P2Y2M12D <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity during the nine months ended September 30, 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.78 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">647,768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding— September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 551258 17.78 647768 15.24 66611 19.15 4042 19.40 1128373 16.24 380196 15.67 45653 14.04 71028 15.84 1391888 16.17 373244 17.34 25439 16.36 0 0 1739693 16.42 24700000 P3Y4M24D NET LOSS PER SHARE<span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share:</span><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,148)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,511)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding—basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,622,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,662,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,065,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,923,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share—basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.03)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised—vested and unvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,737,575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,839,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units—unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">516,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,477,268 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,355,082 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,148)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,511)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding—basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,622,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,662,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,065,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,923,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share—basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.03)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> -39148000 -22511000 -93991000 -48492000 30622440 26662374 28065434 28065434 23923512 23923512 -1.28 -0.84 -3.35 -3.35 -2.03 -2.03 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised—vested and unvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,737,575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,839,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units—unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">516,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,477,268 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,355,082 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4737575 3839077 1739693 516005 6477268 4355082 COMMITMENTS &amp; CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of business, the Company enters into lease agreements with unaffiliated third parties for its facilities and office equipment. As of September 30, 2023, the Company had five active leases for adjacent office and laboratory suites in Irvine, California. On May 1, 2023 the Company amended the existing facilities lease, extending the term for three years through January 31, 2027. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The below table summarizes the components of total lease expense:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company's facility leases had a remaining lease term of 3.3 years and a weighted-average incremental borrowing rate of 10%. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i) minimum lease payments over the next five years and thereafter, (ii) lease arrangement imputed interest, and (iii) present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:79.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases - Future Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,090 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-License Agreements for Lotilaner</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">January 2019 Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (“Elanco”) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone payment of $1.0 million was included in research and development expense in the accompanying Condensed Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2023. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has made cash payments to Elanco under the Eye and Derm Agreement comprised of $1.0 million upfront upon contract execution in January 2019 and a total of $4.0 million for three specified clinical milestone achievements in September 2020, April 2021, and March 2023, which were all recorded in research and development expense in the Condensed Statements of Operations and Comprehensive Loss. During the three months ended September 30, 2023 a milestone of $4.0 million was achieved and paid to Elanco upon the first commercial sale of XDEMVY in the U.S., which was recorded as an intangible asset in the accompanying Condensed Balance Sheet as of September 30, 2023. The Company is amortizing the intangible asset to cost of sales over its useful life of 10 years from the date of the first commercial sale. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2023, the Company is obligated to make further cash payments to Elanco of $2.0 million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $75.0 million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license. As a result of the commercialization of XDEMVY, the Company </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">began accruing royalties payable to Elanco during the third quarter of 2023, which are recorded to cost of sales in the accompanying Condensed Statement of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and accounts payable and other accrued liabilities in the accompanying Condensed Balance Sheet as of September 30, 2023. Royalty expense during the three and nine months ended September 30, 2023 was $0.1 million.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">September 2020 Agreement for All Other Diseases or Conditions in Humans</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco 222,460 shares of its common stock with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020). </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its product sales, net. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with seven of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div> 5 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The below table summarizes the components of total lease expense:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 179000 142000 525000 427000 125000 67000 296000 168000 304000 209000 821000 595000 P3Y3M18D 0.10 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i) minimum lease payments over the next five years and thereafter, (ii) lease arrangement imputed interest, and (iii) present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:79.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases - Future Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,090 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 226000 701000 789000 816000 68000 2600000 381000 129000 2090000 423000 1667000 2090000 1000000 1000000 4000000 4000000 P10Y 2000000 75000000 100000 100000 222460 3100000 14.0003 500000 4000000 77000000 7 OUT-LICENSE AGREEMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in the China Territory in March 2021</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, the Company entered into the China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory, as defined in the agreement, for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis and Meibomian Gland Disease. LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assessed this arrangement and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory; and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial (Saturn-1) and Phase 3 (Saturn-2) TP-03 trials. The promises to provide research and development services for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $15.0 million; (ii) a second cash payment of $10.0 million; (iii) a $10.0 million milestone that was determined to be within the control of the Company; and (iv) $1.2 million representing the initial fair value of the equity warrant. </span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company accounted for each performance obligation as follows: </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Out-License</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Services </span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 within license fees and collaboration revenue as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.</span></div><div><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In February 2023, a specified milestone event was triggered resulting in $2.5 million recognized as license fees and collaboration revenue in the accompanying Condensed Statements of Operations for the nine months ended September 30, 2023. This cash payment was received in the second quarter of 2023. Through September 30, 2023, the Company received aggregate payments from LianBio totaling $82.5 million, comprised of initial consideration of $15.0 million and $67.5 million for the achievement of specified milestones. </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2023 the Company is eligible to receive further consideration from LianBio upon the achievement of additional TP-03 events, including: (i) additional regulatory milestones and one-time payments of up to an aggregate of $22.5 million; (ii) China-Based TP-03 sales threshold milestone payments of up to an aggregate of $100.0 million; (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales; and (iv) vesting of a LianBio equity warrant upon certain regulatory milestones. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the China Out-License with LianBio the Company granted Elanco an additional 187,500 shares of the Company's common stock that otherwise would have been issuable no later than the 18-month anniversary of the All Human Uses Elanco Agreement for its continued license exclusivity. These issued shares were valued at $5.5 million, based on the Company's closing stock price of $29.30 per share on the date this issuance became contractually required.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company made a contractual payment in the amount of $2.5 million to Elanco following the receipt of $25 million of proceeds from LianBio during the second quarter of 2021. During the fourth quarter of 2022, the Company recognized $0.4 million of cost of license fees and collaboration revenue upon receipt of $10 million of cash proceeds from LianBio for the achievement of a clinical development milestone.</span></div>The expenses recognized under the China-Out License were not material for the three and nine months ended September 30, 2023 and 2022. 15000000 10000000 10000000 1200000 2500000 82500000 15000000 67500000 22500000 100000000 187500 5500000 29.30 2500000 25000000 400000 10000000 CREDIT FACILITY AGREEMENT<div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company executed the Credit Facility with Hercules Capital, Inc. ("Hercules") and SVB that expires on February 2, 2027. Concurrent with the execution of the Credit Facility, the Company made a $20.0 million draw.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to draw down the $25.0 million tranche associated with the New Drug Application ("NDA") submission, from March 15, 2023 to March 15, 2024, provided at least $5.0 million was drawn on or before March 15, 2023 and at least an additional $5.0 million is drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2023 and September 15, 2023, respectively, the Company made separate draws of $5.0 million (including SVB's commitment of $1.25 million) from the $25.0 million tranche that became available upon submission of the NDA. As of September 30, 2023, the Credit Facility provides for a remaining aggregate principal amount of up to $125.0 million with tranched availability as follows: $15.0 million currently available related to the Company's NDA submission with the FDA for TP-03 in September 2022; $35.0 million currently available due to the FDA approval of XDEMVY on July 24, 2023; $50.0 million available upon achievement of product sales, net thresholds; and $25.0 million available upon lender approval.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these tranches may be drawn down in $5.0 million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 4.45% with an aggregate cap of 11.45%, or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and increased to 8.50% as of September 30, 2023.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.4 million was derived by multiplying 4.75% by the $30.0 million outstanding principal balance as of September 30, 2023 and is accreted to interest expense through maturity.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and 2022, the effective interest rate for the full term of the Credit Facility was 11.96% and 12.37%, respectively. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows: </span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,083 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,708 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 20000000 25000000 5000000 5000000 5000000 5000000 1250000 1250000 25000000 125000000 15000000 35000000 50000000 25000000 5000000 0.0445 0.1145 0.0845 0.0325 0.0850 1400000 0.0475 30000000 0.1196 0.1237 <div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023 and 2022, the Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows: </span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,083 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 757000 539000 2083000 1275000 68000 48000 184000 127000 33000 46000 90000 105000 858000 633000 2357000 1507000 The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,708 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 30000000 20000000 875000 875000 -358000 -174000 225000 135000 29708000 19434000 RELATED PARTY TRANSACTIONS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a preexisting consulting agreement with a board member who was appointed in December 2021. This Consulting Agreement provides for annual cash compensation of approximately $0.2 million and option grants to purchase 45,134 shares of the Company’s common stock, with exercise prices ranging from $2.01 to $34.72 per share. This Consulting Agreement may be terminated by either party with ten days' notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sponsorship Activities </span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, a board member of the Company was appointed president of the American Society of Cataract and Refractive Surgery ("ASCRS"), a society dedicated to meeting the needs of anterior segment ophthalmic surgeons.</span></div>During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.4 million, respectively, of selling, general and administrative expenses in the accompanying Condensed Statement of Operations and Comprehensive Loss for sponsorship and event-related activities associated with ASCRS. 200000 45134 2.01 34.72 P10D 200000 400000 EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 70 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 235 316 1 false 57 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://tarsusrx.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Balance Sheets Sheet http://tarsusrx.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss Sheet http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss Condensed Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 0000005 - Statement - Condensed Statements of Stockholders' Equity Sheet http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity Condensed Statements of Stockholders' Equity Statements 5 false false R6.htm 0000006 - Statement - Condensed Statements of Cash Flows Sheet http://tarsusrx.com/role/CondensedStatementsofCashFlows Condensed Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical) Sheet http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical Condensed Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 0000008 - Disclosure - Description of Business and Presentation of Financial Statements Sheet http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements Description of Business and Presentation of Financial Statements Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates Sheet http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates Summary of Significant Accounting Policies and Use of Estimates Notes 9 false false R10.htm 0000010 - Disclosure - Fair Value Measurements Sheet http://tarsusrx.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 0000011 - Disclosure - Balance Sheet Account Detail Sheet http://tarsusrx.com/role/BalanceSheetAccountDetail Balance Sheet Account Detail Notes 11 false false R12.htm 0000012 - Disclosure - Stockholders' Equity Sheet http://tarsusrx.com/role/StockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 0000013 - Disclosure - Stock-Based Compensation Sheet http://tarsusrx.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 0000014 - Disclosure - Net Loss Per Share Sheet http://tarsusrx.com/role/NetLossPerShare Net Loss Per Share Notes 14 false false R15.htm 0000015 - Disclosure - Commitment & Contingencies Sheet http://tarsusrx.com/role/CommitmentContingencies Commitment & Contingencies Notes 15 false false R16.htm 0000016 - Disclosure - Out-License Agreement Sheet http://tarsusrx.com/role/OutLicenseAgreement Out-License Agreement Notes 16 false false R17.htm 0000017 - Disclosure - Credit Facility Agreement Sheet http://tarsusrx.com/role/CreditFacilityAgreement Credit Facility Agreement Notes 17 false false R18.htm 0000018 - Disclosure - Related Party Transactions Sheet http://tarsusrx.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 9954471 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies) Sheet http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies Summary of Significant Accounting Policies and Use of Estimates (Policies) Policies http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates 19 false false R20.htm 9954472 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Tables) Sheet http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables Summary of Significant Accounting Policies and Use of Estimates (Tables) Tables http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates 20 false false R21.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://tarsusrx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://tarsusrx.com/role/FairValueMeasurements 21 false false R22.htm 9954474 - Disclosure - Balance Sheet Account Detail (Tables) Sheet http://tarsusrx.com/role/BalanceSheetAccountDetailTables Balance Sheet Account Detail (Tables) Tables http://tarsusrx.com/role/BalanceSheetAccountDetail 22 false false R23.htm 9954475 - Disclosure - Stockholders' Equity (Tables) Sheet http://tarsusrx.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://tarsusrx.com/role/StockholdersEquity 23 false false R24.htm 9954476 - Disclosure - Stock-Based Compensation (Tables) Sheet http://tarsusrx.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://tarsusrx.com/role/StockBasedCompensation 24 false false R25.htm 9954477 - Disclosure - Net Loss Per Share (Tables) Sheet http://tarsusrx.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://tarsusrx.com/role/NetLossPerShare 25 false false R26.htm 9954478 - Disclosure - Commitment & Contingencies (Tables) Sheet http://tarsusrx.com/role/CommitmentContingenciesTables Commitment & Contingencies (Tables) Tables http://tarsusrx.com/role/CommitmentContingencies 26 false false R27.htm 9954479 - Disclosure - Credit Facility Agreement (Tables) Sheet http://tarsusrx.com/role/CreditFacilityAgreementTables Credit Facility Agreement (Tables) Tables http://tarsusrx.com/role/CreditFacilityAgreement 27 false false R28.htm 9954480 - Disclosure - Description of Business and Presentation of Financial Statements (Details) Sheet http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails Description of Business and Presentation of Financial Statements (Details) Details http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements 28 false false R29.htm 9954481 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details) Sheet http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details) Details 29 false false R30.htm 9954482 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details) Sheet http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details) Details 30 false false R31.htm 9954483 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details) Sheet http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails Summary of Significant Accounting Policies and Use of Estimates (Details) Details http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables 31 false false R32.htm 9954484 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) Sheet http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) Details 32 false false R33.htm 9954485 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 33 false false R34.htm 9954486 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details) Sheet http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details) Details 34 false false R35.htm 9954487 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details) Sheet http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details) Details 35 false false R36.htm 9954488 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) Sheet http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) Details 36 false false R37.htm 9954489 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) Sheet http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) Details 37 false false R38.htm 9954490 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 38 false false R39.htm 9954491 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details) Sheet http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails Stockholders' Equity - Shares Reserved for Issuance (Details) Details 39 false false R40.htm 9954492 - Disclosure - Stock-Based Compensation - Expense (Details) Sheet http://tarsusrx.com/role/StockBasedCompensationExpenseDetails Stock-Based Compensation - Expense (Details) Details 40 false false R41.htm 9954493 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details) Sheet http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails Stock-Based Compensation - Valuation Assumptions of Stock Options (Details) Details 41 false false R42.htm 9954494 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 42 false false R43.htm 9954495 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 43 false false R44.htm 9954496 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details) Sheet http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails Stock-Based Compensation - Restricted Stock Unit Activity (Details) Details 44 false false R45.htm 9954497 - Disclosure - Net Loss Per Share (Details) Sheet http://tarsusrx.com/role/NetLossPerShareDetails Net Loss Per Share (Details) Details http://tarsusrx.com/role/NetLossPerShareTables 45 false false R46.htm 9954498 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details) Sheet http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails Net Loss Per Share - Antidilutive Securities (Details) Details 46 false false R47.htm 9954499 - Disclosure - Commitment & Contingencies - Lease Agreements (Details) Sheet http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails Commitment & Contingencies - Lease Agreements (Details) Details 47 false false R48.htm 9954500 - Disclosure - Commitment & Contingencies - Lease Cost (Details) Sheet http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails Commitment & Contingencies - Lease Cost (Details) Details 48 false false R49.htm 9954501 - Disclosure - Commitment and Contingencies - Summary of Minimum Lease Payments (Details) Sheet http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails Commitment and Contingencies - Summary of Minimum Lease Payments (Details) Details 49 false false R50.htm 9954502 - Disclosure - Commitment & Contingencies - In-License Agreement for Lotilaner (Details) Sheet http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails Commitment & Contingencies - In-License Agreement for Lotilaner (Details) Details 50 false false R51.htm 9954503 - Disclosure - Commitment & Contingencies - Employment Arrangements (Details) Sheet http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails Commitment & Contingencies - Employment Arrangements (Details) Details 51 false false R52.htm 9954504 - Disclosure - Out-License Agreement (Details) Sheet http://tarsusrx.com/role/OutLicenseAgreementDetails Out-License Agreement (Details) Details http://tarsusrx.com/role/OutLicenseAgreement 52 false false R53.htm 9954505 - Disclosure - Credit Facility Agreement (Details) Sheet http://tarsusrx.com/role/CreditFacilityAgreementDetails Credit Facility Agreement (Details) Details http://tarsusrx.com/role/CreditFacilityAgreementTables 53 false false R54.htm 9954506 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details) Sheet http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails Credit Facility Agreement - Summary of Interest Expense (Details) Details 54 false false R55.htm 9954507 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details) Sheet http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details) Details 55 false false R56.htm 9954508 - Disclosure - Related Party Transactions (Details) Sheet http://tarsusrx.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://tarsusrx.com/role/RelatedPartyTransactions 56 false false All Reports Book All Reports tars-20230930.htm tars-20230930.xsd tars-20230930_cal.xml tars-20230930_def.xml tars-20230930_lab.xml tars-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tars-20230930.htm": { "nsprefix": "tars", "nsuri": "http://tarsusrx.com/20230930", "dts": { "inline": { "local": [ "tars-20230930.htm" ] }, "schema": { "local": [ "tars-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "tars-20230930_cal.xml" ] }, "definitionLink": { "local": [ "tars-20230930_def.xml" ] }, "labelLink": { "local": [ "tars-20230930_lab.xml" ] }, "presentationLink": { "local": [ "tars-20230930_pre.xml" ] } }, "keyStandard": 279, "keyCustom": 37, "axisStandard": 21, "axisCustom": 0, "memberStandard": 33, "memberCustom": 23, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 4 }, "contextCount": 235, "entityCount": 1, "segmentCount": 57, "elementCount": 477, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 813, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://tarsusrx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://tarsusrx.com/role/CondensedBalanceSheets", "longName": "0000002 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R3": { "role": "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "longName": "0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss", "shortName": "Condensed Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:CostsAndExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R5": { "role": "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity", "longName": "0000005 - Statement - Condensed Statements of Stockholders' Equity", "shortName": "Condensed Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-48", "name": "us-gaap:TemporaryEquitySharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R6": { "role": "http://tarsusrx.com/role/CondensedStatementsofCashFlows", "longName": "0000006 - Statement - Condensed Statements of Cash Flows", "shortName": "Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R7": { "role": "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical", "longName": "0000007 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical)", "shortName": "Condensed Statements of Stockholders' Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements", "longName": "0000008 - Disclosure - Description of Business and Presentation of Financial Statements", "shortName": "Description of Business and Presentation of Financial Statements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates", "shortName": "Summary of Significant Accounting Policies and Use of Estimates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://tarsusrx.com/role/FairValueMeasurements", "longName": "0000010 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://tarsusrx.com/role/BalanceSheetAccountDetail", "longName": "0000011 - Disclosure - Balance Sheet Account Detail", "shortName": "Balance Sheet Account Detail", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://tarsusrx.com/role/StockholdersEquity", "longName": "0000012 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://tarsusrx.com/role/StockBasedCompensation", "longName": "0000013 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://tarsusrx.com/role/NetLossPerShare", "longName": "0000014 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://tarsusrx.com/role/CommitmentContingencies", "longName": "0000015 - Disclosure - Commitment & Contingencies", "shortName": "Commitment & Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://tarsusrx.com/role/OutLicenseAgreement", "longName": "0000016 - Disclosure - Out-License Agreement", "shortName": "Out-License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://tarsusrx.com/role/CreditFacilityAgreement", "longName": "0000017 - Disclosure - Credit Facility Agreement", "shortName": "Credit Facility Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://tarsusrx.com/role/RelatedPartyTransactions", "longName": "0000018 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)", "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Tables)", "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://tarsusrx.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailTables", "longName": "9954474 - Disclosure - Balance Sheet Account Detail (Tables)", "shortName": "Balance Sheet Account Detail (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://tarsusrx.com/role/StockholdersEquityTables", "longName": "9954475 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://tarsusrx.com/role/StockBasedCompensationTables", "longName": "9954476 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://tarsusrx.com/role/NetLossPerShareTables", "longName": "9954477 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://tarsusrx.com/role/CommitmentContingenciesTables", "longName": "9954478 - Disclosure - Commitment & Contingencies (Tables)", "shortName": "Commitment & Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://tarsusrx.com/role/CreditFacilityAgreementTables", "longName": "9954479 - Disclosure - Credit Facility Agreement (Tables)", "shortName": "Credit Facility Agreement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails", "longName": "9954480 - Disclosure - Description of Business and Presentation of Financial Statements (Details)", "shortName": "Description of Business and Presentation of Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfOperatingSegments", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfOperatingSegments", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails", "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details)", "shortName": "Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R30": { "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)", "shortName": "Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails", "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)", "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails", "longName": "9954484 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)", "shortName": "Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "tars:EquityWarrantsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R33": { "role": "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "longName": "9954485 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-149", "name": "tars:WarrantAgreementNumberOfTranches", "unitRef": "tranche", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-149", "name": "tars:WarrantAgreementNumberOfTranches", "unitRef": "tranche", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails", "longName": "9954486 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)", "shortName": "Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-35", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R35": { "role": "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "longName": "9954487 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)", "shortName": "Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails", "longName": "9954488 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)", "shortName": "Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R37": { "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails", "longName": "9954489 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)", "shortName": "Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails", "longName": "9954490 - Disclosure - Stockholders' Equity - Additional Information (Details)", "shortName": "Stockholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "tars:CommonStockNumberOfVotes", "unitRef": "vote", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R39": { "role": "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails", "longName": "9954491 - Disclosure - Stockholders' Equity - Shares Reserved for Issuance (Details)", "shortName": "Stockholders' Equity - Shares Reserved for Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails", "longName": "9954492 - Disclosure - Stock-Based Compensation - Expense (Details)", "shortName": "Stock-Based Compensation - Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails", "longName": "9954493 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)", "shortName": "Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails", "longName": "9954494 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-35", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R43": { "role": "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails", "longName": "9954495 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails", "longName": "9954496 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)", "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-182", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R45": { "role": "http://tarsusrx.com/role/NetLossPerShareDetails", "longName": "9954497 - Disclosure - Net Loss Per Share (Details)", "shortName": "Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "longName": "9954498 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)", "shortName": "Net Loss Per Share - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails", "longName": "9954499 - Disclosure - Commitment & Contingencies - Lease Agreements (Details)", "shortName": "Commitment & Contingencies - Lease Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "tars:LesseeOperatingLeaseNumberOfLeaseContracts", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "tars:LesseeOperatingLeaseNumberOfLeaseContracts", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails", "longName": "9954500 - Disclosure - Commitment & Contingencies - Lease Cost (Details)", "shortName": "Commitment & Contingencies - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails", "longName": "9954501 - Disclosure - Commitment and Contingencies - Summary of Minimum Lease Payments (Details)", "shortName": "Commitment and Contingencies - Summary of Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "longName": "9954502 - Disclosure - Commitment & Contingencies - In-License Agreement for Lotilaner (Details)", "shortName": "Commitment & Contingencies - In-License Agreement for Lotilaner (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-191", "name": "tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R51": { "role": "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails", "longName": "9954503 - Disclosure - Commitment & Contingencies - Employment Arrangements (Details)", "shortName": "Commitment & Contingencies - Employment Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://tarsusrx.com/role/OutLicenseAgreementDetails", "longName": "9954504 - Disclosure - Out-License Agreement (Details)", "shortName": "Out-License Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquitySecuritiesFvNiCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-208", "name": "tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R53": { "role": "http://tarsusrx.com/role/CreditFacilityAgreementDetails", "longName": "9954505 - Disclosure - Credit Facility Agreement (Details)", "shortName": "Credit Facility Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-217", "name": "us-gaap:ProceedsFromLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:ProceedsFromLinesOfCredit", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R54": { "role": "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails", "longName": "9954506 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)", "shortName": "Credit Facility Agreement - Summary of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails", "longName": "9954507 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)", "shortName": "Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } }, "R56": { "role": "http://tarsusrx.com/role/RelatedPartyTransactionsDetails", "longName": "9954508 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-230", "name": "tars:RelatedPartyTransactionAnnualCashCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "tars-20230930.htm", "unique": true } } }, "tag": { "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Future Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r49" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of term loan issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r35" ] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock in LianBio", "terseLabel": "Estimated fair value", "label": "Equity Securities, FV-NI", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r155", "r445", "r526" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://tarsusrx.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r120", "r185", "r342", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r356", "r357", "r438", "r624", "r626", "r635" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r599", "r640", "r650" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r636" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r159", "r643", "r672" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Net", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r132", "r133", "r134", "r242", "r243", "r244" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r156" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r675", "r676", "r677", "r679", "r680", "r681", "r682", "r713", "r714", "r766", "r788", "r793" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r696" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r189", "r190", "r315", "r345", "r473", "r647", "r648" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r302", "r304", "r305", "r306", "r309", "r310", "r418", "r532" ] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued product sales deductions", "label": "Accrued Sales Commission, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21", "r645" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r115" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r43", "r45", "r71", "r72", "r239", "r636" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r115" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r115" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service condition period for full vesting", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r670" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r115" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r43", "r45", "r71", "r72", "r239", "r558", "r636" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remaining three months)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Term loan, net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r15", "r128", "r324", "r339", "r659", "r660", "r784" ] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Interest Expense", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies and Use of Estimates", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r111", "r183" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r103" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense, weighted average period of recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r409" ] }, "us-gaap_EquitySecuritiesFVNIAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFVNIAbstract", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments:", "label": "Equity Securities, FV-NI [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r136", "r148", "r158", "r289", "r290", "r291", "r506", "r649" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r32", "r176", "r245" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails", "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r385" ] }, "us-gaap_OtherMachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherMachineryAndEquipmentMember", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment", "label": "Other Machinery and Equipment [Member]", "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r386" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r387" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r462", "r671" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r116" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows", "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity", "http://tarsusrx.com/role/NetLossPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "terseLabel": "Net loss", "netLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r97", "r110", "r130", "r145", "r165", "r167", "r171", "r186", "r195", "r197", "r198", "r199", "r200", "r203", "r204", "r209", "r218", "r230", "r234", "r236", "r277", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r441", "r446", "r539", "r598", "r619", "r620", "r654", "r683", "r731" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-current assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r709" ] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty expense", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r101" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r116" ] }, "tars_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CustomerThreeMember", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Three", "label": "Customer Three [Member]", "documentation": "Customer Three" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r383" ] }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows", "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of equity warrants issued by licensee", "negatedTerseLabel": "Change in fair value of equity warrants issued by licensee", "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net", "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period." } } }, "auth_ref": [ "r765" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r3" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r687" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r406", "r419" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 8)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r26", "r80", "r529", "r576" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r394" ] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of end of term charge", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r4", "r73", "r104", "r333" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segment", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r238", "r655" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r392" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r392" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (shares)", "periodEndLabel": "Outstanding, ending balance (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r389", "r390" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r717" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (usd per share)", "periodEndLabel": "Outstanding, ending balance (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r389", "r390" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r393" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, at cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r116", "r151", "r538" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r763" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r393" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r456" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r107" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r763" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails", "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r525", "r538", "r672" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on marketable securities and cash equivalents", "verboseLabel": "Other comprehensive gain (loss)", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r162", "r163", "r164" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued for license agreement, share price (usd per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r717" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r336", "r355", "r437", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r540", "r657", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r721", "r722", "r723", "r724" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r46", "r48" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r5", "r140", "r141", "r536" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r387" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/NetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding, diluted (shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r207", "r212" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r146", "r161", "r186", "r277", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r427", "r429", "r446", "r672", "r731", "r732", "r774" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant-date fair value per stock option (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r395" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "ASSETS", "terseLabel": "Assets:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future amortization", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r114", "r508" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/NetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r175", "r197", "r198", "r199", "r200", "r201", "r208", "r210", "r211", "r212", "r216", "r440", "r441", "r523", "r542", "r652" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r89", "r530", "r672" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r61" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/NetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding, basic (shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r206", "r212" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriters' option", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (shares)", "periodEndLabel": "Ending balance (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r381", "r382" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (usd per share)", "periodEndLabel": "Ending balance (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r381", "r382" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r219", "r220", "r229", "r232", "r233", "r237", "r238", "r239", "r360", "r361", "r507" ] }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r383" ] }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "documentation": "Tabular disclosure of unrealized gains and losses on investments." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r251" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Balances of Debt, Debt Issuance Costs, and Accumulated Accretion", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r192", "r193", "r194", "r217", "r507", "r559", "r566", "r569", "r570", "r571", "r572", "r573", "r574", "r577", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r590", "r591", "r592", "r593", "r594", "r596", "r599", "r600", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r678" ] }, "tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units\u2014unvested", "label": "Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member]", "documentation": "Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails", "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r51" ] }, "tars_LicenseAndCollaborationOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "LicenseAndCollaborationOtherMember", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License And Collaboration, Other", "label": "License And Collaboration, Other [Member]", "documentation": "License And Collaboration, Other" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized gain from transactions denominated in a foreign currency", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r110", "r597", "r683", "r769", "r770", "r792" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r465" ] }, "tars_LicenseAndCollaborationMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "LicenseAndCollaborationMember", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "License fees and Collaboration", "label": "License And Collaboration [Member]", "documentation": "License And Collaboration" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r465" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remaining three months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r772" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r465" ] }, "tars_CommonStockNumberOfVotes": { "xbrltype": "integerItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CommonStockNumberOfVotes", "presentation": [ "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock votes", "label": "Common Stock, Number Of Votes", "documentation": "Common Stock, Number Of Votes" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Future contractual lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r772" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "tars_CreditFacilityTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CreditFacilityTrancheOneMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, Tranche One", "label": "Credit Facility, Tranche One [Member]", "documentation": "Credit Facility, Tranche One" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock upon follow-on public offerings, net of paid issuance costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights": { "xbrltype": "sharesItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "StockIssuedDuringPeriodSharesLapseOfRepurchaseRights", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)", "label": "Stock Issued During Period, Shares, Lapse Of Repurchase Rights", "documentation": "Stock Issued During Period, Shares, Lapse Of Repurchase Rights" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r83", "r139" ] }, "tars_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CustomerOneMember", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One", "label": "Customer One [Member]", "documentation": "Customer One" } } }, "auth_ref": [] }, "tars_ClinicalMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "ClinicalMilestonesMember", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical milestones", "label": "Clinical Milestones [Member]", "documentation": "Clinical Milestones" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r31", "r166", "r168", "r174", "r522", "r541" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon follow-on public offering, net of issuance costs of $5,246", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r89", "r90", "r123", "r565", "r621", "r634", "r684" ] }, "tars_ElancoMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "ElancoMember", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Elanco", "label": "Elanco [Member]", "documentation": "Elanco" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in connection with the employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r9", "r89", "r90", "r123" ] }, "tars_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CustomerTwoMember", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Two", "label": "Customer Two [Member]", "documentation": "Customer Two" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r75", "r131", "r172", "r221", "r453", "r606", "r683", "r791" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r43", "r45", "r71", "r72", "r239", "r636", "r694" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r686" ] }, "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding", "calculation": { "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": { "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options issued and outstanding (shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding", "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding" } } }, "auth_ref": [] }, "tars_CreditFacilityFirstAmendmentTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CreditFacilityFirstAmendmentTrancheTwoMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, First Amendment, Tranche Two", "label": "Credit Facility, First Amendment, Tranche Two [Member]", "documentation": "Credit Facility, First Amendment, Tranche Two" } } }, "auth_ref": [] }, "tars_RevenueRemainingPerformanceObligationAdditionalCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "RevenueRemainingPerformanceObligationAdditionalCashPayment", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional cash payment", "label": "Revenue, Remaining Performance Obligation, Additional Cash Payment", "documentation": "Revenue, Remaining Performance Obligation, Additional Cash Payment" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of vested stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r28", "r123" ] }, "tars_LianBioMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "LianBioMember", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LianBio", "label": "LianBio [Member]", "documentation": "LianBio" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of equity awards", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r2", "r13" ] }, "tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments to be achieved", "label": "Revenue, Remaining Performance Obligation, Variable Consideration, Amount", "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration, Amount" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r176", "r177", "r720" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement of equity warrants", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r444" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total interest expense related to term loan", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r104", "r331", "r341", "r661", "r662" ] }, "tars_IntangibleAssetsMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "IntangibleAssetsMilestonePaymentMember", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Milestone Payment", "label": "Intangible Assets, Milestone Payment [Member]", "documentation": "Intangible Assets, Milestone Payment" } } }, "auth_ref": [] }, "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant": { "xbrltype": "sharesItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant", "calculation": { "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": { "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan", "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant", "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon follow-up public offering, net of issuance costs (shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r89", "r90", "r123", "r560", "r621", "r634" ] }, "tars_AccruedClinicalStudiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "AccruedClinicalStudiesCurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued clinical studies", "label": "Accrued Clinical Studies, Current", "documentation": "Accrued Clinical Studies, Current" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from term loan", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r33", "r560" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Draw on credit facility", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r33", "r711" ] }, "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term", "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]", "documentation": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon the vesting of restricted stock units (shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r9", "r123" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r688" ] }, "tars_FollowOnPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "FollowOnPublicOfferingMember", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Follow-On Public Offering", "label": "Follow-On Public Offering [Member]", "documentation": "Follow-On Public Offering" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r3" ] }, "tars_DevelopmentAndRegulatoryMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "DevelopmentAndRegulatoryMilestoneMember", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development and Regulatory Milestone", "label": "Development And Regulatory Milestone [Member]", "documentation": "Development And Regulatory Milestone" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r463", "r671" ] }, "tars_OperatingLeaseNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "OperatingLeaseNoncashExpense", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Operating Lease, Noncash Expense", "documentation": "Operating Lease, Noncash Expense" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Intangible asset additions", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r107" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds(1)", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r736" ] }, "tars_MilestoneDeterminedByTheCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "MilestoneDeterminedByTheCompanyMember", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Determined by the Company", "label": "Milestone Determined by the Company [Member]", "documentation": "Milestone Determined by the Company" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total operating lease liability", "totalLabel": "Total operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r457" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in connection with the employee stock purchase plan (shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r9", "r89", "r90", "r123" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r250" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense for term loan", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r106", "r332", "r661", "r662" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r689" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical", "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r90" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r705" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r426" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (shares)", "periodEndLabel": "Ending balance (shares)", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r88" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets", "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r90", "r93", "r94", "r113", "r579", "r595", "r622", "r623", "r672", "r685", "r712", "r726", "r768", "r793" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Costs", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r420" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 33,104,087 shares issued and outstanding at September\u00a030, 2023 (unaudited); 26,727,458 shares issued and outstanding at December\u00a031, 2022", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r90", "r531", "r672" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r690" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r426" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r90", "r577" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical", "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity", "http://tarsusrx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (shares)", "periodStartLabel": "Beginning balance (shares)", "periodEndLabel": "Ending balance (shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r90", "r577", "r595", "r793", "r794" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r426" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedAmortizationDeferredFinanceCosts", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization of debt issuance costs", "label": "Accumulated Amortization, Debt Issuance Costs", "documentation": "Amount of accumulated amortization of debt issuance costs." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding potentially dilutive securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r41" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r691" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r41", "r42" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock under employee stock purchase plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r2" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business and Presentation of Financial Statements", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r85", "r111", "r112" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": [ "r19" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility, aggregate principal amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r19" ] }, "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "End of term charge", "label": "Line of Credit Facility, Periodic Payment, Interest", "documentation": "Amount of the required periodic payment applied to interest." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r43", "r45", "r71", "r72", "r239" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r92", "r123", "r534", "r555", "r557", "r561", "r578", "r672" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "verboseLabel": "Stock options, unexercised\u2014vested and unvested", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r664" ] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable and other", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17", "r18" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r239", "r665", "r735", "r785", "r786" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accretion of end of term charge", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r73", "r74", "r75", "r76", "r77", "r734" ] }, "tars_RelatedPartyTransactionAnnualCashCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "RelatedPartyTransactionAnnualCashCompensation", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, annual cash compensation", "label": "Related Party Transaction, Annual Cash Compensation", "documentation": "Related Party Transaction, Annual Cash Compensation" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r248", "r285", "r521", "r719" ] }, "tars_NumberOfVestedWarrants": { "xbrltype": "integerItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "NumberOfVestedWarrants", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of vested warrants", "label": "Number Of Vested Warrants", "documentation": "Number Of Vested Warrants" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities:", "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r153" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r687" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r78", "r79", "r601", "r602", "r605" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r467", "r468", "r469", "r471", "r474", "r562", "r563", "r564", "r603", "r604", "r605", "r625", "r627" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r651", "r666", "r668", "r783" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r41" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r192", "r193", "r194", "r217", "r507", "r559", "r566", "r569", "r570", "r571", "r572", "r573", "r574", "r577", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r590", "r591", "r592", "r593", "r594", "r596", "r599", "r600", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r678" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_USGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentDebtSecuritiesMember", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government-related debt securities", "label": "US Government Debt Securities [Member]", "documentation": "Debt securities issued by the United States government." } } }, "auth_ref": [ "r783" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r173", "r186", "r219", "r220", "r229", "r232", "r233", "r237", "r238", "r239", "r277", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r446", "r524", "r731" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r126", "r154", "r186", "r218", "r231", "r235", "r277", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r427", "r429", "r446", "r528", "r589", "r672", "r685", "r731", "r732", "r774" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r601", "r602", "r605" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations before other income (expense) and income taxes", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r218", "r230", "r234", "r236", "r654" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r426" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r294", "r295", "r605" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r295", "r605" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r394" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r687" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Value per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r325", "r364", "r365", "r366", "r367", "r368", "r369", "r478", "r479", "r480", "r659", "r660", "r666", "r667", "r668" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic [Abstract]", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r687" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of lease cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r771" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Smaller Reporting Company", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r687" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and other accrued liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r108" ] }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License agreement", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement." } } }, "auth_ref": [ "r764" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r687" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r41" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents \u2014 beginning of period", "periodEndLabel": "Cash and cash equivalents \u2014 end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r36", "r108", "r182" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r692" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r336", "r355", "r437", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r540", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r721", "r722", "r723", "r724" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of net income (loss) per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r213" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r402" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a02", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r325", "r364", "r369", "r443", "r479", "r659", "r660", "r666", "r667", "r668" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r458" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r403" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r90" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility Agreement", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r118", "r184", "r311", "r317", "r318", "r319", "r320", "r321", "r322", "r327", "r334", "r335", "r337" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r44", "r239" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity", "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of vested stock options (shares)", "negatedTerseLabel": "Exercised (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r89", "r90", "r123", "r386" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r404" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued for license agreement, value", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r325", "r364", "r369", "r443", "r478", "r666", "r667", "r668" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued for license agreement (shares)", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails", "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r373", "r375", "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails", "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r373", "r375", "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r325", "r364", "r365", "r366", "r367", "r368", "r369", "r443", "r480", "r659", "r660", "r666", "r667", "r668" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of equity warrants", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances", "documentation": "Amount of issuances of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r67" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful lives of assets", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense paid in cash", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r178", "r180", "r181" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r43", "r45", "r71", "r72", "r239", "r636" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r64", "r65", "r374" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r63" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net of accumulated depreciation", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director", "label": "Director [Member]" } } }, "auth_ref": [ "r718", "r789" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r66", "r69", "r70" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of equity warrants", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r10", "r68" ] }, "us-gaap_LongLivedAssetsHeldForSaleNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongLivedAssetsHeldForSaleNameDomain", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets Held-for-Sale, Name [Domain]", "label": "Long-Lived Assets Held-for-Sale, Name [Domain]", "documentation": "A name of the assets to be disposed." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets Held-for-Sale by Asset Type [Axis]", "label": "Long-Lived Assets Held-for-Sale by Asset Type [Axis]", "documentation": "Represents the assets held for sale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 }, "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets", "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r63" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r687" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r358", "r359", "r362" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r370", "r470", "r471", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r570", "r571", "r572", "r573", "r574", "r594", "r596", "r628", "r773" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r187", "r188", "r470", "r471", "r472", "r473", "r570", "r571", "r572", "r573", "r574", "r594", "r596", "r628" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value, beginning of period", "periodEndLabel": "Fair value, end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r10" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "calculation": { "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shares of common stock reserved (shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r27" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Issuance costs related to follow-on public offering", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r9", "r123" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Account Detail", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r704" ] }, "tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred offering costs included within accounts payable and accrued liabilities", "label": "Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities", "documentation": "Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://tarsusrx.com/role/CommitmentContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment & Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r117", "r296", "r297", "r637", "r728" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "tars_NumberOfEmploymentArrangementsWithExecutiveOfficers": { "xbrltype": "integerItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "NumberOfEmploymentArrangementsWithExecutiveOfficers", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employment arrangements with executive officers", "label": "Number Of Employment Arrangements With Executive Officers", "documentation": "Number Of Employment Arrangements With Executive Officers" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r144", "r192", "r193", "r194", "r196", "r202", "r204", "r278", "r279", "r411", "r412", "r413", "r423", "r424", "r431", "r433", "r434", "r436", "r439", "r552", "r554", "r565", "r793" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r23", "r74", "r340", "r455" ] }, "tars_RelatedPartTransactionTerminationNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "RelatedPartTransactionTerminationNoticePeriod", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, termination notice, period", "label": "Related Part Transaction, Termination Notice, Period", "documentation": "Related Part Transaction, Termination Notice, Period" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r22", "r147", "r186", "r277", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r428", "r429", "r430", "r446", "r672", "r731", "r774", "r775" ] }, "tars_PaymentsOfDeferredStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "PaymentsOfDeferredStockIssuanceCosts", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of deferred offering costs", "label": "Payments of Deferred Stock Issuance Costs", "documentation": "Payments of Deferred Stock Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Less): Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r465" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r53" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r23", "r313" ] }, "tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsContractualMilestonePayment", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual milestone payment", "label": "Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment", "documentation": "Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails", "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r457" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r119", "r679", "r680", "r681", "r682" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "tars_LineOfCreditSVBMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "LineOfCreditSVBMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit, SVB", "label": "Line of Credit, SVB [Member]", "documentation": "Line of Credit, SVB" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows", "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on equity investments", "negatedTerseLabel": "Unrealized loss on equity investments", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r543", "r725" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r99" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r144", "r169", "r170", "r171", "r192", "r193", "r194", "r196", "r202", "r204", "r217", "r278", "r279", "r357", "r411", "r412", "r413", "r423", "r424", "r431", "r432", "r433", "r434", "r435", "r436", "r439", "r447", "r448", "r449", "r450", "r451", "r452", "r466", "r552", "r553", "r554", "r565", "r621" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of term loan-related costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r333", "r454", "r661", "r662", "r710" ] }, "tars_LineOfCreditFacilityDrawDownIncrements": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "LineOfCreditFacilityDrawDownIncrements", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increments to draw on credit facility at company's election", "label": "Line of Credit Facility, Draw Down Increments", "documentation": "Line of Credit Facility, Draw Down Increments" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized losses", "label": "Equity Securities, FV-NI, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r276" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, issued (shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r89", "r343" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r30", "r432", "r435", "r466", "r552", "r553", "r706", "r707", "r708", "r713", "r714", "r715" ] }, "tars_CollaborativeArrangementFutureCashPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CollaborativeArrangementFutureCashPayments", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future cash payments", "label": "Collaborative Arrangement, Future Cash Payments", "documentation": "Collaborative Arrangement, Future Cash Payments" } } }, "auth_ref": [] }, "tars_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "UpfrontPayment", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment received", "label": "Upfront Payment", "documentation": "Upfront Payment" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r457" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r370", "r470", "r471", "r570", "r571", "r572", "r573", "r574", "r594", "r596", "r628" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan": { "xbrltype": "sharesItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan", "calculation": { "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": { "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan", "label": "Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan", "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r240", "r241" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGain", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains", "label": "Equity Securities, FV-NI, Unrealized Gain", "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r276" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefit from income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r135", "r142", "r203", "r204", "r222", "r422", "r425", "r544" ] }, "tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months", "label": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months [Member]", "documentation": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails", "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and other accrued liabilities", "totalLabel": "Accounts payable and other accrued liabilities", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment received", "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment", "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment" } } }, "auth_ref": [] }, "tars_CommercialAndSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CommercialAndSalesMilestonesMember", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial and sales milestones", "label": "Commercial And Sales Milestones [Member]", "documentation": "Commercial And Sales Milestones" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r189", "r190", "r315", "r345", "r473", "r646", "r648" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r124" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r89", "r577" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Net amortization/accretion on marketable securities", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r110" ] }, "tars_ThreeCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "ThreeCustomersMember", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Customers", "label": "Three Customers [Member]", "documentation": "Three Customers" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r61" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding (shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r89", "r577", "r595", "r793", "r794" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r24", "r191", "r312", "r313", "r314", "r315", "r316", "r318", "r323", "r324", "r325", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r455", "r658", "r659", "r660", "r661", "r662", "r711" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTerm", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual maturity", "label": "Debt Securities, Available-for-Sale, Term", "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r767" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r84", "r421", "r782" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r401" ] }, "tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four" } } }, "auth_ref": [] }, "tars_EquitySecuritiesFVNINumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "EquitySecuritiesFVNINumberOfShares", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities (in shares)", "label": "Equity Securities, FV-NI, Number Of Shares", "documentation": "Equity Securities, FV-NI, Number Of Shares" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r62" ] }, "tars_CreditFacilityTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CreditFacilityTrancheThreeMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, Tranche Three", "label": "Credit Facility, Tranche Three [Member]", "documentation": "Credit Facility, Tranche Three" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation assumptions of stock options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r125" ] }, "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "tars_CreditFacilityTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CreditFacilityTrancheFourMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, Tranche Four", "label": "Credit Facility, Tranche Four [Member]", "documentation": "Credit Facility, Tranche Four" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Additions of property and equipment included within accounts payable and other accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r38", "r39", "r40" ] }, "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution, value", "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services", "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (usd per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r89", "r343" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated incremental borrowing rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r464", "r671" ] }, "tars_WarrantAgreementNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "WarrantAgreementNumberOfTranches", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Warrant Agreement, Number of Tranches", "documentation": "Warrant Agreement, Number of Tranches" } } }, "auth_ref": [] }, "tars_EquityWarrantsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "EquityWarrantsFairValueDisclosure", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity warrants (for LianBio shares)", "label": "Equity Warrants, Fair Value Disclosure", "documentation": "Equity Warrants, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lease, Cost, Total", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r459", "r671" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Out-License Agreement", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r137", "r138", "r143" ] }, "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution (shares)", "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services", "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r24" ] }, "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices": { "xbrltype": "perShareItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices", "presentation": [ "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)", "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services", "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r460", "r671" ] }, "tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Less): Tenant improvement allowance", "label": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance", "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r325", "r364", "r365", "r366", "r367", "r368", "r369", "r443", "r478", "r479", "r480", "r659", "r660", "r666", "r667", "r668" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "tars_CreditFacilityTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CreditFacilityTrancheTwoMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, Tranche Two", "label": "Credit Facility, Tranche Two [Member]", "documentation": "Credit Facility, Tranche Two" } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Lease, Cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r461", "r671" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "tars_LesseeOperatingLeaseNumberOfLeaseContracts": { "xbrltype": "integerItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "LesseeOperatingLeaseNumberOfLeaseContracts", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of leases", "label": "Lessee, Operating Lease, Number Of Lease Contracts", "documentation": "Lessee, Operating Lease, Number Of Lease Contracts" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r191", "r312", "r313", "r314", "r315", "r316", "r318", "r323", "r324", "r325", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r336", "r455", "r658", "r659", "r660", "r661", "r662", "r711" ] }, "tars_LineOfCreditFacilityPeriodicPaymentInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "LineOfCreditFacilityPeriodicPaymentInterestRate", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "End of term charge, interest rate", "label": "Line of Credit Facility, Periodic Payment, Interest Rate", "documentation": "Line of Credit Facility, Periodic Payment, Interest Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r15", "r86", "r87", "r127", "r128", "r191", "r312", "r313", "r314", "r315", "r316", "r318", "r323", "r324", "r325", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r455", "r658", "r659", "r660", "r661", "r662", "r711" ] }, "tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities": { "xbrltype": "integerItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities with contractual maturity between one and five years", "label": "Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities", "documentation": "Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities" } } }, "auth_ref": [] }, "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value", "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tarsusrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r57", "r60", "r73", "r74", "r77", "r82", "r121", "r122", "r191", "r312", "r313", "r314", "r315", "r316", "r318", "r323", "r324", "r325", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r336", "r455", "r658", "r659", "r660", "r661", "r662", "r711" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future lease payments, undiscounted", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r465" ] }, "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant": { "xbrltype": "sharesItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant", "calculation": { "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails": { "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/StockholdersEquitySharesReservedforIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options reserved for future grant (shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant", "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant" } } }, "auth_ref": [] }, "tars_EquityIncentivePlan2016Member": { "xbrltype": "domainItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "EquityIncentivePlan2016Member", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 Plan", "label": "Equity Incentive Plan 2016 [Member]", "documentation": "Equity Incentive Plan 2016" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r465" ] }, "tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "StockIssuedDuringPeriodValueLapseOfRepurchaseRights", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Lapse of repurchase obligation for stock option exercises, prior to vesting", "label": "Stock Issued During Period, Value, Lapse Of Repurchase Rights", "documentation": "Stock Issued During Period, Value, Lapse Of Repurchase Rights" } } }, "auth_ref": [] }, "tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, available for sale and cash and cash equivalents", "label": "Debt Securities, Available-For-Sale And Cash And Cash Equivalents", "documentation": "Debt Securities, Available-For-Sale And Cash And Cash Equivalents" } } }, "auth_ref": [] }, "tars_CollaborativeArrangementMaximumMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://tarsusrx.com/20230930", "localname": "CollaborativeArrangementMaximumMilestonePayment", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum milestone payments", "label": "Collaborative Arrangement, Maximum Milestone Payment", "documentation": "Collaborative Arrangement, Maximum Milestone Payment" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiCost", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/OutLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized cost", "label": "Equity Securities, FV-NI, Cost", "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r527" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails", "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r666", "r668", "r787" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r179" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r91", "r672", "r790" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued (shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows From Operating Activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized cost", "totalLabel": "Amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r247", "r285", "r527" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails", "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal outstanding", "verboseLabel": "Term loan, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r15", "r128", "r338" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/OutLicenseAgreementDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r237", "r507", "r545", "r546", "r547", "r548", "r549", "r550", "r641", "r664", "r673", "r695", "r729", "r730", "r735", "r785" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows From Investing Activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r102", "r600" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails", "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/RelatedPartyTransactionsDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r298", "r299", "r300", "r301", "r363", "r371", "r402", "r403", "r404", "r481", "r505", "r551", "r567", "r568", "r629", "r630", "r631", "r632", "r633", "r638", "r639", "r656", "r663", "r669", "r674", "r677", "r727", "r733", "r777", "r778", "r779", "r780", "r781" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows From Financing Activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued, net proceeds", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r61" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r179" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r160", "r292", "r293", "r644" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r108", "r109", "r110" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r20", "r186", "r277", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r428", "r429", "r430", "r446", "r575", "r653", "r685", "r731", "r774", "r775" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments measured at fair value", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r66", "r69" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails", "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/OutLicenseAgreementDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r237", "r507", "r545", "r546", "r547", "r548", "r549", "r550", "r641", "r664", "r673", "r695", "r729", "r730", "r735", "r785" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails", "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/RelatedPartyTransactionsDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r298", "r299", "r300", "r301", "r371", "r505", "r551", "r567", "r568", "r629", "r630", "r631", "r632", "r633", "r638", "r639", "r656", "r663", "r669", "r674", "r733", "r776", "r777", "r778", "r779", "r780", "r781" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails", "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/RelatedPartyTransactionsDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r298", "r299", "r300", "r301", "r363", "r371", "r402", "r403", "r404", "r481", "r505", "r551", "r567", "r568", "r629", "r630", "r631", "r632", "r633", "r638", "r639", "r656", "r663", "r669", "r674", "r677", "r727", "r733", "r777", "r778", "r779", "r780", "r781" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original issue price (usd per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://tarsusrx.com/role/RelatedPartyTransactionsDetails", "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r385" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r29", "r30", "r96", "r157", "r533", "r556", "r557" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://tarsusrx.com/role/RelatedPartyTransactionsDetails", "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r298", "r299", "r300", "r301", "r371", "r505", "r551", "r567", "r568", "r629", "r630", "r631", "r632", "r633", "r638", "r639", "r656", "r663", "r669", "r674", "r733", "r776", "r777", "r778", "r779", "r780", "r781" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Less): Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r52", "r152", "r537" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r105" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://tarsusrx.com/role/CondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r95", "r129", "r535", "r672", "r712", "r726", "r768" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r239", "r665", "r735", "r785", "r786" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTextBlock", "presentation": [ "http://tarsusrx.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock details", "label": "Schedule of Stock by Class [Table Text Block]", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": [ "r16", "r54", "r55", "r56", "r57", "r58", "r59", "r60", "r89", "r90", "r121", "r122", "r123" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of license fees and collaboration revenue", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r100", "r507" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosures Noncash Investing and Financing Activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents:", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized cost", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r36", "r149", "r642" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r4", "r47", "r50" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued or Effective Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r372", "r380", "r399", "r400", "r401", "r402", "r405", "r414", "r415", "r416", "r417" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://tarsusrx.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r442" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r98", "r333", "r454", "r710" ] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r34" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities and Long-Term Investments", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r81" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r239", "r693" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://tarsusrx.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share, basis and diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r716" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss", "http://tarsusrx.com/role/NetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r175", "r197", "r198", "r199", "r200", "r201", "r206", "r208", "r210", "r211", "r212", "r216", "r440", "r441", "r523", "r542", "r652" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair market value of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets measured at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r66" ] }, "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances." } } }, "auth_ref": [ "r37" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r28", "r144", "r169", "r170", "r171", "r192", "r193", "r194", "r196", "r202", "r204", "r217", "r278", "r279", "r357", "r411", "r412", "r413", "r423", "r424", "r431", "r432", "r433", "r434", "r435", "r436", "r439", "r447", "r448", "r449", "r450", "r451", "r452", "r466", "r552", "r553", "r554", "r565", "r621" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Net", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r7" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://tarsusrx.com/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r205", "r213", "r214", "r215" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://tarsusrx.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r372", "r376", "r407", "r408", "r410", "r670" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r411", "r412", "r413", "r565", "r713", "r714", "r715", "r766", "r793" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://tarsusrx.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "SubTopic": "30", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479359/835-30-S45-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815-15/tableOfContent" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 76 0001819790-23-000080-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001819790-23-000080-xbrl.zip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�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Ÿ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�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�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end